var title_f34_40_35456="Beclomethasone: Pediatric drug information";
var content_f34_40_35456=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Beclomethasone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12644917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/34/7716?source=see_link\">",
"       Beclomethasone (nasal): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/13/44245?source=see_link\">",
"       Beclomethasone (oral inhalation): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12996 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-1E1E8CC54B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_40_35456=[""].join("\n");
var outline_f34_40_35456=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/34/7716?source=related_link\">",
"      Beclomethasone (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/13/44245?source=related_link\">",
"      Beclomethasone (oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_40_35457="Patient information: Cat scratch disease (The Basics)";
var content_f34_40_35457=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83675\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/6/25702\">",
"         Lymphatic system",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/28/9664\">",
"          Cat scratch disease",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/32/28161\">",
"         Patient information: Animal bites (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?42/59/43955\">",
"         Patient information: Swollen neck nodes in children (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?22/15/22770\">",
"         Patient information: Animal bites (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Cat scratch disease (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/cat-scratch-disease-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H109282226\">",
"      <span class=\"h1\">",
"       What is cat scratch disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cat scratch disease is an infection caused by a type of bacteria that is found in many cats. The bacteria don&rsquo;t make the cat sick. But you can get the disease if you are scratched or bitten by an infected cat or flea.",
"     </p>",
"     <p>",
"      The infection causes redness, swelling, and small round bumps near the bite or scratch (",
"      <a class=\"graphic graphic_picture graphicRef83493 \" href=\"mobipreview.htm?9/28/9664\">",
"       picture 1",
"      </a>",
"      ). It also causes swollen &ldquo;lymph nodes.&rdquo; Lymph nodes are bean-shaped organs found all over the body (",
"      <a class=\"graphic graphic_figure graphicRef63854 \" href=\"mobipreview.htm?25/6/25702\">",
"       figure 1",
"      </a>",
"      ). They make and store cells that fight infections.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H109282241\">",
"      <span class=\"h1\">",
"       What are the symptoms of cat scratch disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Skin redness and swelling that happens 3 to 10 days after a cat bite or scratch (or cat flea bite)",
"       </li>",
"       <li>",
"        Swollen lymph nodes, especially around the head, neck, and arms",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other possible symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Headache",
"       </li>",
"       <li>",
"        Feeling very tired",
"       </li>",
"       <li>",
"        Not feeling hungry &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In rare cases, cat scratch disease can cause more serious problems, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Confusion",
"       </li>",
"       <li>",
"        Vision problems",
"       </li>",
"       <li>",
"        Liver disease",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H109282256\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. If you were bitten or scratched by a cat and have mild symptoms that don&rsquo;t last long, you probably do not need tests. But if your symptoms don&rsquo;t go away or you get other symptoms, you might need a blood test.",
"     </p>",
"     <p>",
"      In some cases, a doctor might do a lymph node biopsy. He or she will remove the node or a small sample of tissue from the node. Then another doctor will look at the sample under a microscope.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H109282271\">",
"      <span class=\"h1\">",
"       How is cat scratch disease treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most of the time, symptoms of cat scratch disease will go away without treatment. But your doctor might prescribe antibiotics to treat the infection.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H109282286\">",
"      <span class=\"h1\">",
"       Can cat scratch disease be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can lower your chances of getting cat scratch disease if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Avoid playing or handling cats in ways that might lead to a bite or scratch.",
"       </li>",
"       <li>",
"        Wash your hands after playing with cats.",
"       </li>",
"       <li>",
"        Treat cats for fleas, if needed.",
"       </li>",
"       <li>",
"        Wash cat bites or scratches right away with running water and soap.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H109282301\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/59/43955?source=see_link\">",
"       Patient information: Swollen neck nodes in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/32/28161?source=see_link\">",
"       Patient information: Animal bites (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/15/22770?source=see_link\">",
"       Patient information: Animal bites (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?34/40/35457?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83675 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-109.230.63.219-5CD169F5DE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_40_35457=[""].join("\n");
var outline_f34_40_35457=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109282226\">",
"      What is cat scratch disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109282241\">",
"      What are the symptoms of cat scratch disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109282256\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109282271\">",
"      How is cat scratch disease treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109282286\">",
"      Can cat scratch disease be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109282301\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83675\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/6/25702\">",
"      Lymphatic system",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/28/9664\">",
"       Cat scratch disease",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/15/22770?source=related_link\">",
"      Patient information: Animal bites (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/32/28161?source=related_link\">",
"      Patient information: Animal bites (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/59/43955?source=related_link\">",
"      Patient information: Swollen neck nodes in children (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_40_35458="Complete CBD transection I";
var content_f34_40_35458=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60875%7EGAST%2F68567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60875%7EGAST%2F68567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Complete transection of the common bile duct after cholecystectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 231px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    ERCP demonstrating complete transection of the common bile duct.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Bourke, MBBS, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Complete transection of common bile duct after cholecystectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    ERCP shows complete transection of the comon bile duct.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Bourke, MBBS, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_40_35458=[""].join("\n");
var outline_f34_40_35458=null;
var title_f34_40_35459="Nonurachal adenocarcinoma";
var content_f34_40_35459=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F63219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F63219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Nonurachal adenocarcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 398px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGOAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDgaUGkNKOK+9PzwT3paOvPagimAnejqaUDrQKBi9BSMeBSUuKQhKBR1pRTGBooo64pCClo7UUwFz6UlJmloAbg80U6kIoATvSik+tOHr2oATvRS0hFACGkp1NoGBxRSd6WkMKPpS5zQAT0FDdhLXYTrRQVODkGpI1jCM8r7QOg7msqlaFKDnJ6I3o4epWqKlBasiJ4pBnrQZIieHx7HtSx3saHEfU9Sev/ANavPxGbYelT54vm8l/Wh6mEyHFV6vsprlXd7fLuSCNmOArE+mKaQRx3q5537oHcVOM5Bpz7LyPcMLcDjn+P/wCvXn4TiOjWq+ynHlv1uerjuD6+HoOtRnz26Ws7eWrKIpKV1IJUjDDqKaK+jTPkLDu1KKSl7VSJE6UvWjFJQADrSkc0Uo68igBtApc0mKBh1oGaF96KLABFIKXNHU0AJR2opaAE5xS0lBoAPpSHNL0FIaBiUUtJ0oADRRzR70DCiiigAzSUpHNFACZopMc0UDJqQ06m0zMXPpR1o75oHegAzxijFFA6UAJ9aWloxQFxKOlFLjNADcU4DijHY0oFAXExRilzmigQmO3eg0c5p30oAbyO1GM0tGOaAEoPTFLj1p0ab3VR1JxQ2PcWCJppRGnU9/SpzHbB/L3NJLnb1xVzU7WXTbZHjidY2484j72OvNcq7s05OXB9K+KzHPqlSfJhZWiuttX/AMA/SMn4Wo0qXtMdHmk+l9Ev8y1ql3b6fKqu5IYnGB0pILyGdgsb5cjO3vWRqdqLyeNMt8p4HrVy1jjtXHIeXHPH6VpT4gqwgudJnLU4Wo1KklSul0NgQORuO0D61XndYMeZkZ6EDIpbe7YFww3xN1I5Iqp4gurU3TR2Mzz2wClXdNjZxyMex4rm/wBY8VNtRSSOxcJYKmlzNt+v+RftNksTyEfKvc9KlvlaFzHvXK/3TkfpVPw3cxxkrfRu1u6FRsXcwOOCBkfrT7q/H2CG3jto0aJnJl53OCeA3bjHavMxmZYrEO0p6Hs5flODwqvTgr9/+CytcvtTO/DDnIqB5GkjPmc++aguHIcF+M84pLicCLGMZ4rCNWrFWTZ2SoUW3dIntypBydpHqaZcgQhXH3s8Zquk4Knc3QUrOZYMN95Rn6iqUpvcznThF+6WPOkCBk3YbgjNXLWR43RgcoxGRmsqBiuO475rasNkgxgH8elcs7JndSnLl8jQuVE0SXEYz/C31qoRx71YLGKMCJ2B359KlkUXEZZBiVeoH8VfY5PnUZRhhq2/fufn3EPDk4yqYzDfDu42272/Mo4waWlI6UV9Sj4cBRS0UxDcUUp4oFMYlFLRSAb70YzSmjFACYpcUYpKLAFFL1pDRYYYoI70DpS/WmAlJiloxRYBKKUjnFGKQXENIeaWlFADOlLSkUlAxDRS4/KkxQAlFLRQMlNIKWgdaZADpS0Ud6YhKBRjmlHXFAAOaWjtR0pAJxQOtAGaUUXAMUUdqMUhBiloo/nQAhoo60opgJzS+lBFWpo/skBIGZiM5P8AD7VxY3HUsFT56nyXc9HLcsrZlV9nS6bvoisFJOBTkKIykHc45A7VQFxIybpn/ixilnnCJ97HH45r5vG8Q1JLloKx9llvCdKnLnxMuZ9lt/wTobvXbzVmunZSojAkeNZQEIAA4U9881ylvcSNczPGBGyg8nk88VPaRB5HcNubHG48CqV7m2Lqrbmbk18ze78z6/RadAti3nP5jbnBwTnrTmIScswB9CKdZREwLIwOD+pptyBEhLYOazm+aXKbUkoxuTx3CYdE4DL1rHkRndwvPPWp7ZZGcyJyAeRSMfLdgOhORWkVyNpGcvf1NHSZBFb4brjAo4ubrbEcqo5NMUrHbpu6nr+NV9NuXt7ydYtuHGDkZ4zWfLzNyBT5LIkkiLhvMPGcAGqksUYnVWO5V4HvW5f3gaBo1RCGAOSvIPtWLGw3sQu5yQB7VVGTHXhGRca1UxHbtQMPTODVdI1WQgru7cdKsXsqpGNucVQuLwJB5ikB16D2q4c8tDKryU7Nk9ykcTDymJHcHtVqxc7k29ay0u4pYoyx3dyavwyRh0aDpnn2onT7k0sR2Ny1cOTu4PTBqaEgNlMgg9qzBcqpBTBDH1q9A5JMivg5yVNYuMk1Y66dSM07j75Ak/y9GUNiq59qs3uS8ZXpsAB9ahWN2UlVYgdSB0r9Rwc3LDwlN62X5H4rmNOMcXVhTWik7feMHaij8KUV1XOEDSGlNIadwDrRS0Y5oAbR0pcc0YoAQ0hFOIpcUAJx+NNIp1GPegBo4opcUY7UDEo6mlPSjHegBOc0h6040mKQDe9L/KlxSUDAiil6jFJ0oASkxTjRQA3pRS/WikBIQKMce9LSmrIG0oPFHWlUc0AFB4pTwaQ0AA/CiikIoAKUCgdKXHPFSwExS4o5pe1AhuKTvxTqlt7dpW+UfL3Y9BUTmormk7IunTlUkoQV2yNFZ2CqMtT5EWMfOw3ei81a8yOEtEi4yMZ9T71VkdYgzM2Xbse1fLY3iCUXagtO7Pucv4Tg482Ler6IZ5sKMgILMTzntUer3jhHJPJPWoCqEhckFvvNjOKSGLzgFmww6k9q8PGY2pi7Oq/kfS5fgaGATjQjbz6sy7dzJcM5PfitNLRJsPKxES9ff2q1HaQrJlV4Hc9KhvrxIIzEnB+lefUmmtD0qSk3qLNfWkVmbYW6qC2Q6jDj8ay7swkRtG24lsEEcioYiZ5iD97HAxUcoIaINw26iEbbjqWexc+1EuQRtAGKztSnd5kiToe+eDUk7FU4zvz0qrHFJ5u9zx6VpThFPmZFacpLkiWVEkUY+YDnqamdPPhVVU7+xHNSNGTbqzKx9+wqGOR0b5M7faldXuVGEuWxJNFJNHiQhOmPWo7eA2oJ+83ck1OpUozMTu7E1EoYvj7w681PM3oU6MUk+o9rhEs8bQWOTn1qOwXc/msdoJA57U28tlkVfnII5wOlV7i+NtEEUo6lckYyV6itIQT2OepUcfiLzFBdSpcuVQ/IGH3c57+1ct4nUrcwm2dmjKANxjBz0/8Ar1fv7km0laMBi6hSX6qfanyzWN1o1jApxKAfOaTruJ7EDpgDg5rqp0+U8/E1vaaGdMnlWoQpKrug8sgYH1z371etC8cirHOzwAAkkEEnFW5UhWT/AEKW5kt1ZCqznb5Y7EAZ561IPNaJ9lqfMZ87yM46dh61pUtaxzUIvnuOikO9FB+8a1rNyEdA3tVK1tm4kkUGQnJwMAfSr7lEaNR8pJ5968upNc2h9FRi+XUmtbxFheG6YAxnjHU+1a2lzi5VjjbGBgKK5PVdq36lf4kBP1rW0qVo4l+YBfvHiu6pj6/sqcFL3YnDTyzDe1q1XH3paNli4UxzMh6g4zTCSB14q3LLHcRsxIDqMgjv7Vj3ZuggaWJkQegr6v8At2iqKmvifQ+CfC2J+sypvSC691/n3LEkyoOTk/WnWkolzmMexzWLktKBnPPFalqxDEr06V4WLzvEN80Hb0PqcDw1hIQ5Zx5vN/1p8jTMSJGCyqfxqNZYSSvl4PqDSGbcpUjBqsp3SgLyR1riWcYz4nUZ6K4fwFuX2SNBLZXXKllPvyKimgkiPzLx2YdDViGRlAwatx7n7jB6qeQa9HB8TVYStiFzL8TyMfwbh6sebDPkl96Mc0o6VfvbIoPNhB8v+Jf7tUTX2eHxFPE01UpO6Z+d4vCVcHVdGsrSQ3FFOHekrc5hMUYHY80uOKQj86YXExRjilxSGkMQd6U0dqUdaAG4pOtOP86QdKBiHijtSnrSHpxSAKKMUelACY5ooOfwooGSnrzQaQ5pVz1qiAFFH86MZoAU9KMetA60MOTmkIQU7GcUgpee1ACYx0pTij8KB1qQE+tL3pwGeB1q9DZbYvNnUhegBGPzrDFYqlhaftKrsjrwWBr46oqVCN3+XqMsLM3DbmyI16+/tVi43ISiKERewNWjMsNtCVyFcEqAOCM4zVWR/Nl2cBmr4HM85qYuryw0h+fqfqWTcPU8uo80knUe7/RFKSMNuZOuecVVljY9RlfU+ldLFZYty4AA27j/AFrAvIHVDIGwADxXlOrZ2Pa9jzK5nvJtwANqsce5qzYxYYoO/wClYxuC1yiYPBrQtbrFzImAADkk96qTb1JjFK6RpXxjhtsA4z3rmJ2LuzE/NWl+9v5G5IjHTPQUyeGKJlVcnHLsR19qyjpLU6LNq0SpaRGJQzKQP1JpbiECXD5Lnn6VK8pdhgHA6D0qN2z81VKo29Bxw6jHUrzIoc7fypEXJUsenYd6bcyGOSTzVKkY4NRK7Erxyea3UXY5HOKdjau5me0ZAgQcDIPpVBQvRSQT70QpNJIASAOvJ608JL5ykKvGe/SpUEtGynVbWiFe2kKqIhgY5J45oeM2yYdyWPUYqSWdsCInnGXOO/pWumj6hqekpeJAwtkV/LbA+cIMtz3xVWM+ddTl57kKWCFSSuMnnFZFwwebI7jB966VLCKVHZ2Eb4O0bcjp0rJngMyYjt0BQYY55JrenKOyOKvGTd2ZQkeMmJl+XGMkU+WNI4ysOAM5B9KmMUndTwfTinMEBU7OnXmtrnLy6Ee5IygbLheWPQfSr0Wvbb9pbdPKiZVVCzZZMd+Kq3KpeRywQ+YI8hmcDnHfilsdCjnKhJpypjIUkYDnPTH9OvFaRinuYVKkoPQ04NchuBhBsKjnH86m853kWRgzDoM1h3dne22ozxXMRhl+VjEFwOgwcfTmtyIk26ZYFs1yVqMI6xPRweJqydplq5hF3GJAf3gGQKi84x2rEdQOKtgCOMbucCsvU38u3K45LVzRTk0j0ZtRXMLBevuHOFrq7K6Z7WNpWGCPu47e/wBa4FJG+XC5ya67StXa0LQuiNGyeWdygleQeD2+tLFU7LmRWEqqb5WS63paQKl1bKRGxG9f7pPp7VWjGEwOCea628RZ9AnDMpkABH+0Mj/61ccHIfniuWnOUo+8dbik7ISWZgSFBBPFWbNQqHjJPNQW0DSSAnvk10Js4rLTZJbpDvkTbCFx94nv+FVq9irKJSt3PJYfL2xVqC4DzbRwvSpNOshNChkkjhVyV3tk7cDNUNPVckM4Vie/vUWe5Ss7m/FOVZUcZUj07Vk6ra/ZrghP9W/zL/hV2MkRjbhsH73rUl2n2iwdcfPH84/rX0PD2Plh8QqUn7s/z6HyvFeVRxeDdaK9+Gvy6owaQU7HJoAr9DPyMSjFLQaYDSKKU0hHtQMQ0Ud6DxQAd6QgY5paQ0DA8UlLij8KAEHNBpaKAExiilPTg0UhjjR3HPNFCiqIFoxS0HpQAUHJpBnPBp3c5oEGM0uQF96B1pcetSxDOppQK6PwtpMN3Hcz3sZ8lVxGTkKX9KglgcXggit0SMH5m28EfWvEx2eYfB1PZTTb8rf5n0mWcM4rMaSrQajF973/ACIbOz8m2+0vyx5UHovuafNrDW2nNBMTLE24BWHQ9iPTnn8atatBKbcyqkj2648zapwPTn0rm7qV52eHyyzu4UD0P+FfE5jmVTHVXKW3RdkfpeUZTRy2gqcN+r7sdYziGNpHzI5PAHT8K0nkFxZgLZkTMwPn5IIGORjp+NXbLTvssZhuojG8QAy67ecZ71p2UliVEVxcCEbgA5XcB65xXmOSR6t76mVDftaLEkkcjRZ6evqRTNUtvl+ZSOh2nqKt+JL62aWS00HM0GxfMllQBmI7j+6OegrHtll8ne/mDg5DepoU76MFGy5jn7iDfe7o1XC8+wFU4cSXkpPcHArX82EyFQY0EpPLZx0pLjSpbfyJ1gl+cZQ7eHHTg9+Qa6ISstTCpHWyJnZbeBVQAyH+H3qlOplZIkySvJA7mo452cyuRtZTg59fSowX83IwD2xWMrpnXSirEiR73CqMsewGSaPE1lJoz+ReI0V3tDFMg4BGR06HpxXQ+HRYW2nane3ckqXUMDG3VR1f1Jz2yPzrz3Ub2XULyRpZWdvvM7tkn8a6cPS5tWcGLxPKmkRSxOJ1RmDlvm4ORW1a26Fw2eQOvpWZpqO0zHkjFbttC3knHVjxj+ddFaVtEceGp83vSJ4LU3CsyHCr2I61ctNGnlclVy+eM9K2vDVib9UjSIIyEFyOnTrXa2sdvpjJ8zSXbN0A/l6VxyfY7eZR3+4xLDwVbx+Q96FmlkUMqA44+g6fjXNeKtAn0K4aWGVxZNnAzwmf4TXpVjvF9LK6hSVHzscke2PeovEcEV5p7RMgkWVsEGiM2mcsveZ4eTPdSqlsmS5wCeBmux0HwTdyIslyUIzzijTdJi0jxEraocxjmLsPbNejpqCrAq2gDZH3j0H0raVRNWRkk07mTB4P0+TT5ba4t87u4GCD615V4r8J3Gj3TIVfyifkfsw+tex3OtPZBZJJImyPmAPSnW9/H4hQWyWiTmVgirkHcT6UqbkncU/7yPnyz0+RyxRW3r0wcVLeyag0yGU5xgqFQIRgYHTvXtl74Q0V7h1UTWkudoUng46g+9U7/wADQxzkGQnbg4J7fhW/1ixj7KMjx3LM259+/oQx5FWAgjwVBL98HpXo+teC458fY3ZH65kPFZp8D3EEQKXSmU/eODj8KTqxki4RcGc5eAfZkVFZpsfMDwB9PWopZba+ht42tkQxJtbGf3hyfmOe/OPwrT1XR7vS1VpCjoeNyE8VRt5IY2mimiVy4/dvkjac9fes7W2O5TUnqZssa20bLHHgswOSOQB6VoWu2cRs6qrFiWl5/UUs9uZI2ViCV6Gq2n/61o2wy55zWc23HU3oqKlobP2uTykRXLKSBzxgVnTROLl1OetXpZFjkSN1G1hxVy10x7qeOOHBlJwuW4b2ya5dtEdiXVmj4SjsY9Ts5NVRnslcGVV6ke1ReJNRhv8AW7qSKNYYDIWSGMcKPStvxhNp9lJaQafbiHyLVFmBOS0uMsSfqa4RJgspkfBLc8+9W00uUzjaT9odVoWrDT545bi1ivIEV1EM3CZK4ycdxWBbOkt9K+PlJOAegqvPcyMCo4TGMGorUfP7VLTtqXFK7aPTJLDTpPBFpqdmzreRTi3uI8fKSQSDn8KyLTDSMAQVYYYelU9HjkeCRusMY3tuJ259/epdP+eY7c5GDx9a1pTcakZJWtb8DOVLmhKEndO/49DElTZIynqpIqPHNXNSUpqE464c1VHvX65B80VI/AKkeSbh2YgowKVRnNIasgCKTFLQaAGmk7U480hFAxtKBSnGKTpSGGKKB0ooATFGKWgigBuOOaKdjiigLjuvSkxg0dacKokPwoFBxmlPWkAnSgjJpRgnFGOaYgoGeaXjFSRRPLIscalmbgD1qZaK7Gk27I6vwzdW39gTwSGX7TFMJFC4wYyORz3yKv6VqFhdy3kepId7KWhkUYYEA8emO/TtWTapHZWiqNsj/eK5/wBY3TAx2HNXLDS7FbI3OtTzLGWAEVsoZ3yM/h+Nfmma1YV8ZOdL4fz8z9nyTDVcLl9OliPi/FdUjG8QajJJcxQu7W8KwjbsU4kXnDlQerVTWI3cQu3Zo5NwQueBnHr61elu9OtoruKK22TFTsyd7A5BHOcDjr1rPl1OZNCu7O3lYW0jLPKkh5BAweBxjpz1ry1roexKXKrmdrN/fQXQivLiZ7fhhz7Yz9eBUmmaq7lrd49+V3Iccg9qsaAU1SCC11OIup+WNyeQOw+lb8unLaJ/osSx8AdOT+NZ1LRWq1LhPn1jsZGmW7LPI0zHJGcHirN+SqSBueDz2pZQEby2y0p5PtVS+nHkbG4xxms7+6Xq2cvNGdjHGNpzwelWrjWroWkNut1MYY8FFDH5evT06np61XkbdHNg5BaqDYwR710027WZlOKcrss2xMoKqCSTnpnJqU5jm2gfPnGO4NQ6bqE9lJIbZlRyVYPtyQVOQR6ciq11eSCTzCx8zO7d3z61Tp3kkhRrcsHc1vGepaaqrHo0EsETxJv82Tc4bHzdOxPauM0+3luWJjXljgZ7Uk4nvrnYufmPJNdXpVhHCgUnIUdu9djkqUdNzyY03iJ+SIdNtvJjKsuF7t3PsK2NLt2lkJfckJONqj8qfYac9xcAqjMM4weldjY6b9ihS5u4neJ22QxgEee3TAPtx9elccm5u56kIxpxsa1uhsNOtLeAAXUyAdPur/ePqetaMMMdtE8jODKOTIeSa5vR74ySz3EylrlsgJ3AHGK27m4xZI5BIfsaUtjjd5SGLqizStGD2x71u+TDEhhaJWe3XMjiTcCeTkH0wQK5oadFEktwrAgcHaD1PT861LtNvh5pnlHmTowKrwVAFKmu4VrW0PLvEF++qas7sSFDYTnoB0ro9Ku5TaRW6yAM3Gc9PeuPvkMkpFsC0ueAvU1p2MkUG2dJFcQqpeOY43nPIGP5Vty6EwaZ0V3IPsXyRh5Bz1znntWXoWo3Wnk3WnzIjI5IUnlD2NN1DVbvUWmuPKggkIVj5EexY0UYGB2/rWObm1tZkE26aIrudUPUkcflVU11RU1paSOibxub68YalEFkzksnTPriu5029F3ZRFJTLBjIbspPBz6c14EryJMXYA7+mDzXoHwxvnBv7N2YqVDBT0HP/wCqlKPVmbiloj0XVLK4tS7SLuVFDEryAD0rMuFDW8ckTM0bDBZhjDdwK0kuppLJoXOYl5JK5+ik+ma550a2uCjbtgOMe9Z2QRT6hLaC5haGZVZSMEHvXCeJ9F/sqaG4jObeRtuP7relejSsAqsuM9c1j65bx3VlJFIAQ/zY9xVRvHc1S5tjgkKyoSWH1A5FU7GMRXhVgOOR71o6xbRWU6C08wp5Y3M64ycc/hmlstNn1Oa0gsEL3LnAA+mf6GlJO1kdEJJ+89Cy9skgVpg7KoJQr644/Wt3RdGN3oElwZ0jeLcV38bsY4X35AxVfT7G7m0n7WseYF3HeCOi4zxn3FV9R1pZdRZ4YBawRRpGqKxIJA5b8TzXMlZXZ1KTfup7GPqVz57EMxL/AMWeufWsxSA3vUlzN5sruB8zsST6k1GqZwe9a7Ijd6lhT5ox2q1ZwN5i8fhUdnGMgnkV6J4Es9Mt5X1TXEEtnbqWSLP+slGNqn2Oazs5OxpKfs481rnPNLNDZ+R91JOWA74NdX8LtOS+8RW8dyY1hUl5A3ZQCf6ViSk6hqV1eGNY1LNKVXhVHoKs3Nnc6T4ai1Rd0f8AaEjxRENg7R1P9K78vwksTWjFdTzs1x8MHhKlSWmn4mDr8kcmt3z25/ctM+zH93Jx+lZ3U08/nTCO9fqUY8qUV0Pwyc3OTk92L26UUnOaD0pkgO9IfpSmjpTAQ02n0hFA7jaO9O7UHmkAgHFBHAzS8HpTcevSiwBRilI9KUCgY0/SinUUBcUAUtKoyDQRxVE3Gkc0HpS0GgBB+tKBk0cf/WpQPekwFC4zniuj8JWyCK8vpWCJDtTec/KWPX8Otc3n15+tL4ine1udMt4JWhhntVklRT8rtlsMR69K8fPKrp4SSjvLQ+g4Xw6rZhBy2jqdhFd2UU9/dvC96kSlYAwwDz95gPbnHvVG7nMlpJqiQzQSll2tFHhAx7Z7H0qPwpcRLdq19A15bKqvNDG5XcmCWzj/ADxW34z8PwTaLDe6HLLcaGg/1qktLZMf4ZF7pz+ua/O4x9pofreIrKg0rb/1b1/M4HTprNbi6n1CMyyKMRwDoT6k9gM5+tQvBJcWoZ7SXyJJPLMpBALDBK56Zwf1qDS9Rhhg1K2uJmhuZlEaMoG1/mGQx7L3/Ktuy1m1tEW10yGQvIPKLzuJEIIAYhcYDZH3h2q/Z8ln2MZVfa3iupqeG0Om6hFeBVd7fBAcZHoBXRajqETwXMQgWSWV/NEoGPLGT8oH5VjTWd6dPhuRAwgkYhX9Tx26496n1KV5pi0kaAkZO0YHTtXFzSu0zvVOOhmTiRUaTa29ueaytc8mFXhbaL1X2uI3DxsuBggiu88IaDe+LZ7i3jYKkEZMk0h4U4O0fnXAXli0BkSYYyxwQODg44puPKr20CNSLk431RiImUkx3NU5I8Ssp9OK3LG2byJXOCFkwfyrLvoyJGI+7mtItqVibqWpnzfu2x0z61F5TXMmADgdTVrWLaSOGF5G+aQBlAYHj39KgtpSre4Fd0FomebVnq49C3DbeUg8sAbuNxFdBpMUUnmBpNzIoKqB945x+GKz0jWG1hlmYO0pO2NT8y47n0zXQaHEjMyRA+VnIkK4LL6VlJtvU3pxUUn1Og0S2KLvEnl7lKgbsZ+tJrWpTPIgjJK2a4hXgbcc/nnvWtM8FhoguJYmMryhFXZ8pQDufdsdPSuXiUSFozjc/wCVQu4pu+hpeE4wFSa5lVJbh8s7chAauwzRPM8VqDJErnEknAx7CsyKZreOC3faJt+w9xxWzGsSRBU6qM59aJaKxjctWdrFu2vKcZycn5ar+K9Sjh067kGANhVfpjFPt5DJHdSBsSRplQqk4A7+n515v4t1l5rhrI4AJyT7U4xvsTKW7kzPiMguC+Dh8becVoaPaF9StzMAbd36epHOKw7G8tlE8V7E0waNhC6uVMbgcH3H1q14a1SWS+tIC+BExZc9A2Ov6YreVN7mSq20R302mGeGcOG8peVGPvDH9K4nUbe3gW4Iy0nBjK9x3zXpV1dh9lwilInTHDZHT19a8+1jbBIxk+fDkbTwAM8c1lFtM0lJ21OWtVkmuFijjd5Gb92gGWOf1Neg/DK2n+3TyRIz9ELY5BPAH51wkclwl+Ly1Z4plfcjoSCp7EEd667w7qF1pNzGJwyOcSYz1J5BrSox04to9TkmeGaeG5JilkzGUzhsj1Haub1a7mJ2ysWZV2/gK5/XvEt1eeIDczMWlkYMT0FdBqxk+xxXEsJR2jD7T6GsLMcdGr9Rtrcb5DHv3Y+6cdahl/eyLzhwcVU0+6S3l/eQ+YhGdpO0sO2D2qRJt8wOcHODmqkro3ho7kd5p4md1PO/saxbK1e0uGE/+pRgp55IOenvjNdZOq+UGB3OKglUMHk+zpMxjZQr5xyOv1FKO9mataXQzXr7QLi9tpNMtrkLn/SUD4VumMcceh+lcZrhZbt22hVb5sDsK1dIgn1K/e3DnBjeZQBn5lXPQey4q34snt7zRbIW1okLWabHlB5mBPUj15rJ6ybNYLlSjucjbx75MkZFPkTy2II4Parmm2zSuqRjOcV03j7wi3hyewWSdZVuIlk3qOAe4/CptJpstyipKPVmV4W006jqEFuZY4UZsvJIcKijkkn6Zrq/GGp6VO8UGiQtb6fboELseZ2H8ZFcrp7lI3SNsBhtYjuKns7F9XuzCJ4reGNC5klbCgD+tOKvogmlzczewlrLPqF3FZ24IEjhR7knArsfi7O9vqlhoasPs+mWscYVTwXIyxrP8Hw2Fv4rsZHLNZW7rJK3+7yT9M1jeKNTOs6/qGoc4uJmdQewzx+lfV8NYdurKq9krHwfHGKUaUKEXvqZBpAelO780hA7V9qfmwYpMcUo6UGgY0YHTrSU7g0mM0AJR60d6KBhRilxR36UANHFLS45o20guIf0oA9aX2NKRgdKAuNxRTgOaKAuJzmg5pSOeKDjg1QgB9aKD6Uo5FADTTqKTP50AHrVfxWjvqun7AzCKzj3YHTOTVodRXU+JLS2g1mzldWVH023cqOQRyDz+FfO8Rz5aCXmfWcHw58Y32X9fkcxp109uiOgZS6lGOcZB7Vqw+KJtIgYaUjWjSW7QzfOXE4buQeOO2OlReIrWy/tG4utHkd9NRgqs+cjI98d81neKYIlvxDFdx3TxoA00bHy2PX5cjjGcV8KotPQ/VJOM0uY4++Hmyscd62vh7YzT6yzFv3UCFyTyPQVn3Nu0eCxHPvXo/wkhs7vQtfgEiC/Qxzoh6vGudwH0yDWzbULI42o+0U33LF9NdWhM4m8y3mYIygYHHQD0HA6Vaa7+y38NzKiS5QBkIypBHIx9Ks6vI0nh1BHNCotrncIwRv3EfeA9Biqv2hWgX7GPM2hk8yYfMwJJDema87W+j7Ho7rVd0Rapex2s9hJ4cuZoLi4XybiDeR8+7AOe4OQfbFYfiXUL02um2V2FdYFfy9mCSCxJPHbIptyqterD5DSzOyiNlchlbPTHfNLrjyah4guQFa3a3i2FQoPl7FCnI/Dt61tBqaM5rka8jZ8CQ6fPoXiN7yJ3kjhGyQMAq5Vse5OQK891RyWUP1A49hXS+GNRm07TNQtWtVkhvUwHbBMbIc7h+BP51z8thc3izSRoNkWNxJAxk4/rWlr2sYwvCUrmbFCGkBcfLjr2NIsCG52FkUFhhicAVu3GmvFZ/OdjpkMhByh9xWSUEWTsVyPmw3cVdOpd6mVenpodFctFeaZYkw+Vc28RjVVUYkjBP7wnuxJI+grY8N2zJBuZjhe1ZWgWEJ1COOMyRRHazhiGYIQCTx17nFehQaW8N7JaFTM6yceUQd/cfnVVNtCaDtqzF8UXLMunWrNkopK46Af/rNY9qw+0r5zEIDyVGTWncWF3qXilYbV/mSB22BsAKFJYD3x2qnp8Qkuo4ijMrMMgDJx34+lZXZpoY9xJINTwxzsbcDn15rpI70G2U7ucc1i6jbqt880Um+NmxnHXHTjtT4pOOuBjFQ27u5ly6nTeGb+HbrCSvMrmxl8ryzgE993tjNeW+IbdpNYE4crEEAY4zzmu0hSARSef8qyoTFIGztYdiB69P1rEure3uobsmQ/aoIw8UY/jOeR+XNb0pNNGVaKs2c7bWcKWclw7bdvQmqvh1/K1aC4QHyVlCbvc9K052cQNHsCl0KvkDAB71g75LRRFGd3zbzt7Y710x1TOKTakmz1vVrqKONdsbIjMcRDop9K4/VVa6hlZnJbdlj6CtqS5E9lZPgybNu8FuWzWfILf7eYo8mBgQSwzjI5rmjozpn7yuc1ZXgV4ldSGQhs46/WtbVtVt5dRvZ/IljEy5twG3bDkYBz261ia0Da6pvXayk8D29K0Y3tJ9USO+BjsXlVnZF+ZEJ5x9Bmuiy3JhN8vKbOieZr11Y2PmRBhmMMy7NpJyQx788Z9637vVJI9I0/7RcpLFb7oDbnAaMZzn369fwrJ8Opb6XJctbO0SOJJYZS2WxgmMcd+lUPEqxtcKLJ5jEygnzMZ3d+nbNTJLZFU7uzZo3Vw4Mf2eNpQFyjbsdcY49OtbNlG8wWUL1GTXMQXhjggTaWwuwtnmu80ufAimh2h8AZ6hvcj+lYvQ6YyZG8L4UAHHQ471bsbcbysxwrDGfStJQkyh9uGJ+bgAfhV6O1WTSbnM20wSLKkf8AezwT0+lZR3udDqe7Znnl8sGlrJ5EbpqKyttfd8jRsCCpHrk9fegW8t94H1SZwsdvaFCXI+YyMQoT6YyfwrZ8ZTWv9jwwxW6G8EhJnxghQQcH16nr6Vd8YWy2/wALNLWBUSS5dTMQuDKdzNxjrjIzn2rWULSbIVVqMV1bOC8Ga/PoGsRXkEVvM8YPyTLuVgRgjFXPE+t3fiCcO5bygxdYt2RGTjOPQcdK52NDE53Ag/StO2IEZbPzMMfQVhd7dDs5Yp89tRsMvkIUAyWOKsIJFnaNkZZAOUPBH1qlA5S7WTaCVbIB6V0Glzyvqn9pX375g3muSOGx61tRpOclCG7IrVI0oOpN6JXFuJRp+mCGCYtPdr++AH3Uz93PvjNYueKmvJ2uryWd8bpGLHA4FRV+mYDCxwtFUl8/U/D82zGeY4qVeW3TyXQMUmMdKXGKAK7TzAHTrQfpS4oHv0oAjxS0vXr0pcDHFAxhGKUdaX9aMYoAMdfSkA5pwPY0EUBcbjnilFLijgUBcTFIQaeRSUBcTFFLjmigQ00UppOxpjExS9qMUtFhiUHg0o60fxUxCjk465rr/EeqnRbvw7OywXUjWIysiBl3B3BVl+hrJ8JWqXOtQNPGZLaJt8oAzxWlqr2kmoyOEDRwruMgT5kUn+dfI8SYqKcaC33PveDcvnNTxTdle3r3/r1OY8WXVvHJLDZndAJ2IPTIxxx+Jrm5p127+x7GpvE1xbG6kFk8jwZypkGG/GufkuiDhs4r5enT5lc+6xFbkaii5dTZjLenArsvgWLWXxXdw6gVCyWE+wt2YLkY/KvPpZN8ZNdf8IL1NP8AGEUsqB8wyKA3IJ25GfY4x+NatJRdzjlJzmlE9OuNVjGjtp726uiNIysBghmAAOe+PSs6xsWnaOKJ1jdgWLM3AH9OKdqa/u2miiYM5Z9gXgAnt7Vfm/s7ToVn1OZfOUhjGh+bdjv6CvIje/vdD2mkl7vU4zxLBdaW3nbmjdGBBI2tg8ZAqpCbZrUG5guPtEhLCbuQSOx/Hn3qzqerXPijXXlWH7TEvztEDs3KOAAPQZHAq+8bpDbyGzkSNGXzQj5YtuJCgHp06VrCOjsTKb5knuR6y9npN7EsmnM9pLCTHIrFWOY8Dk5BwxyfpXJ3ErS3ckrKFy27YvAH0rqLkXOqPPcXW+KxtH2rC38DnouO319qwbyJEvCqgsh6nHatZydiKUE5N9Tbe2N9BNdxqfJBEbLuJ8oH7qnP865S8heK/WFMtvO1QBkknsKv299JbCVUZnjkIz+FN1We3+1abcrI4ZGBlEa4ZMN2PQnFRTTdS/QVeNo2NbQbYpcKXZg6HDD07YNereHiLadJ14KKxBAz/Ce1cF4Ya0liuPKWWRzJmIyYwY+eWH96vQ9MuBYxfaHtRPFEh8yMnGVIx1/Gt92c1TSDscNMwbWWuHjJWHg+WSpIxyc+vNN0yRnuGWNYiJQUR3O0rkdc9vSr948+mtfwwxgxXC7XWVPmA649jWeqw/Y4njyGORIGPRs8Y/CouiraENyIRv8ALQsjIB8/GxsDJ4981CGthp8qmNjMQNj7sAHPOfw4q1dKZIioUAlMDA7isoKfKG8c1FyJLuZ7zyrAQ28RFsMccZHaiGCOaN5raRi5PzAjr9BS6jqtvLZCKIMrowwuflDA/fx3OOKqwTXCeS9lNE0wfEkZ5POcEf59K6I01FHLUquTG3q2x0a5eQgSgEbgfu4riNMuYZZ2d3K5OFH+NdT4gtpxHdCZkht2ALREYZm/oB19xXBGSBLwNErIoI+XqM9zXTSglGxxVajcj07Sr0WdyscDhCo2oSRyCCCaq3yS27qIJFkJ+YnsOvH1rAlnmDwXcRzGo2Yx1Fbt2EGlAW5R2lXchDZ2n0rOULO5sql1Y5y68yW68yQE4yFxWle27reCB9yzL8pDdvUVf0zTwdMiluYzvfKxn3DYJYenBqtGyTX+4F2kYMWJqnJbFU4P4ujNzSMw2qxRDAPHA7VaNkJpPnxsXufWtzwbbad/pj6lwsdrK8YJwC4X5Rn6mqECFwFHOTk1jfudWl7IZe6ejR7Il5xjIHek8NXJgvxaykhWP5GtrG54AwO1RgZNZVnCIvFsSjksx24XPODjis7Xdh3tqd0g2qqgHOM5rVspNttcKTtMkJBJbGRwce/IqlbwA20bOxEnp6j/ABrU0iS3t9Ttzcwm4hzgxL1bPGKztZmjaa0OE8aQwpao8bBSuPMG7lixIxj6DNaegeNLUnQv7RskuIbC2NvIrcgnJw4HTIHeszx6IY7raSI7N5CPM2bsYyQPWuIZ7i1l3qoAcA8nsehFaym+XQ0VJTtzHpHxDuvD2reHof7L3x6jBMdu6IKXjIyckcHB6V57pP2ZXJ1BZpYAD8sTBSTjg5PvirsrPJZGWIebtALBe2f8Kp29q5/1g2euTWdNVKr0WptFU6ELSlp5kkEJlkRAAB9MVe1CdAi21uSY0+8394/4VXaTYCkXA6Me5qDPNfbZJlDofv6/xdF2PzjijiSOKTwmF+Hq+/kvIDzQpGeaD1pK+lsfCj2UY4pmPSlJzR3oWgkIOKRvU8U7jHSkPTmgYxRTtuKB19qWmO43FKBS0D3oEIRzmilGM0uM0BcQCjGTSjilxzQK40jFJipOtG2kFyMDJoqQKaKYNkRFAFOxgUgGRTKuJigdKdSY96AuNHWlI/ChuuetLjJ5ouB3vw1FouleIJ7oSEwwqwCnGOoB9+cfnWR4seJtHspoN4Nx5nmgfcwpAUfhyfxrG07UJLHz0Q5iuI/KlX1XIP8AMCrT7rvQXjt3xHbSmQwMcl938Q+mMV8Vn+X15VZYmKvGy/RH6VwhmuGjRhg5ytO7suj3Z57fRb3IU9PWsiRCHORmuqvVceaIwpSQANuAyMc8HtWXHZkvkjvXgU6iSsfX16DnK5lW8Lu+FTJ967f4V2wTxxp630BlhkYxnb23KQD+dZsdiwI2DB6n2FaehlrTWLOSFz5iyqRg5yc8ConXb0CGCile+p6movNK1K4ijVRcJC8JSVcjaVOc59q878U29xJIspZ3SVQ4kbo3rg9+c12vxD1eC5a6urdmEk8oTbgghVQZz+PH4Vg3F6W0XTbGZVa2A80qOTuPB5+nauGVrtdjvo8ySm1qzB0+C0S6hdzPNbh0LsP3bDjkbu3eunSOZrYrJujltR56ueGZiQck9yOOak1sWcGdI0i/kbQbh4p5MpuZW25Oe/BNP16aOXRoJFuBFLEixJBjgqBy31zWrejOeT5mmZZ1XUL24vrjyWSGadnkePO0Oy428+ozWZqELwwNIqjEhC5PUUaS91bQlXZlt7tt4Gfv7TjP55qaS3muxtjkkkeaQJHCBwWPHH6VMm3ZG1JKPoU7PQLu4gaaFd8QxuZSCBnkA46VRv7EIrRkhnHoOhrsWsTo2oz2FkwzHJteQ+o4OPxzVaSwDs7Ff3jHJFYupyysKpJSRF4FhaaQoSEKoAWJAHUDB/OvU57RLKVYNQDNHjEgi5YjHavNtCnn0K+ubKWxiF0XRZJJV3bI+uMe/HPWvRr3VJrVFntd4d7cIHkIbGRyR+uK9BNJXPPqc0mktjlryMfZ1YcoemazI2+yXEcpVWQnHzDI/EVqTt+68vptHWq8VpLeultGFDTNhWbpke9Y7vQ30S1KyIzNyOewHpWReQSSTLbRHyvNJUTMMquBnp64BretpJIo0jkUfKxzxyMjHX+lcj4i1SSPxBJYBwLV0UvhQT1zn61dJJs5K10Zd3aQW0M1tHskILTxXUhKMyDI2bemTwcdqqaelyRG8EbiJzguBxnPc1fvI7aeOCN5QTJwzEkmME9cfritXQ76TS7U6XclJLCO4kwxOFdx6kZ7enrXRo0YyWxzXj+9szZEWryIQAhVn3iRhwzBuCAeCARXmTSYZg24N2H4103i6Fc/u4pFZJHMjb8g5Py4GOMfrXLYUA/3veuulFKJ5le7kdjLcAaFBOgATG0gdM1m2N/cwqFkZwp6be9aeiWSrpqSzHdtJJXqP/11U8yA6k8cmBG5yMf54pK2o3d2Z1Xh+4iXY8kriSQE4ZflDfWlS1nOqxCFd0aHLEdAO9ULK8MNutuHidUIEbBQSozknPX8fat2G0drqeO1u4DNG27zDMqRypx90tjJ/pWTjrdHWqtoJHQxwXCac8qRyC3lPls5X5Wxg4B9c4qxZwfu8Dqf1pmm37XFpDZvLM1kziUQoeA3Qt9cV1raXbW1ubmJZym8KFfHKY4c9xk9B7GuZHY5GRHEAVD9ufoaNUuIV1fRroQRG4jXa2wjDAHADD+91Oc88VYuNvmD6dTWFrKF7y2gjIVnOSScY49fpS2C1z0TT4I5dH1K8Vyk1uEQpkDgt1Ofy4qhDMvnxNMz+XuG/Z97HfHvT7RHtdJ2KQI7hQrnIIbGDj8Diq4YeYiAA5bpisp6vQ3prcx/iVak6exR22RyhlyBnkHGf06V58ZJLyyxKgMkYChyeijjAFez+LBJpthJJdRiObzYZEMcSnZIMkKQfxzxXm2iQw6hLqit50TTkvHGAMFg3RumBgnpTeisaUal9RnhGwnubqNYo0kLB2UNJtztUsQfrUM6NGEG5SGQMCvTkdPw6VBqj/2Lf3Vkrn7RG5jkK9Fx2rWvb3+09Jtri5CLdo3lKqIFUxBQAeO+Qc+ua9/h1qniPZyje/XsfMcYKVXBurTnZRtdd7mV2oHvTiKO1fdn5TcYRzQM+lLjvR2xTGN74xS/hQRzS96QBSdqcaTtQIToKB+tLg0YFMBBx1pcUv1pMYoABTuBQBS4pCExjFKBxxTjz0oHXBoFcAPSjqeetLjAzil7cUCuIB6UUq5zRQJsr4zRS9+tGOTVGonejtTscUhFADe3SjrTqTkUAIR+NS20zwSB4zg/0qOrem2/2i5CNgIBubPTArKrKEYOU9ktTbDwqTqxhS+JtW9SbxFpVtHFbTL5geeJJGjC8AtnofSsO5hls4N4iBTO0N1x+FdjbWbjLSkySPyFHQemBWLrCAboghVw2Dkcj2r8lxeIh7ZumrJs/ecFSqqjGNaV5JavuclJcyHKgMATyfWt74eWD6n4x0qBcMpuYyRjsGGahkhVE6V1fwvQ2WpT6hGyI1s0bBmwerHkDvziojVUnsaVISSbTLni2zi07xPqVpdQlkDExgDA3Z6/QiqLQRC0Zp/lMaZLR/MBnpn061peI7q61HVrkX04uGYCPzm9Ac8UXGmWF1MIINUU28inzjFC2Rg8ZXuMDNFlK9jRNqMVLexk2NnIsxv4LsWtvHkxu+Cz46jbnPp2qK/dL3TnkhkBSIBmB4JJ6ge1ZfiK20+22R6ZeTTSKuSZoigkznDJ6Lj1ps9rHpujW7yPI97Od7bZRhYyP7vXOe9NQfLZGUpJNNj7C5tXW0ijSRZQzCRmYEHOeAOwrpdK1qwsL/T7+WzZ57FlXy0bbvAzhyT0OcVxuklIb5WbLxkhvlqa8mEzTGMPsL/LuPI570OTjr1NYwU1Z7HoviKaK9uhfIiRtIof5Txk8/5zWC8h++pOQc5B5FR2NxJ5UVtdENIqDDL0I61m67dfZdQa3hOXIAAJAwcZNcrvUqOyMuVQjbsNS6nvPEMk1qkoeXhsMWLuByefzr0vTIHGgQC4PmSKSn3uFA5/rXjVheSQ3ygu3UnPQ89a9b0S8j/sZHcZcnrnqPpXp2srM4732KF4pE2RjZ6+9WdEuEstVt5rh4tkKtIqS5ZScZCnHqaluljkUn7vfAq/dWQl0O1tYobdp7ncyXXmZLkEfu8H7p5x2+tRa2qHOatyvqY+pTWd1PdTxzLvk2TBAOjN95fwry7xxi21lJwXWWWIKpH3TgnOffkV2TWtwk9yWKxRwKQ75DBnAJCDHcgGsLxTbG908TmIO0ClmGduR3wfyP4UUZ2mm+pFeleGhzug6jahBa6vE726FpFaIASK2OmfQnGc5qZtQf7T5JHkWpLSRxbsgEgckepGOa5z7QI8gE+5NUbzVFj2xxsMucE45A9M12cjbOWU4xirs09amM+8D5pHPLZ61yM1uEuggIdmPIFbMt08aF1yWx+tYsAcpJcb1L79uM/N65x6VtBOxx17XO81O2jt9N0xtMl/eKh82J/usR1/Oua1SJJLwui7SeSB0B7inQIrafFKt0z3Bdg0OD8gGMHPvz+VLu2nI656kUtUUlGepPYKVCk8Dv71t6fdrDqS3N1AtzCoK+U7EAjGO1Z0IjkeJVJVmADFjxn/AArS1mx/s+WSEOk+xzH5sZyjkdwfSspNtnZCMUtTrtAa2bUWhsp0mgZBLlc4jJHK/NzwePwr0a5uLM+FLdPMka/aQMqlMKIxuBwe/JrxnwJNjUJ0UcvHn8jXfWKkkjnB5rCp7srF0lzxTfQ04kZwHYVlXcP2jXYkyQgU7iOwroRsW0BwN3el8OafbyTXF3dyKIoyhdD95lLAcD25NTuU5W1JEdo1SM/MpHYdKnVFaRHGAF7d6W5EJupDb7vK3HZu64pFlVFJJHHrWVjaMrrQo3/lan4gtbG9ZzAweSR2DYZiNiAHuctxniuL0NX06ZriSLzY7eYK8bZAJBPBP1Bqhq+p3Euvb7aV4XhfIeNiCSDnPX6dPSrtidsTPMrM7ncrEkZOeTROSSSW5pTi03fY7jw3oaan4m8R6pr1hbGKCyadyEwokcBlOPXB/QVialoTpolzqNsxlsYrlY0dhgkMuenaux0LU4rjUfE1y7vGh0/Pkucq21AuG/pWH/wkMN58N59OuHRJoJ1WKNV5YcHcT3xhh+Ne3lVSSxVPl7/8D8j5zO6V8BXUtrL5dV+JwhHekNSY70zpmv0A/JExh6UHpTjikxxTGIKO5xSk0HigYig8nsKSnr/qj9aTHNAXEI6Zo6inOOOtItAhKUUZAByM0D0oAUUoxSUoHPNAgpyjrSjt6U5R8pPv3oJbDHrQB0pxyB0pMd6CRQMEUUqe4ooJZUI55oxSnk0LznNM3EPNFO70h6UAJ2pD0paD1oGN6Gul8KaeZoLy8P3Ydq/ia5v0ru/CoSPwTqErSgObxFCDqRsPNeRndV0sFUkux73DNKNXM6Sl3v8Acb9vf22geH5Lp7QT6hdKVhdukK9CceucYry7U70yXLyyNmR3LHA9a2tbvWlwOUjUYVdxOPWudS3ku3naCB3WJQWYdEycAk/Wvyxy9o0lsj9tpUlTTk93/SJ9OWC+uxHc/urZFLtjq2BwM+5rS8KWtzN4jso7BVL+cvytwCu4VhWuIDL57mMgd1zu9vaug8ETxv4r05zN5Qicyg+6qSAfrjH41UFeSRNW6i2ux0XinSVi1C8F1fW9q8cpIJz8y8kBcfT9a5K+8UwSJDGunxRyC2EMrgdSCcMAOhxgH1pvjvUm1PVJJEiMSEligOcc9vYVykccil22EqOua3nKN3yl06T9mnPcn1C/MkiMS7qqhFyclR2H0rJlum5X5tvT6Crzsp2ru3cZAHY1ozWWnW3hrzrgXT6pcPviGAI0iBxk8ZJJ6Y4rWkktzkrtx2MzRJpFuoxIq+V/C+fvdsD35rTunVUyBhi5ySetZek3EDRvFOMGP5kxwSc1amk+0AkDlamulzaFYNtx1Z09jcpJbbnfaEAIAH3iO1czq9097qhm2kJnJFaOlHzLCSM8Mp/Om6P9iOqxJqjyx2jBtxjUMxIHA57E4FZ0FaoViV7jHtOLvUraZLSFTGEykS7QwUc/icc+9do0kkNpbEwmCG5BmhQnPyEnHPX/APVXMeHtkGpXG5VkZIW2Js3q5yAR7cEnPbFdJdkT2scx3/aMbtvBUJ0Xb+WOa7JfCcNNWmXYb7bAwkPA4DH0qNNTMSPHayfuphtlU4O4ZzgelZZLzWxGGRiOtSWUQMoUISoQlsJk5A5NZ819DaUElc6K++yDS3ksXaKWdcXNske6EJ2IPUHIArlNRswYyrFSmOgPtXTWthCQjX1wlq0kZn+YHDr2VccZPPXpiue1GWOaOVFbJ3ZXHHFDjfcwi7aHjviawlge9a3CrBDgtlwDgnHGevJ7Vx5zuyM8HjmvQvGsCzwu6kiVWzt9RXDLMEj2sgPfPpXpUn7qPGrr32bNnPEkW6bYxZSuGGR0rJ023WbVoYHuEgidtrTOCVQepxz+VSwX0Zh8po8k8DHanWVpPLMGGVAPWmvdWpLvUa5ToTZNbFVcJuZchlPUf0+lTaGkUGsWst+v+hF/3m6LeMY5+U9cU6OzndUaXcS/zbietbVo19BpphiVBH843OoLYcBWAz24rB1FfQ7/AGT5VcwbaMPqUccKeYWkAVR/FzwK2dWu/P1KaO/P2W2dmZkjUN5bY6AfUAVkz2zxZdsDHIquWMhPO7v1o3DZ2NnwS7R60CQoVkYHPX8K9PtUkSKO42r5TsUHzDOQPTrjmvMPD8y21/ASMnOB+Nd/BcS+WIMRcMSJMc8gcE+nHT3rCq7s3pQ5Uzed28oAEZPFKjiJcAZYVUaYGGMfxZAzU0jqo3MwPrjtUaFJNl2C5Z87YyWAyNwqtqV8tppszuMykZAx37U555FiXYvJ5yOtcf4ovZlKLh1XBbcR976fSlZPRGsVbVmU0bjWZory3e1nDfOr5yD3610dxLNJH9+SfT7D5I3VNuELZH0yTWE9zPqEzahqEhdyoXe3UgV0/gCWzur64t9UMgtbyJ4OMYHGQee+amMVKpc0bcYX6oo2E880F3tbYZgFJPQjqc/kKqysNqxR/wCrTp7n1NdR4l0aTQrV4mYBWl8tFyN23GdxA6ZBFcuRX3OR4KFOn7Z77H5lxdm06lX6pB+7o35vp9xH/DTSpKk1JjinN/q8e9fQnxVyuBzxSEce9SAHFIVoLuRGgjrTsUuMk4oHcYOgpy9yaMccUKKAEPJpMU8DgmhRmgLjMdaXHpT9vFA6HgUBcaKcPvYpQOacBzQS2Cgk5FOTPNSKMdqAPmoIchuMrQRT8fu8d80m0g80CuCgUU5AC1FBLZQIoAwadihVzQdNxOppKeQARTQOc0BcTHGaMZNOUZB9qO9MLjcVueHxM6z24B8t1Lg54yo/wp+haDLfQpdOE8h5PKjUuAXbGfwHvRqbXNlKYvJEZX5drDgdq+Wz7NqNOEsLy8zej7L/AIJ9rwvkeIqVYY7n5Undd3/wGZ+pTFgw5rR8OX0EWiGK5EfySeaqBOZWz91z6YzWdPdW7BdzHzNuWyuMH+tZqSusspQL5Z5x/Wvz6PuXsfrDakrM3de1CDWrqWVLK209FXAFvGdgJ6ZPr/hWVoF5Po1+52QypcRmEs6btme6+h461R8y5gkOwsYpGG5f4W9/qM1s2VsiT/6UjtCQSQDgq2OMVSk9JAuVR5ehb1uaya0gMSQ+ckYyedzHJJ9s84+gqj4X06517ULixhl+zW7xF5WwCCF55J6DPJ/rVhXQI9u0aHePvEc5qs9yNOlilhJV9+HwcAqe1bRs7TtoJN2cFuZz6R5rSJp8cswRC77VyQB94/T3rFvywVI5pGJ24XJyAB0H0r1LXNOu/BUOl6hpt027UbMlgVHyhvvLjuMEYNeWap80hZj15Apw0lZmEv3seZaroZ81sWUlCCRx9K0NJt5lEx2O4iAZmHIVc4yfxIrKS4ZGK9z696syTTrbOUJXj5iK7JRclynnxqeznzdTpbLMMh2n5HGM1J9gluLljGAwRNzdyozjiuc0jVvNiMDsN69zW9KjG1WXcgxwCT1/CuVRcJ6nfKaqwvHqaGl2zyWFzPCrMsMe6VC5AYHKh+vYkcVZ0q6+zTeUz53D8Aax5Lxhaxpbl4zKuJcNw3OcY9OlTWTurYPyOOjVve+hz8tlc6+EQ3JLLIiFR82Tx7YFaMECL4fe7itGJWQxyTO/ysCv3QB0PB5rntLKyRFVUCToxz1rQgkeSL7Ju/dJk4B7n1rOKtKxU9Y3Rb0DULyJQbaN5VtpVmfK7k7j5u4HJH41ha2Et76WLy2iGcFccj65/wDrV1ng17Ox16CXUFYxlgAEON55GCcgAc859KwfiPFFH4lu/KEYicKyrFKJAoI6ZrS2lzG96lrdDyzxIqOzAoGHIya5xVikwrKvH4V1Gq+VNMybsE9K5+a1CSlgOB3rphL3TiqwvIptaxCYGJQMelbNnCBGMDHFQxWu8/KeR7V0ljBblFVyobHA75pVJ6GtCCi7oowyNDKPM6Dt7VoxTSXAby42yemOwrVs9G+1TK8o+RRwDxmt210yGyjfKKA3I2nNcqlfY65cqWp53qNrMATI3zdhS6XaW0NrLLcIpBIVQSdwPXIHpXWag0LkbYx0wcis8WjS5RiFU87q1VVo5nTjJp2MiCMy6gn2eNixcFVr0GCLypw2xST2YZxmszSYre2nVII/nfClu5rXd90zFgQvJBx1I7Vm5Jo0SbvYebmV71Y44gViH3j0z0pqPubB7Hoam02aNEQ3iNcwFji3VyN5bpgj/JxWdPJsmdFV0YHgEc496UnoawjrY2JbhfJ5KggZz6CuIvwz/ajeytJIr7IDFICu4nJPuMenetvU3KaK+18vI2xh0C/jVDwXFLPcNK8ojhs45J1Bbb82Mce544pxfcqa6FAqZUigHCgc8V1HgSZbfxJpwUZAkUcrnGTjgVla5DFp9y8Fs6ys0UZDK2cAqCf8Kg0e4NpNFOfmkVwwyemDUc1pq/Q2UOeD8z1P4wNL9stIXQiCIFYW24LrhefzzXnJTkmuv17Ur7xNHfaheqUlgCkxFceSucAD8DmuT6rX6JklaNXCJx6Nr8T8U4pw08Nj2p9Un+Fv0GbeDTSvWpsgIKjYjJr1z51NkRXimkZ4qQnkelIeD1oLuRbOlIBhjipM0gPNBVxgHApRwwoXlvajI5FAxyrlPbNCJyaEbA+lPDBWNBLbG7cOBTVUgn0qQv8AMcUikHI60BdirHkA0oTGeKdE2Dj0NOc4JIPGaCW3ccqFsdqcIxkZFNjk564qV3+figzbdxHhwi8cUrwlc8c4qeaUyIi4A2jHFSebv8wADpnmlqTfzKsNs7bcL1orTtyu2FQOcdaKhzaN401JXuctnilT1ppPA9aRcba0NrDhzmlBAA5pg6Up6E+lAWFVutITxxTF70ZwtMdixFcyRjEblR6A8VO10JSDJnP51S7D1oB5rhxeXYfF/wAWN3+J6WBzfF4DShOy7bo3dD0+x1OWcXbugVRggjOSeuO+Kq+I7nzJ9nkIhgXYJI1xux3IFVLW4aCfevfgg9xUs00cgOPMGecHGBXy+a8P1XUX1OK5Wv63Ptck4ro+yazCfvp726fIseHoJRapezRlY3YqjkAgFeo9jW/rradLoNvLaPL/AGqJG+0Kx+Vl7FR2rm9PdRsg3uEZ+54BPGaLyYxTOiuG2MQSOlfOY/LcRgklUjZP5n1mW5rhcybdCd+V9mvzMieZkuElByEOSuamLNPOBw0DjPPasvUJ8TybQATzU/hu7ka+jslCsZ2CR7v7+Rj8KwoRdj2KkktT0DUpU1Twppo+0WxmsmaDyhnzdp5BJ7gdK4HUtMd5BGoZ5HOFAHc9BXbahY2+jz6lb6uk41aTHkqmAiuTycemOlc9dxXS6dHfmW38ouVjy4Dgg/3euOKzlFqdyYW5fd2e3z1PP9XtJrG6mt7hCk0LlHX0IPSqU+oM9sY+h6mup1y1e9eS9klRnlJeRQMYPeuP1CxdCWj+b29K9GjUjLQ8rF0pr3kia2+7HIhOSOa6bT5ZJ7QRMCVU7hxXPeGbiE6hbwXluZFJ2hQ23JPAyfrXW3FvJpN8bUunmI5HynIwaeJta5ngpPmsizIqi2TaMFO3pWncyQNAjW8ZjjAyATk49z9aq2hiuLWQLDI9yQChU8KAfmyO/H5UyeBoESQOSjgkL0xWC11R2SvHRm5oUqSMFB4YEE9MVpaQVjVsAEs5yfWuH0+6lSUpF95jge1dbZmSANGxVgvcHjNUtHciPvKxcl1IWtwknlq/lOHKN91sHofasrWb8391c3UnlxkkFY40ChR6ADtVm/khFghMYFx5rnzPM3bl6Y29sfrmsCZxcFgirHsUAeprK7TN1FNXsc7q8edSeXIG0AdKypo5Zi21RjNbWrI6TB35B4Jqjn+6fzrpjLRHBUVpMqWkMquS/AHbNbFinzhlwMHr3FV1XABPfrirULrGw4471E5XKpux1tt5phDRSjGOeaZLfy+UUBZmPoKp2dxmNNud3ak8x885wDz7Vjpc6ldrUq3koUfvHAJ65pdM1C2ZJY5SGwuQvQlsEDn0HWqOozYzxnB7+tRaVbK1vLc+U7OrbfvYHPTAx65qoq+pE9DesWdJhOF+VeF+prrI11C95kdHuL6QxM0gDuNuDnHUAYHNYljp1xJAbqCBRDuEboG6tjnA6/X0q7BBM2Jo7dnZVZsEkExjgsD6ZzyKpRaFdWLWnPDb6iLjyBeTo7qYiv7rdztPuOpx7VivKx3MW6sW+UdPoKveIdSufPs5JIvsxkjEi4AUv2ycdRwefrWO8wVG3n5m6AcCpkzamvtElwItQVLfzDG4dRhjwRzknA+lS3DJ9ltbSzjA3DEjoCDK2c4/DpxVPSmhVppbktuyPLI6E55z+Faurblt7K5tYlgtWDxrIOrkY3H268Vk5XuapcrTIPEmmCO9jvYrmIRTWqSHAP3goBAA9aSxsJL2K2GnAPeBwqIOrtnjHvVnUJY7ixt4PLInRRHtUdQO/wBeabb2ywTKtszW8u/7hckL369Rip1nOyKV4wubOk6vPYjU/tivI88Lw3Al+8W9z6ggVzYbgnNWb+ciFIRxuG9ueT6VQDHBFfouRYN4bCq7vzan45xfjo4zHuMVZQ0+fX/In3DAqNjTN3Sms3ODXtnyyiSFgB1pu4Hmo2ORTegoKUR5b0OKQN3J5pnfrQTzQVYejYJpCeaZnnNBznigdh5Y8UrvluvFRnpQeoxQFh5fk4oRiDTAeTQDQFiyJcN14pC+cg+tVye4pd3IoJ5CyHwADUhk5GO1U93PWpM80EuBcNx1AoE/JNQSgBY2HJIzUYcYNBCgrGhFckOp9PeiqCP8wopNXCzjsV6EOMkUE8UztTOmxJGRk56YpucikBwKAeP60BYQcdKWm0vSmMUGgGkpAadgsPHvT1NMFGeKRLJQT1BqVpSwxIAw45PWq4PFKSTisa1CFeLhUV0bYbE1cLUVSjKzQ+ewspYslzu5+XFX/AnheHVfFum2pciNpQzY64Xnj8qzs9q6T4fXpsvFFtOpKsqvjHc7TivGqZNhqFCTSu0m7n0lDiTH4rFU4c1k2lb/AIc0Ndsri8utburq1E7FgZOxjUHAI9PSvOb+GOMgxzOo5JB5wa9G1y/uru0vEghlEksm92XJyPeuNurLfpXnAgytMU2f3QBnP5mvz2r8VkfsVK8Y6mFpWn32s3T22nxmVljaVhkABVGSTn0FUL2HEXzDDjpjoa9M8X3Nvp1kNPtrA2jtDG52gLmQqMsB1AIzx715teuWJBb2xWvwuyOW7muZ7GLDGgu0JOBnrXW2EsN1OXurhwUTbG7jOccKD+lc5DC1zdRxxD52YKCeADnvXS6josttqNxp9+0UksfyxywybkDdTg9/Q10tpK8tjhcG5OMNy/NqkEZhurS2YSNGIJV24QELjIIxyetaNvG19p7jmONDvUFd3OMc9x0qrqngLULfRdIuo9QgZ78mSFASSoXqXz+VQaDdXdnKbaWbIkA8x4myCh6qazlGNro0oznJuMtu43ToY45Ch/1wySCa37eYNbNgqSR+VY93FDPdyGJlwCV3L1IB71opZv5UU4csrruHUbeehz1/Cs1PQ3cOVmdcSGGbB5DdR71DqVzDJdrNFGsPmLuMatkDnH4cDPNaOqJm2a6SHzPL+U5HygtwCT/npWTpgttM8TxLrcRntoZNsyxP+oI646++KSQTmkiPUR58JG1QVFZcsOyQp8pK8ZU5B/Gt68kE2rSuVfyLl3eKSQYLKScMQOn0rEuraSFZJY1ZoFfbvxxuIzj61qjlqrqQclsBc4FPiPzDdxzUFtMyMyg43dR6U8SIsp4z/Q1bhdGClZm3aiQpiEKT7nHFTmOWZshgiryR/jUemunkMm5CTyM9qfPfhogmMsuST2rOVKx0U699DPvYvNnESfxHaDXRWVmTLHptkTGMBJDvBWQg53HHp2+lc7HueXdkluTz6V3HhK30251SIPNJG8UReNCAAZAAQueOCSRzV04kTqdTZ+0aRp/gp0VJF1Jle3KOAwZmPMvXjpwPWq0K2Nulq0F60krQMFeUqxVcFQFGePQ/73A4qh4vv7W5n3QWwS8YC4mJzuLsPu89R349gK4WW8uRK93LtBn3EMVHBzzj0NVKSjuKlTc+p0HjCzWx1gWkUqz7FXcEYlVJGdoPcciqdu0ayCO73s5AESgZGSec96n0I2yos0iCaQfwufl+vvVTUXa4upGjjELM5cMgO2PJyFFYO2rO1OTSXYRplM+bhH8qPPyrwSadFrdzfQtZKQtmG8zywOhHT8PaqU9zPc+cjqWcAtK0ajjHGSO3JH50sWhXtqttK20faF3ptcFjnPYfSs3FqNjRVYt3Ovtmk0ZjdyI41JAjQL1CZP3m9OOgqvZ3DXWqLJM4+VizO/QsepNYlg1yk6fv4oxIzRs0jZ4HXcOuK2rWwtWuV8+2kikcrKkLMWTa3TIJzjvz606bUWm+g5p8r03K+u3yX2s3c6IiCSQkJEMqo7Y9BWW0sxJEcQHuzYrR1HEUz26lcI5B29OtU81+o4ZTlTi5aabW/wCHPwvH+yhXlGHvO7u73V/K1iOIT790sqkdlVcVLnmmk0V1JWOCTuOznIpM8c9KbmkB4NNCsLnmkJz1ozmkpjHDvQTTQaU+tILC9qMcdaTPWgHjigBR15pBwaQGgEE0DFpc4po6UvJpiFB6VI3QGowelOVgFOaQmh5YnFIzD0+tNzn2oFArDwSMAUU0HiigViIHtSZpM80Cma2FP5Uo700HmlzQxCHr9KXPFIeaM00MKXPNJRn86AHKT3pc00UdxQKw8NTgfWmdaUUmJodnmtLw4R/bVru4DMV/MGszkVd0QqusWDP90TpnntuFY1481OUe6ZvhJ+zrwmujT/E6jUr25ltl022kii835SSDuODwufetXUb7SE8L22lyWrWjYkBuxtdnxyFHQ8nHJqj4tto9K8RXbC3V4g+xPm4X/Gq019YSacovLZ2mX7i7eCD/AExX5U3yt8z1/Q/feVVIxaWm+hwWr3t3q1551zKzlVVAT6KAB+grBv38vIYEH+ddVfSQwKwjQFieB6CufvraS5OXI8zkgDtXPTnrqb1YXVomhYWsI8KKFtPMvLmcyfaRklEXjy8e+c5q7o1vJeWhj3wAI28mRwrcZOAe3f8ASsXTIZo3iaUSPDExyqttOO+D2q3GkkM263MsClsg/wAWAc8/lW86sW/I5KdCUVrudJYatd2c9ndRFS1qMxhuRjJJBB69aq6p4knMt2bOKGzjuTl0hjA/I9R17VB5iNDErO/mkMSpQgKc9j3zWZqED+UZnwNh24B5574/CsVKS0T0NXTjJ3a1EW7kMUiI22ZlJRgwHT19a2dE1aaK3VLxjIygBVJLBRnOB6VycaeYpPTB4JrQlvHlZWVzvYZ44Gfwre2mhhe0rPY62LUbaS1KyMdsZO6MdXVu3581wNxcSvHKRJlEfADDlq2tzFWQuxbIJUKRn6+vNVL2yDq1zczA7uw+9gAYOK0jJJWZnOm27x2NJbsXnhq2jggm83T3Z5JQSy7XIwT/AHcMAPfNYmvzzTx/aIMrGzAlFJ27h1/GtXS9LnkFvbwuF+0hgAGyW2/wso5ByOM1nzoIYJo5UXnuRyp9RTi9TOa91mLbtNIhYJle5BpRcbmG8gv0PFFtdtZxyq5BVTnNZscf2mSS4MjFy2QvbFbrrc89p30OlimCKCPxPSnvfxldqj5jWVNbsn3QWAUMcdqoSXCiQDOGzRypg5OJ09pcF5mKnaVGOO+etbEkezTo7oblOSvJxux/d+nFcjbTuwRVORgkVs3eol9PzLbl4oF8pYzJjazfx8e4zjvUNXdjog+WKbLtvdSzTTXF4DcWybTJuk2tIBwqKfy49BVKO1JjzOducnYecDPQfnUlrrFzNepdXxW4eRSCHHAyu0EAcAgdDVsnEslw8S5Z22KW34Hv61Emtl0OmEJWu9LlixmSysbeKaNVV8srLjcVzVaacS3IVJMQHqT2+tZl00xuSXc4U4HB/MDtVmEKiq8blm4bBXG32rGXu6m1P3ny2Hrbo8si2kTtyWG3JOOvNaxZrSximguJo78PxGyAr5fGCp65yCMVlXD3+n3EM24xNMvmoY2GcHI6DpnnitvX5RqOmWa7oXnt2MbTQjAkGAVOPbnnvUpvVtmrpqyjEoRyTNLK0qxea5JZimCCev0rqNOkluEe7vr/AMuSOMlWK5L7QMA/yFclEri4CL/+utzUZPKtYrYEZ2gnacjH/wCv+Vd2VYZ4zEKn06+h5ue4yOXYOVb7Wy9en+ZHLdW91cyy3KMHkLOXB6knPIqlMU8xjEpEfbPWmdaaK/SKdFU37rf3t/mfi9bEyrK00r3vdJJ/gOHtR9Kbn3ozW5z2A4pPpQKCaBiHk8UvfFJ9KSgY4UHnNIDzSk80CG54pR096RuKM8UDHduKaKQGk5zQFh/Tk0mRmjtSCgBwPNOBpuefegUCHg80Z4pv8qPWkKw8ZopgPNFAmhho70lH1pmgvSlJxTc0uc0AHeg8mkpR3oAVTzzQ2PxpOe9FACil6H3pop1AgBp2fWmijNMQ7NOjcoysO3INNWlapeojsfE10bkRzAmQyIkobsflGRj1qnDqW+1a389vLIxgqCT0OM9hTNFuFudNktpD88ALLnuv/wBb+tZ0c6QzYm3eXnDADPHqK/Lc0w08PiJ0vu9Gfu2S46GOwVOsu2vk1uVo7E3OouZBi3TJZgRkfQflVadBE7LGo2g9a1Y5rKWW4dGZUUfuywwZOeOO3FGppBO8ZXIJRSMDg9iD6EY/GvL5fc0PaTvLUy7bztQk8hI1UQxgExpg4zxn1PvXeWnw91jVNKi1a3eGRZGJZpHxjnBJrnY7z+wfE6RyOstrDH5DtEoG4Hkn/aOT39K9O0Lx7YWvg42t9ay7GmMeU4G1uePf2966aUIS0kzz8XUrQs6K/wCGOdt/C2mx6ZqralI0b2jvCJs8b8DBZcZC5yN3qayNY00ahoFnFpNwmoXbBprrCBVj8tMYDYGRt/OumXT7vWITd6NdTWmmWBeW5julBeVSQ23/AGlwBw3pxXPRXl5p3gnUb61NnG15JJbTBl2yENg/JzjgA8Y4BrRwSWxjCcm3rrf+v8zyW6+SXgkMT0HatZkjk0+1MUaxNGuJnycsSfvHPQY9OKj0yzjvdUMVxMkDKC2ZAcEjt7U+11SPTzfLB+8uFcCKTIMYAPJ2kc57UQvbUus1zWW5ZtUVvJuomV5F3Fl6Yxjmm6zC8yGfLNvwCMYCiq1pOyRTzOuS/wAwTbwT61cUGbT0eVxk8sue5H8qmVrm1NO2pS0HXLvSNUgvIljleAOI1kGRkggk+vWqms6lG4d3tzGsknBz936+1aUGnxrK7zAqmMKAeM+1V762g84M4yVOSD3q4yV9TCrSfK+Xc5bU0dwgQAJ1yOrZ9aZayNbLlQpBIOSMkV0l1YKIRICFTIAGOue/6VC1khjGAOa6YzTR5s4uDuMXVrTyhtg/eFdrDPBPr7Vzet3ETSJ5Q+YLg+9aN7CIYZAO9czNyevStIxW5jOo2rHSaJdefdQx7AWxgA9PxrWj33E0zth1T5trAncT9K46wYpIuCfwrrtBLTSMFYCPGGJHepqaam1BuXuiFljdVX5Me9btuIZXhEk5DycsY+SB7+9EkNo0NuEswzLI8/zSAbkHBU9+uP1qpaxiR5WAC5OCB0rjaS1PWvKXu7WIZ45UmcrudFIy2OBnpmtzSYrH7Pf/ANpzOkqxg2/lfNvfPT0xg9e1ECSLHK0Z2qV2MT0ORjGD171NqFhFZyR25ZDMiAvs5O49Vb3HSs5/zFx/lIGi02J5mtpriV8r5TdMcfNuB9+mKfZoUcREBc9OOlIBCjKSqlzjitbVJ1Fussiq8oULv7kAYwf05qbpo11TM6KIS6iqB8M5IwDz6ZqTUopLe/nhuF2yRttIPbHT9Kr6heWtldxS2pklhWNQPMAB3EfMPpnOKrxajLcu8kioXbnkZr3MjzCngZTlVWjtax8vxRlNbNYUoUXa173JqKdHPBKv71TFJ/s8g1c/s53jD27CQH+E8GvrqGc4OvZRnZvo9P8AgH57iuGsxwt5Sp3S6rX/AIP4FD60VYubO4tgDPE6D1I4quCK9OEozV4u6PEnCVN8s1ZgeKbSk+lNrQSF7UvSkNHagAPBo5zxSCl70mAfWjtxQetITQAHBpDweaB70hoGOJyKM00etL0oAXPNGeab24pevFAWH+nNBNNFB60hDjRTc0UBYQ8+tAPFJ70hPNMoXvRSd6DQgDvzTgab1xRmgB1KDTB1zSg8n1oCw4c9aKQUdjQIdQD69KQUHg0xDwcAU7HfIzUeaVe4qWhNE9rO1tOskZ5H6+1X7mOK6h82EY3DkdwfSsnp1qzZzbNyOcI3f0PY14+cZZDG0eZL347f5H0nDedSyzEKE3+7lv5ef+fkU/IaKU7CcHsTUV5cyqFBY8kcZ7itKQMzMrKBIvf1FZlyvmNg4yOK/Oa1GVN2kj9mo1o1feTL+nxJeb4S6CaVTtLttAYkY5PAFdFaar9p0vTNEurT7DOreU9w2VABP3tvdiOCfQcVxllBNe3Jit8b0QtljgAAZNTS3EsgUzlmkxxIWOeOlQnyrQc4qb1Os1OCPTrXUZINYI8m42xwM+TcKMYOwfjnPHauc8T6/e6/dvd3yqHYjasQ2IMDH3eg4FT6fBfX1mtihmeASfaJgIhlCfl3ZPJFZWq2JtLiW1nLJKjfd29fx9MYq9bdkZcivq7sxZpZHuZZ3bzZDnLPzknv9at2Olj7It1du6JJuMQVQ28rxg85HPc1A9qY7dJi67XbG0HJ6+ldBYWkM4HkxlQgwSx5b3I7H2rXntE5pU7yKaxAxJ5atnGD6bqJxKZmjkUpKgwU7k+laiXfl2b2hlfKSAhMDbt69fXNV1tGe5E7SE+ax3Efqaj3ZK5pecHoZkWprHIUG0O3yfvBnZ/hWjPpQS1iuZZCRIpZPQ4OCKz9S0cTSvJDkbe+evuataelxIiQy8hVwGznA9qSsjR3e+hVuSjCTYpC8bOeg96qSC4QJJgeSOPr71rxwpBI63cTOoVuFbGOMg1Vi2tpDwvEGkEoZHDHKrjkY6YzjmumlK255uKpN6o5rVpODhgcfw1z8UXnSn6122p6E9xayy265aNDI/P8I4/qK5S2Xy5wHBHbj1rpT0POau9TW03SN8HnNjB4H4dTW1bwjT4ZCFG1yFU5+7UugALaSW3zSXjOEjCDcD68/UitCTT45DHBcttQZztbo3oawqPod9BJarcr6YsMjM20SYGVZqiuHWGREUiME5zW0uli3ibyjg46Z7VhXsEkbhm+Yqc8jr7VzLyOyUpP4mdFYsSkTSzRhBnaXUEk8cdM4q1rJF1fNOYo0WToYxgHBwT707RdRgvrG3t5FWM2xZ+B9/dgYz+FMvhEG8p5ZNkMR8rHKgk5A+nJ96c9YFJWkUdPW3aG6glWMXQkEiStnO0ZBT9Qfwp6GG5luIri58p40zGNud7ZAwfTjPPtVY7490sahpCAOexpVs/LDmc5ckM5HVQe31qqVCVRxhFXbYYjEQoxlUqO0Ur/AHGFf+XOSRKVKHGwjmmWUhjP96revxB4EmjjClG2ll9McVm2kg3DPB/nXVjcFLCydKWrRwZbmcMfBV4aJ/podBap506EgAkfhXZWduLOyj87cbqRyrxspHlqMYOfU1heHb2Kzil3xRu1xG0Z84ZRRjO4Y5zkV0mlytPbxSXDlyifeY5IHp9K81R5mkt2elVqKMW3okVvFl9ttEtIsgSAMwOCeP8A69cnir2qTteXkkp6Zwo9B2qpsPpX6lluEWEw0aXXr6vc/Ds2x/17FzrdNl6LYZj0pKk8s0hQ+ld9zzroYOtHrTtpzQR60XHcaOtGDTwBSnFFxXIic9RRgn6VJgE0uPpSuO5CRzSd8VKAKMCi4XI6TPNSkAUhUUXC5HS/WpAopNlAXGUZGfen+X6GjZxSHdDeoxRS7OM5op3FcjP0o60maCaCxeaD0pPWjtTADwKKT2oxQAopeppvenCgBR05opM54ooELmlB9ab3pw6UAKKOlA4ooEH1pQaaelOFFgLsGZbZtvDxfqDVW5QFBJF/EOR71Ppmft9uoBO6RVIXqRnpW/4xsdPsnSPSrhrmNUG6QrgB+pHuBXxXEGFjCrz30l+aP0/hDHyrYb2LWsNL91/wDg1eSKfdGSrZ61fS6mz88hds7juxwfai8s1wNmVc87fT8ahRcZUkcjg18pPTRH28ddS2L+5jbeZdznjLc1S1NridwzuSz9WHWp7d1hSQyRF2wNrZxt55OO/Fanhy5SHUmu5fKZY0YLHKu4PkY6VnF3auwm+VOyIdH8JyXGhXOpTeYiwuhUkYGCcZ9euMY9DXQaBoklxDGFOxJZNhc9ASeM1nxfaby0kk62dqVXaW+4GJxx3Gc81Yt9RntrUojlc1o5RdrrQwUZWeplaxZtp97dRFVnlDmJNmeT6+tW7S1m/sm3mkONuQQexqG41Qnzp3giM0ahFdeucfex6471h3mt3d1FHGjt5IboB69aunBW0FUq8rSZuyQH7Pv3cfewPQ1WiURyu68Rt7cZqnpl4GcRSvuJPH0q3qAUqgV2GD92paLVTmQ2eKRp40hjDsXVgGGQTnoR6VPHZ/2fY3kd2IxPHO0LhHGVxkEfT3qO4nkWEMmUlj6tnn0yPfms+1jubm3uIbVZJpGDSOACx+UZJ/ADNawdmc9f4LsjuptumvtYbWXb9ea4i9cLMCv3s1tX94I7JAW469etcyXM0+7IwT0rrpp2PLqNJnoOlSyRmO5icL5yZ3EDg45+laknlmBF8zcWIIZR+dc3aRNHDARuwRn6Vt2U8MEJMiksOOf6VhKadzthTcbXNaOfMYhHLcYOODVLWFKQMxBBzzVW3umklYx8Ko4Ddau3Bkltisi7n659vSskjo5kzP8LCCa5zdSmKIjA56n0rpdavC1/DGE2m3jEasnA47n1yMc1xk0HlkKFaNwclfQ10MvnGCKS5fdKVAz6jHGfeqpLmfKa1GlaTC3heZyibU2guxPf2/Gor2cyOUByoOSf7x7mrMN1c26ThSvkzRlG3DJ44GDWaTX2HD+FjZ12tdl+p+d8Y4+opRwsXo1d/on+YjoskbI4yjDBrEubB4JysfzAcq3TIrdq4bqGW0t4ZYRuh3YkXqQTnB+nP513Zxl7xVNSpL31+R43D+b/UajhVfuP8ABmTpi3DyBSrOOmMV2DSfZNKKOCsrjywv+zjrWXFewwLmCMl/Vu1V5bhpHLu2WNeTlmQ1I1VXxGltkeznXFUKlCWHwurkrX7D8UneojN70nmjFfX2Pz3lZOO+aTiofNpPM75oHyskbvURpfMBppPNBSQUdqTtSDNMocKM03NLmgLC9qSkJpM0gsPNFNz2pM8UBYf24opvUc0A80BYfmkpueKM80gsONFMz2ooCxCaD7UlGeKs1F9qU4pp4oH60BYXPNHNJilFABRQaM0AKDS02igQtKKQUpoAXPFL9KToKKBC96UdaZ0pc5NAWLNlcta3cU6fejYMMHniujsLWLUmxLciOBlaQs33sgE4+tcmK3dA1H7JZ3keFZmTjcM4HfHp2rws+wkatB1rax/LqfVcJ5jPD4pYa/uz/Pp/kVtVtY7S6W3tZzOWyWOAAgwMYPc9a59pSl1LAxB2twwNdIs0a2SO257l5eRgYUDP4nisjVkhnaOOKJUuCS3mA/ez0Br87tfc/XI6aEaL5jDceD1GetXbq7WCGO1SBVEfzGTYA5OOQSOoo+zrGkbqCrgBWBUja44YfnWfqs0rv+8Pfp644qLct0x6SNLQ9cayvfNkt4LuPYUMc4ypH9PY02G68+UqqnCguR7Csm1TdkAYbritK2VPJYH+IcsODRq9CEknch1W+imYBUSGMrtA24BqOxsNwIdt2Rxjt9KisrNr/wDdk+Y2Tkd/auksw9q0cVwoYpgbuOgreKZy1bXuZyaMEIkYEH734Uy6UfMhJB+vU10wlUhn3AjHA9KyL62aSXeoCt1yO/tVOJnCZk3MpkhJ3KzYxt7/AFrDv7+W1h/dStGzqVLKSCQeo/Kte5sUV/MSXa2eh6VyeuSH7ZIpwQDwDWlGKcjPFSfIjH1CcuOTkAYqrpjiS4jUngHNTzpuUj1qpoi/8TSND1LYI9K7dOVnlO/Oj1SK2f7HG5UlEGHAHKgd/wBaqXsu87ByAeqjp9ajsHmQvsdthzx2OPWrSSBGIYhnfsB0rzrW1R7kpXfKVnmeDKxRyOcjDIOGBrVgnn8ot5e1VG0jd26022haNgyOQOuAOhqaS1ihYOr5dsBu4yapWaJScWSarpUkFw08jrI2EZnDbuSMgfWprlhIkSxRvlUG8E5y2OcV0VtqdilvZpDBHdXKyx7lkGQ6/MCuD7EVhXULJbz3pUpDcSMkQGODu5H4Cu/B4Z1cQoR+0cWNxn1bCyrTXwr732KVxKhVY4wQo/vEHHtnv3qvkZopByM1+h4ehDD01Thsj8dxeLqYytKvV3Yvb2opM8UVucwtGaSikAUtIaQnimMU0hPtSUdqAsLk0uTimjmjvSAfuozTD7HiigLDt1G7NMooCw/f0FLuqOk70BYlzRuFQ57UZoHyk+c0mcVGGxSEn8aBcpLnmjNRcml5pBYk9aKauSaKQiKjOaKO1WaC0Z5poo60AKD14pRSdxRjNIBaXtSd80elAh1JQP1o70AKO9H1o5oBpiFbjApAcUHmgc0AFLScCigB2RTkdo2BQ4pg9KKTSasxxbi7p6mnBIs+GwFdQcqOn1FQ3UEUEDuxJlPINVY3Mbh0OCOauXUguIQyqCRyR3B/wr4nPcn9k/rGHWnVdj9M4Y4i+sRWFxUveWzfX/g/mR6bIJYZIriTAB3h8ZIOeT71ds9M+13ii5KAYIBbpnGRn2rJtLxrSUNDII5geG2g/mDVvWDc3NvHcQTNM9wo81UX7pXPGOoAFfNxS5bvdH185Sc+WOx2Gm2/h6G3uNK1K5RRExmSSEYMzdBgnoMdQfwrkrqEAFIQDG/APpkcCsm0Mlqwa9yQRjjk+1JcatFNNFEoYDgMzHvznFNtTFGPs7ts2NOuUFqDHAYwuQX3cse5qy9wWfjlu2axLKTy2+zg4Rj6ZrXZNiBudw7Y60NszlYJLgRs2SBnvTbm5Xyvl5x2zUEyyC38zarZPTv+VU0+0TOqAIFJwXYgYp2bMr2YGSKQOvJZMkbq4/xFEFuBJGcqeD7GupSwuIszSb0hkbG8j730pmp6VaOF8p2bJySTxVU/3crsKqVWFupxNvayXRCxKT3PtVUQG08RQqRg9TXb6NFGl1NYQxFpCPm29cVU1bwzP/acd3GybVHzqeNoroVS7scUqFkmt7lq3QvbhVOA3cVs2nkw8MgJArEt7lLV1XcHIyMjoe1aBuGZDgAEj8K5WmtDtbV20a7TqF+UoFbjpzms25mQGQR844wDjBx1qtILkqCCgY9F9arQSuY33JkElRnv64q4oiVTsang3V5LbVd1yq4lHlqjDOTuHT0PHWrV6SHAZDG3JK5OAc8nHbOM1R0WSexu4b60iV54JBLH5gH/AOqrmo3b313JczY82T5mAOQDX0mQ4fnq+0ktEtO1z5PifFOjhfYxlrJq+uttfwK9LSUnXNfYn50GaWkGc9aQ0DHU3vRQaBhnnmgnJpKKYBR2NB4pKAHIpY4FSiLiiD7pqTnNSQ27kXlehoMXPBqU9aMUXFzMh8o+tHlcdalFBoDmZCYjjrSeUfWrGAKTbjrRcfOyHyvegwnPUVMetGKLhzMh8n3pCmO4qeopKLjUmyM8UoOCaQ9aOwxQUPXqaKRT1zRQSyHjjijIz9aTuKX0qjUWkHvQO+KKBCj1oHSk7Uo4oABTqSikIOKXPrRxik6UAKKBRnjrRn86YAKKQUde1AC9+TSknimngc0vbigBRRmkzRnigQv0PNORirZU4NR59KXNJpPQaundEr+VKMSooz/EowRVzT7t7MRKr7ZEUrHIB2Pas7NKrso4OB1rxcfklLFK9P3X5I+lyriXEYJuNa84+b1XzNG5uUa2WDUE+YR7oHVR69z3HX3rifEI+y3ELo6kyDfhe1dLMvnRsycSIMkDuK5HVLaW41KMyfu4m43noBXyFXAVMLX9nU/4c/QKWbUcbhPbUf8AhjZsb3zLeOTlSxxn3rbS9llWNHYr/d9xWBo0FtJbyQuzjn5GHTPv7VK1rPDI2ws7L021xzhZnZCfNFM2jMwXHIYfxZqm7qzF5HBx0A6Vkm+nBYFiexBFRLO8jZUkAfpT5TO+p0El67R7XnkK8bgxyDjoKqyXSgbVbg8VmAvISDyvfd61MVREGFYuD1p8rYuayH6fLP8A2z9o2YymHPoOxPvXQSyJNCIyu6QHOT1x3rJtJfLES4b95ycjtUtzPhiFIJ6Z9qmUdblQnaLXcz7uykuJWCqqjOPl7+9WILaaOIK77sdwOcVY+2AgkLlsbSe+Kia6w3zMdg7ire1iLtu487o+ZG+bHA65qyzxPEEEYO0ck+tVAySEOTjOc+mafbL5ocbiqY5PtRClOclCCu2EqsKcXObsluXY3KW0gVVCvhenPBzUXc0M+cADCgYA9BTc1+i5dhPqlCNLr19T8nzjHfX8VKslZbL0Q8npTaTNFdp5dhxNJTc0E8UDsLSmmk0uaAD+dHekyKAaAFJopM0hNAFiA8EVJuqorEcjg1IJTjsaLESjqT57UtVvOOaDMfSlYXIyyOlJ2qBZSSOOa9C8P/DDW9Us0uZ2gso3GVWbJcj1wOlY1q9Ogr1HY1o4WrWfLTV2cLSE4NerR/Bu8z8+rW4+kR/xqg3wzKRuz6kPlEhwI/7rhPXvnNcv9qYX+f8AM61lGLf2PxR5vnPWl/GvTpvhpbQiXOoSsUEx/wBWBny8fzzUr/DWwjmnQ31wxjaZc4UfcjDD884qXm2G/m/BlrJcW/s/ijyzrUUvtXsA+GulrOY2ubr7+zOR/wA8fM9PXipIPhto8k0StJckM0QOHHRoyx7eoqXm+G7v7i45Jiuy+88YOaO1ezWfw70N/s/mLcneLbcfMx/rCwb+QqSL4e6E0KP5M5ysbcyn+KUof0qf7Yw/n9xp/YmJ8vv/AOAeLDpRXtT+AtBSKciCXKxzsCZT1SUKP0oo/tig+j/r5j/sPEd1+P8AkeHZpDQTSevpXsHljgeeaWmijOKAFNL2ppJFAPFAWHn1oB5pv1pQaBWHE0meaQn9aKQrC9aOvHpSUDgZpgL1ozSfWj+dACk0oNNNICaQWHg0mcikNFMLBS9qGGMUlAC5/OgGkoFADlJUhlOCOagvbZblf3eV/vIOfxFS0VxY3A08ZDlnv0fY9LLczrZfU56eqe66P+u5nWcbKxTYwZDxxitS41Ce4DLJGcjvjA96j+gp2a8dcOUus2e9/rdWXw00vmZ80ih/3iIeMHjmmSTxlfkjBPYBa0isbn95GrfjzQNoyEUKvoK5Y8PVPacrl7vf/gHbU4ro+yUowfN2/wCCZMdpPKCz/Jn161OtjIr580dOpq/S161PI8LFe8m36nhVeJMbN3i0l6FN7adusy56cZquLKb592WHXg1p0dSKJ5FhXGyTQ4cS42Mryaa7WMWd2iYAbkx1GKnBS5gVQHEh9BWg8aOQXUMR7U8EqMLwPQV5/wDq573x6eh6i4sXLb2evr/wCC3szAo84YHZd3J9zVjOAAOFHQDtSKMmkr2sFgKWEjywV336nzuY5pWx87zdo9ugoNGfSk7mjoK7jzbDs0d6bmjkGgLC5ozSdetJQFhQaXPSm0UDsGSKM0lLmgBe1BPNNNFAWHDnrRuxTaM0BYdmjPHNNzzSUBY7b4SaZDqnjW0S4QPHCGmKnoSvTP4kV9C6zqiaXDG8kTybyQAvHQZ/yK8P+Ai7vGEz4+7av/Na97kuIEJEksS7eSCwGK+TzmbeIs+iPqslglh2+7K+iakdTgkka2e3KPtw5znjrWfb6dLdWzMx8ot5se1l55m3Z/IfrWsb+0UNuuYF2jLfvBxVhGDKrKQVIyCOhryT1jF1LSpRbXUsLeZKyz7YwvLeYRx+GKsSaOsjysZmHmGVsBem9Av6YrTGfWndqVxmDeW0UWp2kHnDzbh3YA9QBDsyBV2LSI0aN/McshQ+mSqFP5GpbuwW5vrW6Mro1sSVCgYORg54z0q5nPNO4jJtdJEVzhiTDGsHltnklN3X86lGl20MX3pAqKoJz2Vi4/WpbzUra1uYoZ2ZXkGQQpIAzgZPbkgVRk8R6c1uHV5zE6EiWNDjG7b17HPFGrAg0a2t9TsZzKJVbzJoXU5UhWff0PttP40Vp6JaW9nYIloZjExMgMzlmyeTkmihvsI+P6KUCkPBr9DPgApeKOlB5oASlpDR1FAC0UUpHWgBKUdKB+lL2oEAxiilA6YooASlHqaBS496QhCDTR1NPOfWm96AFHtQAKOgoHpQAHJNJ7049KSgBKKdgUYpgIaTqadikx0oAQemaDxS45oNACUU4jGDSfw0BcTtRjilbigdaAE9qKU0YpAJ0pOfxpaKYwBxSD3oNAOKAAUmDmlpKQC4pDTjnFIOaADFByaUYpDQAlJnmlo70DEoo70UDE60UUtAADyKTGaWgdaAExxij60HrQaLAdJ8P/EX/CM+I4L5lLwkGOVR1KHr+XWva0uPD+p3R1Ea5aCCVxIU3BWOMcHJ46Y4r5xHX3pd5715uMy+GJkp3sz0MJmM8LFwSuj6PSXw7bSO0Ot2UYEvmouQwU4xjryMVdbxTpUEaxw+I7BY0UAbo8n9CBXzIWNIWzXJ/YkHvN/gdf8Abk+kF959Jv420dfveKLX/gFvUTeO9DHXxOf+A24/wr5wLGjcTT/sSj/M/wAP8if7brfyr8T6Kbx7oORnxLcn/dt1/wDiaY3xA8PL18Qag3+7Cv8A8TXzzuPFLuNUsloLq/w/yJ/tqv8Ayr8f8z6An+IHhCbYLm5vLhlXZuaNhuGc84wOtMPjzwSIWiQTpG3G1ImAHIPGOnIBrwHcaA2TT/sWh3f3/wDAF/bWI7L8f8z6FufiX4YaONFvNSjVBgeWpBP1NFfPhY0U/wCxqHmL+2sR2X3P/M//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photograph of surgically resected cystectomy specimen with adenocarcinoma of the posterior wall and dome of the bladder.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cristina Magi-Galluzzi, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_40_35459=[""].join("\n");
var outline_f34_40_35459=null;
var title_f34_40_35460="Left ventricular apical thrombus with contrast";
var content_f34_40_35460=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1204px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/85959/Left_VAT_with_contr_video.mp4?title=Left+ventricular+apical+thrombus+with+contrast\" style=\"width:496px;height:352px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 588px\">",
"   <div class=\"ttl\">",
"    Left ventricular apical thrombus with contrast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 568px; height: 490px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transthoracic echocardiogram in the apical four-chamber view using an echocardiographic contrast agent that opacifies the blood pool. The mural thrombus is seen filling the left ventricular apex.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_40_35460=[""].join("\n");
var outline_f34_40_35460=null;
var title_f34_40_35461="Amitriptyline and perphenazine: Patient drug information";
var content_f34_40_35461=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Amitriptyline and perphenazine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/51/824?source=see_link\">",
"     see \"Amitriptyline and perphenazine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F133929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      PMS-Levazine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Children and teens who take this drug may be at a greater risk of having thoughts or actions of suicide. Adults may also be at risk. The risk may be greater in people who have had these thoughts or actions in the past. Watch people who take this drug closely. Call the doctor right away if signs like low mood (depression), nervousness, restlessness, grouchiness, panic attacks, or changes in mood or actions are new or worse. Call the doctor right away if any thoughts or actions of suicide occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700570",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a higher chance of death in older adults who take this drug for mental problems caused by dementia. Most of the deaths were linked to heart disease or infection. This drug is not approved to treat mental problems caused by dementia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691728",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anxiety.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701501",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to amitriptyline, perphenazine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703425",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bone marrow disease or recent heart attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697320",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have Parkinson's disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697166",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an overactive thyroid, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness, trouble moving around, or stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11463 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-9EF4B3CCD6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_40_35461=[""].join("\n");
var outline_f34_40_35461=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133929\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018423\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018425\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018424\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018429\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018430\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018432\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018427\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018428\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018433\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018434\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?0/51/824?source=related_link\">",
"      Amitriptyline and perphenazine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_40_35462="Triprolidine and pseudoephedrine: Drug information";
var content_f34_40_35462=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Triprolidine and pseudoephedrine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/13/18645?source=see_link\">",
"    see \"Triprolidine and pseudoephedrine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/59/7093?source=see_link\">",
"    see \"Triprolidine and pseudoephedrine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F231800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aprodine [OTC];",
"     </li>",
"     <li>",
"      Pediatex&reg; TD;",
"     </li>",
"     <li>",
"      Silafed [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F231801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Actifed&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F231813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alkylamine Derivative;",
"     </li>",
"     <li>",
"      Alpha-/Beta- Agonist;",
"     </li>",
"     <li>",
"      Decongestant;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F231804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Cold, allergy symptoms:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid  (Pediatex&reg; TD): 2.67 mL every 6 hours (maximum: 4 doses/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Syrup (Aprodine&reg;): 10 mL every 4-6 hours; do not exceed 4 doses in 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet (Aprodine&reg;): One tablet every 4-6 hours; do not exceed 4 doses in 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F231809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/59/7093?source=see_link\">",
"      see \"Triprolidine and pseudoephedrine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Cold, allergy symptoms:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Liquid  (Pediatex&reg; TD):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-12 years: 1.33 mL every 6 hours (maximum: 4 doses/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Syrup (Aprodine&reg;):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-12 years: 5 mL every 4-6 hours; do not exceed 4 doses in 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Tablet (Aprodine&reg;):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-12 years:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     tablet every 4-6 hours; do not exceed 4 doses in 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F231805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F231793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pediatex&reg; TD: Triprolidine hydrochloride 0.938 mg and pseudoephedrine hydrochloride 10 mg per 1 mL (30 mL) [cotton candy flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral: Triprolidine hydrochloride 1.25 mg and pseudoephedrine hydrochloride 30 mg per 5 mL (120 mL) [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aprodine: Triprolidine hydrochloride 1.25 mg and pseudoephedrine hydrochloride 30 mg per 5 mL (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Silafed: Triprolidine hydrochloride 1.25 mg and pseudoephedrine hydrochloride 30 mg per 5 mL (120 mL, 240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aprodine: Triprolidine hydrochloride 2.5 mg and pseudoephedrine hydrochloride 60 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F231781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F231794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of nasal congestion, decongest sinus openings, running nose, sneezing, itching of nose or throat and itchy, watery eyes due to common cold, hay fever, or other upper respiratory allergies",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14188080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F231811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness, fatigue, headache, insomnia, nervousness, transient stimulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, appetite increase, diarrhea, nausea, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dysuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pharyngitis, thickening of bronchial secretions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F231797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pseudoephedrine or any component of the formulation; MAO therapy, severe hypertension, severe coronary artery disease",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F231785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use with caution in patients with a history of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease); contraindicated with severe disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use of triprolidine (potent anticholinergic agent) due to increased risk of confusion, dry mouth, constipation, and other anticholinergic effects; clearance decreases in patients of advanced age (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not for OTC use in children &lt;6 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): When used for self medication (OTC), notify healthcare provider if symptoms do not improve within 7 days or are accompanied by fever. Discontinue and contact healthcare provider if nervousness, dizziness or sleeplessness occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F231810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F231789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F12808381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14456831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal antihistamine use has generally not resulted in an increased risk of birth defects; however, information related to triprolidine is limited. Refer to the pseudoephedrine monograph for information related to decongestants.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14456832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Triprolidine is excreted into breast milk. Based on data from three cases, the estimated exposure to the nursing infant is &lt;1% of the weight-adjusted maternal dose. Antihistamines may decrease maternal serum prolactin concentrations when administered prior to the establishment of nursing. Pseudoephedrine is also excreted into breast milk. Refer to the pseudoephedrine monograph for information related to decongestants.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Pediatex TD Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.938-10 mg/mL (30 mL): $74.64",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F231798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Actifed (AE, AU, BB, BE, BF, BH, BJ, BM, BS, BZ, CI, CY, EE, EG, ET, GH, GM, GN, GY, ID, IQ, IR, JM, JO, KE, KP, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NL, OM, PE, PY, QA, SA, SC, SD, SL, SN, SR, SY, TH, TN, TT, TZ, UG, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Actifedrin (AR, BR, CN);",
"     </li>",
"     <li>",
"      Actimin (MY);",
"     </li>",
"     <li>",
"      Beatafed (MY);",
"     </li>",
"     <li>",
"      Becanden (TW);",
"     </li>",
"     <li>",
"      Colfed (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Consudine (TH);",
"     </li>",
"     <li>",
"      Eugen (TW);",
"     </li>",
"     <li>",
"      Fedac (HK, MY);",
"     </li>",
"     <li>",
"      Hiscifed (TH);",
"     </li>",
"     <li>",
"      Histafed (IL);",
"     </li>",
"     <li>",
"      Histamine-Care (IL);",
"     </li>",
"     <li>",
"      Lapifed (ID);",
"     </li>",
"     <li>",
"      Nasafed (ID);",
"     </li>",
"     <li>",
"      Peace (MY, TW);",
"     </li>",
"     <li>",
"      Tosumin (TW);",
"     </li>",
"     <li>",
"      Trifed (AE, BH, CY, EG, ID, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Triprodrine (TH);",
"     </li>",
"     <li>",
"      Unifed (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Valved (ID)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F231784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to Pseudoephedrine (Systemic) monograph.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Triprolidine is a member of the propylamine (alkylamine) chemical class of H",
"     <sub>",
"      1",
"     </sub>",
"     -antagonist antihistamines. As such, it is considered to be relatively less sedating than traditional antihistamines of the ethanolamine, phenothiazine, and ethylenediamine classes of antihistamines. Triprolidine has a shorter half-life and duration of action than most of the other alkylamine antihistamines. Like all H",
"     <sub>",
"      1",
"     </sub>",
"     -antagonist antihistamines, the mechanism of action of triprolidine is believed to involve competitive blockade of H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor sites resulting in the inability of histamine to combine with its receptor sites and exert its usual effects on target cells. Antihistamines do not interrupt any effects of histamine which have already occurred. Therefore, these agents are used more successfully in the prevention rather than the treatment of histamine-induced reactions.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F231796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Also see Pseudoephedrine (Systemic) monograph.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Triprolidine: Extensively hepatic (Simons, 1986)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Triprolidine: ~2 hours (Simons, 1986)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, serum: Triprolidine: ~2 hours (Simons, 1986)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Triprolidine: Urine (~1% as unchanged triprolidine) (Simons, 1986)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/40/35462/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simons KJ, Singh M, Gillespie CA, et al, \"An Investigation of the H",
"      <sub>",
"       1",
"      </sub>",
"      -Receptor Antagonist Triprolidine: Pharmacokinetics and Antihistaminic Effects,\"",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 1986, 77(2):326-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/40/35462/abstract-text/3944383/pubmed\" id=\"3944383\" target=\"_blank\">",
"        3944383",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10304 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-11D65C23BF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_40_35462=[""].join("\n");
var outline_f34_40_35462=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231800\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231801\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231813\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231804\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231809\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231805\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231793\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231781\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231794\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14188080\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231811\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231797\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231785\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231810\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231789\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808381\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14456831\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14456832\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324042\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231798\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231784\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231796\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10304\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10304|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/13/18645?source=related_link\">",
"      Triprolidine and pseudoephedrine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/59/7093?source=related_link\">",
"      Triprolidine and pseudoephedrine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_40_35463="Left-sided heart failure - very high power";
var content_f34_40_35463=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F79671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F79671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Liver biospy from a patient with left-sided heart failure (very high power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hepatocytes have been replaced by RBCS. The sinusoids are not dilated. There is no increase in mononuclear inflammatory cells as is seen in hepatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_40_35463=[""].join("\n");
var outline_f34_40_35463=null;
var title_f34_40_35464="Obstetrical management of gastroschisis";
var content_f34_40_35464=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Obstetrical management of gastroschisis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/40/35464/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/40/35464/contributors\">",
"     Courtney D Stephenson, DO",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/40/35464/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/40/35464/contributors\">",
"     Andrew P MacKenzie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/40/35464/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/40/35464/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/40/35464/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/40/35464/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/40/35464/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/40/35464/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroschisis refers to a full-thickness paraumbilical abdominal wall defect associated with evisceration of fetal intestine (",
"    <a class=\"graphic graphic_picture graphicRef61463 \" href=\"mobipreview.htm?10/38/10851\">",
"     picture 1",
"    </a>",
"    ). Widespread use of antenatal ultrasound examination and maternal serum alpha-fetoprotein (MSAFP) screening has made detection of fetal abdominal wall defects, such as gastroschisis, feasible in the second trimester of pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE AND EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of gastroschisis varies from 1 to 5 per 10,000 live births and is similar in male and female fetuses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The variation in incidence is primarily related to maternal age and geographical location [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/5\">",
"     5",
"    </a>",
"    ]. Studies worldwide have consistently reported that young women (ie, under 20 years of age) have a several-fold higher rate of affected offspring than the general obstetrical population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/6-11\">",
"     6-11",
"    </a>",
"    ]. This is likely related to lifestyle factors that characterize this population (cigarette smoking, use of recreational drugs, alcohol consumption, low body mass index, increased frequency of genitourinary infection) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/7,12-17\">",
"     7,12-17",
"    </a>",
"    ]. Conversely,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    use in the first trimester appears to significantly lower the risk of gastroschisis (adjusted OR 0.41, 95% CI 0.18-0.94) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gastroschisis rates are higher in nulliparas than multiparas and in non-Hispanic whites and United States-born Hispanics than in foreign-born Hispanics and blacks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Developed and developing countries around the world have reported an increasing incidence of gastroschisis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/8,19-21\">",
"     8,19-21",
"    </a>",
"    ]. As an example, a study of data from 25 population-based registries in 15 European countries found the maternal age-standardized prevalence of gastroschisis increased almost four-fold from 0.54 per 10,000 births between 1980 and 1984 to 2.12 per 10,000 births between 2000 and 2002 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/3\">",
"     3",
"    </a>",
"    ]. Similarly, data from the California Birth Defects Monitoring Program from 1987 to 2003 showed a three-fold increase in prevalence of gastroschisis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several hypotheses have been proposed to explain the pathogenesis of the gastroschisis; all involve defective formation or disruption of the body wall in the embryonic period, with subsequent herniation of bowel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Failure of mesoderm to form in the body wall",
"     </li>",
"     <li>",
"      Rupture of the amnion around the umbilical ring",
"     </li>",
"     <li>",
"      Abnormal involution of the right umbilical vein leading to weakening of the body wall",
"     </li>",
"     <li>",
"      Disruption of the right vitelline artery with subsequent body wall damage",
"     </li>",
"     <li>",
"      Abnormal folding of the body wall resulting in a ventral body wall defect",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Gene polymorphisms that interact with environmental factors, such as smoking, may play a role in pathogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/23\">",
"     23",
"    </a>",
"    ]. The maternal immune response to new paternal (fetal) antigens may also play a role in the development of gastroschisis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/24\">",
"     24",
"    </a>",
"    ]. There is no high quality evidence that any drug causes gastroschisis, but a possible association has been reported for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/25\">",
"     25",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/17\">",
"     17",
"    </a>",
"    ], and vasoconstrictive agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19190?source=see_link\">",
"     pseudoephedrine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of gastroschisis appears to be higher in areas where surface water agricultural chemical levels are high and when conception occurs in the spring, the time when agricultural chemicals (eg, atrazine) are commonly applied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. The possible role of these chemicals in the pathogenesis of gastroschisis requires further study.",
"   </p>",
"   <p>",
"    Gastroschisis has not been associated with maternal",
"    <span class=\"nowrap\">",
"     intake/deficiency",
"    </span>",
"    of any micronutrient, macronutrient, amino acid, or fatty acid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all cases of gastroschisis are associated with an elevated maternal serum alpha fetoprotein (MSAFP) level, thus, the possibility of gastroschisis, as well as other fetal anomalies, should be considered in pregnancies with elevated second trimester MSAFP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/1,32,33\">",
"     1,32,33",
"    </a>",
"    ]. In one series of 23 cases, the MSAFP level was elevated in every case, with a median value of 9.42 MoMs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/32\">",
"     32",
"    </a>",
"    ]. In another series of 20 cases of gastroschisis, the median MSAFP was 7.0 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/33\">",
"     33",
"    </a>",
"    ]. An elevated MSAFP is an indication for thorough ultrasonographic examination of the fetus for anatomic abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/57/18329?source=see_link&amp;anchor=H19#H19\">",
"     \"Pregnancy outcomes predicted by serum markers assayed in Down syndrome screening\", section on 'High AFP'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, maternal size - date discordancy may prompt an ultrasound examination that reveals gastroschisis with oligohydramnios or polyhydramnios.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND ASSOCIATED ANOMALIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;On ultrasound examination, gastroschisis consists of a relatively small paraumbilical abdominal wall defect, usually to the right of the midline, with visceral herniation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63613 graphicRef57805 graphicRef76768 \" href=\"mobipreview.htm?43/27/44473\">",
"     image 1A-C",
"    </a>",
"    ). The adjacent umbilical cord insertion site should be normal. The intestine usually is the only herniated organ; other intra-abdominal organs rarely pass through the defect. The intestinal mass lacks a covering sac and floats freely in the amniotic fluid.",
"   </p>",
"   <p>",
"    The exteriorized bowel appears cauliflower-like because fluid between bowel loops results in acoustic interfaces at both near and far bowel walls. Visualization of the bowel is enhanced by the highly echogenic edema and inflammation of the walls in addition to the dilated lumen created by multiple volvuli in the free floating loops. The stomach and intra-abdominal loops of bowel also may become dilated due to obstruction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/28/34247?source=see_link&amp;anchor=H8#H8\">",
"     \"Prenatal sonographic diagnosis of fetal abdominal wall defects\", section on 'Gastroschisis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to omphalocele, gastroschisis is not generally associated with malformations outside of the gastrointestinal tract. A study of pooled data from 24 international birth defects registries including over 3300 cases of gastroschisis concluded that about 10 percent were associated with major unrelated defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/21\">",
"     21",
"    </a>",
"    ]. About 2 percent of cases were part of a recognized syndrome. Cardiac defects were detected in 2 to 3 percent of cases, however, this may be due to ascertainment bias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/21,34-37\">",
"     21,34-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, additional gastrointestinal problems (eg, malrotation, atresia, stenosis) are present in up to 25 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/34,38\">",
"     34,38",
"    </a>",
"    ] and are probably related to vascular disruption caused by herniated bowel. As an example, disruption of the superior mesenteric artery may lead to volvulus or to \"apple peel\" jejunal-ileal lesions. Meckel's diverticulum and gallbladder atresia also occur, but are less common. Gastroschisis is termed &ldquo;simple&rdquo; when isolated, and &ldquo;complex&rdquo; when associated with coexisting intestinal abnormalities.",
"   </p>",
"   <p>",
"    Oligohydramnios is the most common amniotic fluid abnormality, but polyhydramnios may occur, particularly in fetuses with reduced bowel motility or obstruction.",
"   </p>",
"   <p>",
"    Of note, a study that used magnetic resonance imaging to evaluate the morphology of gastroschisis in 24 fetuses found that the three fetuses imaged in both the second and third trimester showed increased extracorporeal displacement of bowel in the third trimester and three fetuses with bowel dilatation suggestive of obstruction all had small bowel stenosis at birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/39\">",
"     39",
"    </a>",
"    ]. The stomach, duodenum, liver, spleen, and bladder were intraabdominal in all 24 fetuses and, in the absence of bowel dilatation, the fetal stomach was in contact with the fetal bladder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     OBSTETRICAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is wide variability in the antenatal management of gastroschisis due to a lack of evidence to guide clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Initial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of chromosomal abnormalities in fetuses with isolated gastroschisis is not increased above the baseline population risk. In the study of pooled data from 24 international birth defects registries described above, there were 41 chromosomal syndromes among the 3322 cases of gastroschisis (1.2 percent of the total cases, which included isolated and nonisolated) and the most frequent abnormalities were: trisomy 18 (15 cases), trisomy 13 (14 cases), sex chromosomes anomalies (4 cases), and trisomy 21 (2 cases) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/21\">",
"     21",
"    </a>",
"    ]. Based on these data, we suggest chromosomal evaluation if additional non-gastrointestinal structural abnormalities are identified on ultrasound examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;We perform serial ultrasound examination every two to four weeks for assessment of fetal growth and amniotic fluid volume. Growth impairment is common, occurring in one- to two-thirds of fetuses, depending upon the criteria used (birth weight for gestational age below the third percentile versus below the 10th percentile) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Deficiency in growth may be due to loss of protein and fluid across the exposed bowel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/42\">",
"     42",
"    </a>",
"    ]. Because the most commonly used formulas for estimating fetal weight rely heavily on the measurement of abdominal circumference, these formulas tend to underestimate the weight of these fetuses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/43\">",
"     43",
"    </a>",
"    ]. Siemer and colleagues developed a specific formula for estimating fetal weight in fetuses with abdominal wall defects using the biparietal diameter, occipitofrontal diameter, and femur length measurements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/44\">",
"     44",
"    </a>",
"    ]. This formula appears to estimate fetal weight in these fetuses more accurately than formulas using abdominal circumference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. Intrauterine growth restriction in fetuses with abdominal wall defects is predictive of an increased risk of adverse neonatal outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fetal growth restriction and amniotic fluid abnormalities are commonly accepted indications for increased antepartum fetal surveillance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/35\">",
"     35",
"    </a>",
"    ]. In our practice, we order fetal surveillance with nonstress testing or ultrasound (ie, biophysical profile score) for all fetuses with gastroschisis, beginning at 30 to 32 weeks of gestation, because these pregnancies are associated with an increased rate of fetal demise late in the third trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/48-51\">",
"     48-51",
"    </a>",
"    ]. A nonstress test and amniotic fluid index (AFI) (ie, modified biophysical profile) is performed twice a week, or a biophysical profile can be done weekly. Although fetal heart rate abnormalities are common in these pregnancies, the value of this approach has not been proven and the optimum type and frequency of testing are unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prolonged exposure to the toxic environment of the amniotic fluid may damage the intestines. Gastric dilatation, bowel dilatation, and bowel wall thickening have been considered poor prognostic signs by several investigators [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/53-58\">",
"     53-58",
"    </a>",
"    ], but others have not found the presence of these abnormalities sufficiently predictive to influence clinical management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/40,59-67\">",
"     40,59-67",
"    </a>",
"    ]. A systematic review including data from 10 observational studies (n = 273 patients) concluded there was no strong evidence that fetuses with isolated gastroschisis and antenatal bowel dilation greater than 10 mm or greater than 18 mm were at increased risk of intrauterine death, postnatal bowel resection, length of time to oral feeds, or length of time hospitalized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/68\">",
"     68",
"    </a>",
"    ]. However, the small number of adverse events in these studies precluded making a definite conclusion about the significance of prenatal bowel dilation in fetuses with gastroschisis.",
"   </p>",
"   <p>",
"    There is some evidence that extraabdominal small bowel dilation &gt;25 mm is associated with short-term prenatal complications, including nonreassuring fetal testing and intrauterine fetal death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/57\">",
"     57",
"    </a>",
"    ]. In one small series, the three fetuses with external bowel diameters of 27 to 28 mm had these adverse outcomes, while 11 fetuses with diameters of 5 to 24.5 mm did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/57\">",
"     57",
"    </a>",
"    ]. Adverse prenatal sequelae may be related to umbilical cord compression by the dilated bowel or severe uteroplacental insufficiency. Other series have observed that intraabdominal dilatation was predictive of bowel obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/69\">",
"     69",
"    </a>",
"    ] and associated with increased neonatal morbidity when multiple but not single loops of bowel were dilated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We perform serial targeted sonographic evaluation of the stomach and bowel (both intra- and extraabdominal) to look for significant dilatation or acute changes (ie,",
"    <span class=\"nowrap\">",
"     thickening/edema).",
"    </span>",
"    If such changes are observed prior to 34 weeks, we administer a course of glucocorticoids to enhance fetal maturation in the event preterm delivery becomes indicated. While we do not intervene solely on the basis of bowel wall thickening or dilatation, we feel Doppler interrogation of umbilical venous and arterial flow should be considered in the setting of peri-umbilical bowel dilation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intrauterine growth restriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/70\">",
"     70",
"    </a>",
"    ]. In contrast to extraabdominal small bowel dilation, intraabdominal bowel dilation may be indicative of small bowel atresia, and thus a chronic condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision on timing of delivery is based on a combination of factors, including gestational age (fetal lung maturity), ultrasound findings (fetal growth profile, amniotic fluid volume, appearance of fetal bowel), and fetal testing results (NST, BPP, umbilical cord Doppler if fetal growth restriction is present). We do not consider bowel dilatation alone an indication for early delivery if fetal growth, amniotic fluid volume, and fetal testing (BPP, NST) remain reassuring (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Follow-up'",
"    </a>",
"    above). Consultation with a maternal-fetal-medicine specialist, neonatologist, and pediatric surgeon before delivery is recommended.",
"   </p>",
"   <p>",
"    Coordinating the delivery at a tertiary care center is preferable and provides optimal conditions for the neonate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/71\">",
"     71",
"    </a>",
"    ]. There is an increased risk of spontaneous preterm delivery; nevertheless, over 70 percent of pregnancies complicated by gastroschisis complete 37 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/9,35\">",
"     9,35",
"    </a>",
"    ]. Elective early delivery based only on the presence of gastroschisis is generally not recommended because it does not decrease the need for silo closure or the time until enteral feeding begins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/72,73\">",
"     72,73",
"    </a>",
"    ], although this is being studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/74\">",
"     74",
"    </a>",
"    ]. No evidenced-based recommendation for timing of delivery can be made at this time.",
"   </p>",
"   <p>",
"    As with omphalocele, there is no clear evidence that mode of delivery alters outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. A meta-analysis of observational studies evaluating the effect of mode of delivery in fetuses with abdominal wall defects (gastroschisis, omphalocele) concluded there was no significant relationship between mode of delivery and rate of primary fascial repair, neonatal sepsis, pediatric mortality, time until enteral feeding, or length of hospital stay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Labor and rupture of membranes have not been proven to adversely affect outcome, although too few patients have been studied to allow a definite conclusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/79\">",
"     79",
"    </a>",
"    ]. In general, cesarean delivery should be undertaken only for the usual obstetrical reasons. Some investigators also suggest cesarean delivery for gastroschisis with liver involvement, however, this is a relatively rare finding and may actually represent omphalocele complicated by rupture of the surrounding amnio-peritoneal membrane. There is inadequate high quality evidence on which to base a recommendation in this setting.",
"   </p>",
"   <p>",
"    Some studies report an increased rate of cesarean delivery due to nonreassuring fetal heart rate tracings in combination with amniotic fluid staining (meconium or bile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/80\">",
"     80",
"    </a>",
"    ]), which occurs in 70 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/20\">",
"     20",
"    </a>",
"    ]. Fetal heart rate changes could be due to cord compression related to oligohydramnios or fetal hypovolemia related to chronic loss of protein and water across the exposed bowel. However, others have not observed an increased rate of operative delivery prompted by fetal heart rate changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     APPROACH TO THE NEONATE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Delivery room",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal fluid losses are 2.5 times that of a healthy newborn in the first 24 hours of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/81\">",
"     81",
"    </a>",
"    ]. The neonate is at risk for insensible heat and fluid losses from exposure of the eviscerated bowel. In addition, third space fluid deficits from sequestration of intestinal fluid can be significant. The initial approach to management of these newborns includes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wrapping the bowel with sterile saline dressings covered with plastic wrap. This preserves body heat and minimizes insensible fluid loss",
"     </li>",
"     <li>",
"      Inserting an orogastric tube to decompress the stomach.",
"     </li>",
"     <li>",
"      Placement of peripheral intravenous access to provide fluids and broad-spectrum antibiotics that cover maternal vaginal flora (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Stabilizing the airway.",
"     </li>",
"     <li>",
"      Keeping the neonate in a thermoneutral environment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Synopsis of surgical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the operating room, the bowel is decompressed by aspirating stomach contents and evacuating the large bowel through the rectum. The size of the defect is increased 1 to 2 cm to minimize trauma to the bowel during reduction. The abdominal wall is manually stretched and the bowel is replaced, taking care to avoid creating intraabdominal pressure that is too high [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/81,83\">",
"     81,83",
"    </a>",
"    ]. Although primary closure is successful in 70 percent of cases, if it is unsuccessful, a staged closure with a silastic silo can be used, as in omphalocele cases. If primary closure is unlikely to be successful, a preformed silo with a spring-loaded ring can be placed at the bedside to cover the herniated intestine quickly without suturing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prolonged postoperative dysmotility is a common problem and interferes with enteral feeding. Studies in animal models suggest dysmotility is due to delayed maturation of the enteric nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/85,86\">",
"     85,86",
"    </a>",
"    ], possibly as a result of prolonged exposure to amniotic fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroschisis has the most favorable prognosis of the abdominal wall defects because concomitant non-gastrointestinal anomalies and aneuploidy are not typically present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/88\">",
"     88",
"    </a>",
"    ]. The overall survival rate for live born infants with gastroschisis is over 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/40,63,72,89-91\">",
"     40,63,72,89-91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gastroschisis in infants can be categorized as simple or complex based on the presence or absence of intestinal atresia, stenosis, perforation, necrosis, or volvulus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/92\">",
"     92",
"    </a>",
"    ]. Approximately 10 percent of cases are complex, and these infants have significantly more gastrointestinal, respiratory, and infectious disease complications in the neonatal period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/93\">",
"     93",
"    </a>",
"    ]. The postsurgical course for these infants can be lengthy (in one study: mean 53 days, range 8 to 307 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/67\">",
"     67",
"    </a>",
"    ]). Long-term gastrointestinal problems related to bowel adhesions or short gut syndrome have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/80,94\">",
"     80,94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     RECURRENCE RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an increased risk of recurrence in families with a child with gastroschisis, which suggests that genetic factors play a role in causation. Thirty-seven affected families have been described in the literature and 10 familial recurrences have been found among 412 cases of gastroschises in population-based registries, yielding a recurrence risk of 2.4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35464/abstract/95\">",
"     95",
"    </a>",
"    ]. However, non-genetic factors are also important, which suggests a multifactorial inheritance pattern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastroschisis refers to a full-thickness right paraumbilical abdominal wall defect associated with evisceration of fetal intestine. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The defect is secondary to a vascular accident in the embryonic abdominal wall (ie, somatopleure) that disrupts normal development. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maternal serum alpha fetoprotein is elevated in virtually all pregnancies with gastroschisis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is based on sonographic visualization of a paraumbilical abdominal wall defect, usually to the right of the midline, with visceral herniation (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef63613 graphicRef57805 graphicRef76768 \" href=\"mobipreview.htm?43/27/44473\">",
"       image 1A-C",
"      </a>",
"      ). The adjacent umbilical cord insertion site should be normal. The herniated intestinal mass lacks a covering sac and floats freely in the amniotic fluid. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis and associated anomalies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      About 10 percent of cases are associated with malformations outside of the gastrointestinal tract; additional gastrointestinal problems (eg, malrotation, atresia, stenosis) are present in 25 percent of cases. The karyotype is abnormal in 1 percent of cases, usually in the setting of associated abnormalities. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis and associated anomalies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the delivery room, the bowel is wrapped with sterile saline dressings covered with plastic wrap to preserve heat and minimize insensible fluid loss, an orogastric tube is placed to decompress the stomach, peripheral intravenous lines are inserted, and the airway is stabilized. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Approach to the neonate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Overall survival is over 90 percent. Approximately 10 percent of cases are complex, and these infants have significantly more gastrointestinal, respiratory, and infectious disease complications in the neonatal period. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Obstetrical management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest offering invasive testing for fetal karyotype when gastroschisis is associated with additional non-gastrointestinal structural abnormalities (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Isolated gastroschisis does not appear to be associated with an increased risk of chromosomal abnormalities. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Initial'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We obtain serial ultrasound examinations to follow growth and amniotic fluid volume at two- to four-week intervals since these fetuses are at risk of growth impairment and amniotic fluid abnormalities. We also obtain targeted views of the intra- and extra-abdominal bowel to look for significant dilatation, thickening, or edema. If abnormalities are detected, closer fetal surveillance is warranted. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the increased risk of fetal demise late in pregnancy, we suggest antepartum fetal surveillance (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the absence of standard maternal indications for abdominal delivery, we suggest vaginal rather than cesarean birth (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). There is no high quality evidence that cesarean delivery or elective early delivery is beneficial. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Delivery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/1\">",
"      Morrow RJ, Whittle MJ, McNay MB, et al. Prenatal diagnosis and management of anterior abdominal wall defects in the west of Scotland. Prenat Diagn 1993; 13:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/2\">",
"      Mastroiacovo P, Lisi A, Castilla EE. The incidence of gastroschisis: research urgently needs resources. BMJ 2006; 332:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/3\">",
"      Loane M, Dolk H, Bradbury I, EUROCAT Working Group. Increasing prevalence of gastroschisis in Europe 1980-2002: a phenomenon restricted to younger mothers? Paediatr Perinat Epidemiol 2007; 21:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/4\">",
"      Overton TG, Pierce MR, Gao H, et al. Antenatal management and outcomes of gastroschisis in the U.K. Prenat Diagn 2012; 32:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/5\">",
"      Martin RW. Screening for fetal abdominal wall defects. Obstet Gynecol Clin North Am 1998; 25:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/6\">",
"      Goldbaum G, Daling J, Milham S. Risk factors for gastroschisis. Teratology 1990; 42:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/7\">",
"      Reid KP, Dickinson JE, Doherty DA. The epidemiologic incidence of congenital gastroschisis in Western Australia. Am J Obstet Gynecol 2003; 189:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/8\">",
"      Kilby MD. The incidence of gastroschisis. BMJ 2006; 332:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/9\">",
"      Lausman AY, Langer JC, Tai M, et al. Gastroschisis: what is the average gestational age of spontaneous delivery? J Pediatr Surg 2007; 42:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/10\">",
"      Fillingham A, Rankin J. Prevalence, prenatal diagnosis and survival of gastroschisis. Prenat Diagn 2008; 28:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/11\">",
"      Gill SK, Broussard C, Devine O, et al. Association between maternal age and birth defects of unknown etiology: United States, 1997-2007. Birth Defects Res A Clin Mol Teratol 2012; 94:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/12\">",
"      Penman DG, Fisher RM, Noblett HR, Soothill PW. Increase in incidence of gastroschisis in the south west of England in 1995. Br J Obstet Gynaecol 1998; 105:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/13\">",
"      Waller DK, Shaw GM, Rasmussen SA, et al. Prepregnancy obesity as a risk factor for structural birth defects. Arch Pediatr Adolesc Med 2007; 161:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/14\">",
"      Draper ES, Rankin J, Tonks AM, et al. Recreational drug use: a major risk factor for gastroschisis? Am J Epidemiol 2008; 167:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/15\">",
"      Feldkamp ML, Reefhuis J, Kucik J, et al. Case-control study of self reported genitourinary infections and risk of gastroschisis: findings from the national birth defects prevention study, 1997-2003. BMJ 2008; 336:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/16\">",
"      Mastroiacovo P. Risk factors for gastroschisis. BMJ 2008; 336:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/17\">",
"      Mac Bird T, Robbins JM, Druschel C, et al. Demographic and environmental risk factors for gastroschisis and omphalocele in the National Birth Defects Prevention Study. J Pediatr Surg 2009; 44:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/18\">",
"      Feldkamp ML, Meyer RE, Krikov S, Botto LD. Acetaminophen use in pregnancy and risk of birth defects: findings from the National Birth Defects Prevention Study. Obstet Gynecol 2010; 115:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/19\">",
"      Vu LT, Nobuhara KK, Laurent C, Shaw GM. Increasing prevalence of gastroschisis: population-based study in California. J Pediatr 2008; 152:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/20\">",
"      Tan KH, Kilby MD, Whittle MJ, et al. Congenital anterior abdominal wall defects in England and Wales 1987-93: retrospective analysis of OPCS data. BMJ 1996; 313:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/21\">",
"      Mastroiacovo P, Lisi A, Castilla EE, et al. Gastroschisis and associated defects: an international study. Am J Med Genet A 2007; 143:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/22\">",
"      Feldkamp ML, Carey JC, Sadler TW. Development of gastroschisis: review of hypotheses, a novel hypothesis, and implications for research. Am J Med Genet A 2007; 143:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/23\">",
"      Torfs CP, Christianson RE, Iovannisci DM, et al. Selected gene polymorphisms and their interaction with maternal smoking, as risk factors for gastroschisis. Birth Defects Res A Clin Mol Teratol 2006; 76:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/24\">",
"      Chambers CD, Chen BH, Kalla K, et al. Novel risk factor in gastroschisis: change of paternity. Am J Med Genet A 2007; 143:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/25\">",
"      James AH, Brancazio LR, Price T. Aspirin and reproductive outcomes. Obstet Gynecol Surv 2008; 63:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/26\">",
"      Werler MM. Teratogen update: pseudoephedrine. Birth Defects Res A Clin Mol Teratol 2006; 76:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/27\">",
"      Waller SA, Paul K, Peterson SE, Hitti JE. Agricultural-related chemical exposures, season of conception, and risk of gastroschisis in Washington State. Am J Obstet Gynecol 2010; 202:241.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/28\">",
"      Winchester PD, Huskins J, Ying J. Agrichemicals in surface water and birth defects in the United States. Acta Paediatr 2009; 98:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/29\">",
"      de la Vega A, L&oacute;pez-Cepero R. Seasonal variations in the incidence of some congenital anomalies in Puerto Rico based on the timing of conception. P R Health Sci J 2009; 28:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/30\">",
"      Mattix KD, Winchester PD, Scherer LR. Incidence of abdominal wall defects is related to surface water atrazine and nitrate levels. J Pediatr Surg 2007; 42:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/31\">",
"      Feldkamp ML, Carmichael SL, Shaw GM, et al. Maternal nutrition and gastroschisis: findings from the National Birth Defects Prevention Study. Am J Obstet Gynecol 2011; 204:404.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/32\">",
"      Saller DN Jr, Canick JA, Palomaki GE, et al. Second-trimester maternal serum alpha-fetoprotein, unconjugated estriol, and hCG levels in pregnancies with ventral wall defects. Obstet Gynecol 1994; 84:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/33\">",
"      Palomaki GE, Hill LE, Knight GJ, et al. Second-trimester maternal serum alpha-fetoprotein levels in pregnancies associated with gastroschisis and omphalocele. Obstet Gynecol 1988; 71:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/34\">",
"      Moore TC. Gastroschisis and omphalocele: clinical differences. Surgery 1977; 82:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/35\">",
"      Carpenter MW, Curci MR, Dibbins AW, Haddow JE. Perinatal management of ventral wall defects. Obstet Gynecol 1984; 64:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/36\">",
"      Mahour GH, Weitzman JJ, Rosenkrantz JG. Omphalocele and gastroschisis. Ann Surg 1973; 177:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/37\">",
"      Kunz LH, Gilbert WM, Towner DR. Increased incidence of cardiac anomalies in pregnancies complicated by gastroschisis. Am J Obstet Gynecol 2005; 193:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/38\">",
"      Abdullah F, Arnold MA, Nabaweesi R, et al. Gastroschisis in the United States 1988-2003: analysis and risk categorization of 4344 patients. J Perinatol 2007; 27:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/39\">",
"      Brugger PC, Prayer D. Development of gastroschisis as seen by magnetic resonance imaging. Ultrasound Obstet Gynecol 2011; 37:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/40\">",
"      Santiago-Munoz PC, McIntire DD, Barber RG, et al. Outcomes of pregnancies with fetal gastroschisis. Obstet Gynecol 2007; 110:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/41\">",
"      Netta DA, Wilson RD, Visintainer P, et al. Gastroschisis: growth patterns and a proposed prenatal surveillance protocol. Fetal Diagn Ther 2007; 22:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/42\">",
"      Dixon JC, Penman DM, Soothill PW. The influence of bowel atresia in gastroschisis on fetal growth, cardiotocograph abnormalities and amniotic fluid staining. BJOG 2000; 107:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/43\">",
"      Adams SR, Durfee S, Pettigrew C, et al. Accuracy of sonography to predict estimated weight in fetuses with gastroschisis. J Ultrasound Med 2012; 31:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/44\">",
"      Siemer J, Hilbert A, Hart N, et al. Specific weight formula for fetuses with abdominal wall defects. Ultrasound Obstet Gynecol 2008; 31:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/45\">",
"      Chaudhury P, Haeri S, Horton AL, et al. Ultrasound prediction of birthweight and growth restriction in fetal gastroschisis. Am J Obstet Gynecol 2010; 203:395.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/46\">",
"      Nicholas S, Tuuli MG, Dicke J, et al. Estimation of fetal weight in fetuses with abdominal wall defects: comparison of 2 recent sonographic formulas to the Hadlock formula. J Ultrasound Med 2010; 29:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/47\">",
"      Nicholas SS, Stamilio DM, Dicke JM, et al. Predicting adverse neonatal outcomes in fetuses with abdominal wall defects using prenatal risk factors. Am J Obstet Gynecol 2009; 201:383.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/48\">",
"      Crawford RA, Ryan G, Wright VM, Rodeck CH. The importance of serial biophysical assessment of fetal wellbeing in gastroschisis. Br J Obstet Gynaecol 1992; 99:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/49\">",
"      Brantberg A, Blaas HG, Salvesen KA, et al. Surveillance and outcome of fetuses with gastroschisis. Ultrasound Obstet Gynecol 2004; 23:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/50\">",
"      Adair CD, Rosnes J, Frye AH, et al. The role of antepartum surveillance in the management of gastroschisis. Int J Gynaecol Obstet 1996; 52:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/51\">",
"      Towers CV, Carr MH. Antenatal fetal surveillance in pregnancies complicated by fetal gastroschisis. Am J Obstet Gynecol 2008; 198:686.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/52\">",
"      Kuleva M, Salomon LJ, Benoist G, et al. The value of daily fetal heart rate home monitoring in addition to serial ultrasound examinations in pregnancies complicated by fetal gastroschisis. Prenat Diagn 2012; 32:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/53\">",
"      Bond SJ, Harrison MR, Filly RA, et al. Severity of intestinal damage in gastroschisis: correlation with prenatal sonographic findings. J Pediatr Surg 1988; 23:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/54\">",
"      Luton D, De Lagausie P, Guibourdenche J, et al. Prognostic factors of prenatally diagnosed gastroschisis. Fetal Diagn Ther 1997; 12:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/55\">",
"      Adra AM, Landy HJ, Nahmias J, G&oacute;mez-Mar&iacute;n O. The fetus with gastroschisis: impact of route of delivery and prenatal ultrasonography. Am J Obstet Gynecol 1996; 174:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/56\">",
"      Nick AM, Bruner JP, Moses R, et al. Second-trimester intra-abdominal bowel dilation in fetuses with gastroschisis predicts neonatal bowel atresia. Ultrasound Obstet Gynecol 2006; 28:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/57\">",
"      Heinig J, M&uuml;ller V, Schmitz R, et al. Sonographic assessment of the extra-abdominal fetal small bowel in gastroschisis: a retrospective longitudinal study in relation to prenatal complications. Prenat Diagn 2008; 28:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/58\">",
"      Huh NG, Hirose S, Goldstein RB. Prenatal intraabdominal bowel dilation is associated with postnatal gastrointestinal complications in fetuses with gastroschisis. Am J Obstet Gynecol 2010; 202:396.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/59\">",
"      Sipes SL, Weiner CP, Williamson RA, et al. Fetal gastroschisis complicated by bowel dilation: an indication for imminent delivery? Fetal Diagn Ther 1990; 5:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/60\">",
"      Lenke RR, Persutte WH, Nemes J. Ultrasonographic assessment of intestinal damage in fetuses with gastroschisis: is it of clinical value? Am J Obstet Gynecol 1990; 163:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/61\">",
"      Babcook CJ, Hedrick MH, Goldstein RB, et al. Gastroschisis: can sonography of the fetal bowel accurately predict postnatal outcome? J Ultrasound Med 1994; 13:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/62\">",
"      Alsulyman OM, Monteiro H, Ouzounian JG, et al. Clinical significance of prenatal ultrasonographic intestinal dilatation in fetuses with gastroschisis. Am J Obstet Gynecol 1996; 175:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/63\">",
"      Skarsgard ED, Claydon J, Bouchard S, et al. Canadian Pediatric Surgical Network: a population-based pediatric surgery network and database for analyzing surgical birth defects. The first 100 cases of gastroschisis. J Pediatr Surg 2008; 43:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/64\">",
"      Cohen-Overbeek TE, Hatzmann TR, Steegers EA, et al. The outcome of gastroschisis after a prenatal diagnosis or a diagnosis only at birth. Recommendations for prenatal surveillance. Eur J Obstet Gynecol Reprod Biol 2008; 139:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/65\">",
"      Mears AL, Sadiq JM, Impey L, Lakhoo K. Antenatal bowel dilatation in gastroschisis: a bad sign? Pediatr Surg Int 2010; 26:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/66\">",
"      Alfaraj MA, Ryan G, Langer JC, et al. Does gastric dilation predict adverse perinatal or surgical outcome in fetuses with gastroschisis? Ultrasound Obstet Gynecol 2011; 37:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/67\">",
"      Durfee SM, Downard CD, Benson CB, Wilson JM. Postnatal outcome of fetuses with the prenatal diagnosis of gastroschisis. J Ultrasound Med 2002; 21:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/68\">",
"      Tower C, Ong SS, Ewer AK, et al. Prognosis in isolated gastroschisis with bowel dilatation: a systematic review. Arch Dis Child Fetal Neonatal Ed 2009; 94:F268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/69\">",
"      Contro E, Fratelli N, Okoye B, et al. Prenatal ultrasound in the prediction of bowel obstruction in infants with gastroschisis. Ultrasound Obstet Gynecol 2010; 35:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/70\">",
"      Kalache KD, Bierlich A, Hammer H, Bollmann R. Is unexplained third trimester intrauterine death of fetuses with gastroschisis caused by umbilical cord compression due to acute extra-abdominal bowel dilatation? Prenat Diagn 2002; 22:715.",
"     </a>",
"    </li>",
"    <li>",
"     Bianchi, DW, Crombleholme, TM, D'Alton, ME. Gastroshisis. In: Fetology, McGraw Hill, New York, 2000. p.473.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/72\">",
"      Huang J, Kurkchubasche AG, Carr SR, et al. Benefits of term delivery in infants with antenatally diagnosed gastroschisis. Obstet Gynecol 2002; 100:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/73\">",
"      Logghe HL, Mason GC, Thornton JG, Stringer MD. A randomized controlled trial of elective preterm delivery of fetuses with gastroschisis. J Pediatr Surg 2005; 40:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/74\">",
"      Serra A, Fitze G, Kamin G, et al. Preliminary report on elective preterm delivery at 34 weeks and primary abdominal closure for the management of gastroschisis. Eur J Pediatr Surg 2008; 18:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/75\">",
"      How HY, Harris BJ, Pietrantoni M, et al. Is vaginal delivery preferable to elective cesarean delivery in fetuses with a known ventral wall defect? Am J Obstet Gynecol 2000; 182:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/76\">",
"      Salihu HM, Emusu D, Aliyu ZY, et al. Mode of delivery and neonatal survival of infants with isolated gastroschisis. Obstet Gynecol 2004; 104:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/77\">",
"      Puligandla PS, Janvier A, Flageole H, et al. Routine cesarean delivery does not improve the outcome of infants with gastroschisis. J Pediatr Surg 2004; 39:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/78\">",
"      Segel SY, Marder SJ, Parry S, Macones GA. Fetal abdominal wall defects and mode of delivery: a systematic review. Obstet Gynecol 2001; 98:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/79\">",
"      Strauss RA, Balu R, Kuller JA, McMahon MJ. Gastroschisis: the effect of labor and ruptured membranes on neonatal outcome. Am J Obstet Gynecol 2003; 189:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/80\">",
"      Hunter A, Soothill P. Gastroschisis--an overview. Prenat Diagn 2002; 22:869.",
"     </a>",
"    </li>",
"    <li>",
"     Townsend. Abdomen: In Sabiston Textbook of Surgery (16th edition) Philadelphia. WB Saunders Co. 2001. p.1478.",
"    </li>",
"    <li>",
"     Bianchi, DW, Crombleholme, TM, D'Alton, ME. Omphalocele: In Fetology, McGraw Hill, New York 2000. p.483.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/83\">",
"      Olesevich M, Alexander F, Khan M, Cotman K. Gastroschisis revisited: role of intraoperative measurement of abdominal pressure. J Pediatr Surg 2005; 40:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/84\">",
"      Pastor AC, Phillips JD, Fenton SJ, et al. Routine use of a SILASTIC spring-loaded silo for infants with gastroschisis: a multicenter randomized controlled trial. J Pediatr Surg 2008; 43:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/85\">",
"      Vannucchi MG, Midrio P, Zardo C, Faussone-Pellegrini MS. Neurofilament formation and synaptic activity are delayed in the myenteric neurons of the rat fetus with gastroschisis. Neurosci Lett 2004; 364:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/86\">",
"      Santos MM, Tannuri U, Maksoud JG. Alterations of enteric nerve plexus in experimental gastroschisis: is there a delay in the maturation? J Pediatr Surg 2003; 38:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/87\">",
"      Fran&ccedil;a WM, Langone F, de la Hoz CL, et al. Maturity of the myenteric plexus is decreased in the gastroschisis rat model. Fetal Diagn Ther 2008; 23:60.",
"     </a>",
"    </li>",
"    <li>",
"     Angtuaco TL. Fetal Anterior Abdominal Wall Defect. In: Ultrasonography in Obstetrics and Gynecology, 4th ed, WB Saunders Co, Philadelphia 2000. p.489.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/89\">",
"      Luton D, Guibourdenche J, Vuillard E, et al. Prenatal management of gastroschisis: the place of the amnioexchange procedure. Clin Perinatol 2003; 30:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/90\">",
"      Baerg J, Kaban G, Tonita J, et al. Gastroschisis: A sixteen-year review. J Pediatr Surg 2003; 38:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/91\">",
"      Fratelli N, Papageorghiou AT, Bhide A, et al. Outcome of antenatally diagnosed abdominal wall defects. Ultrasound Obstet Gynecol 2007; 30:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/92\">",
"      Arnold MA, Chang DC, Nabaweesi R, et al. Risk stratification of 4344 patients with gastroschisis into simple and complex categories. J Pediatr Surg 2007; 42:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/93\">",
"      Bradnock TJ, Marven S, Owen A, et al. Gastroschisis: one year outcomes from national cohort study. BMJ 2011; 343:d6749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/94\">",
"      van Eijck FC, Wijnen RM, van Goor H. The incidence and morbidity of adhesions after treatment of neonates with gastroschisis and omphalocele: a 30-year review. J Pediatr Surg 2008; 43:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35464/abstract/95\">",
"      Kohl M, Wiesel A, Schier F. Familial recurrence of gastroschisis: literature review and data from the population-based birth registry \"Mainz Model\". J Pediatr Surg 2010; 45:1907.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6753 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-A7177AF1CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_40_35464=[""].join("\n");
var outline_f34_40_35464=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE AND EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS AND ASSOCIATED ANOMALIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      OBSTETRICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Initial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      APPROACH TO THE NEONATE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Delivery room",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Synopsis of surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RECURRENCE RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Obstetrical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6753\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6753|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?5/6/5218\" title=\"diagnostic image 1A\">",
"      Gastroschisis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?1/13/1235\" title=\"diagnostic image 1B\">",
"      Gastroschisis2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?24/54/25442\" title=\"diagnostic image 1C\">",
"      Gastroschisis1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6753|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/38/10851\" title=\"picture 1\">",
"      Neonatal gastroschisis 3",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/57/18329?source=related_link\">",
"      Pregnancy outcomes predicted by serum markers assayed in Down syndrome screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/28/34247?source=related_link\">",
"      Prenatal sonographic diagnosis of fetal abdominal wall defects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_40_35465="Treatment of diuretic-resistant ascites in patients with cirrhosis";
var content_f34_40_35465=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of diuretic-resistant ascites in patients with cirrhosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/40/35465/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/40/35465/contributors\">",
"     Jos&eacute; Such, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/40/35465/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/40/35465/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/40/35465/contributors\">",
"     Paul Angulo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/40/35465/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/40/35465/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/40/35465/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ascites due to cirrhosis can be mobilized in approximately 90 percent of patients with a treatment regimen consisting of dietary sodium restriction (usually 88 meq [2000",
"    <span class=\"nowrap\">",
"     mg/day])",
"    </span>",
"    and oral diuretics (usually consisting of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19145?source=see_link\">",
"     \"Initial therapy of ascites in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will discuss the approach to the 10 percent of patients who appear to be diuretic-resistant. This topic is also addressed in a guideline (updated for 2009) issued by the American Association for the Study of Liver Diseases (AASLD) (",
"    <a class=\"graphic graphic_table graphicRef70375 \" href=\"mobipreview.htm?5/18/5422\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/2\">",
"     2",
"    </a>",
"    ]. The AASLD guideline for the management of adult patients with ascites due to cirrhosis, as well as other AASLD guidelines, can be accessed through the AASLD web site at",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Pages/default.aspx\">",
"     www.aasld.org/practiceguidelines/Pages/default.aspx",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diuretic-resistant ascites in patients with cirrhosis is considered to be present when one or both of the following two criteria is present in the absence of therapy with a nonsteroidal anti-inflammatory drug (NSAID), which can induce renal vasoconstriction and diminish diuretic responsiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An inability to mobilize ascites despite compliance with dietary sodium restriction (as confirmed by a 24-hour urine collection containing less than 78 meq of sodium or urine sodium less than the urine potassium on a random sample) and the administration of maximum tolerable doses of oral diuretics (400 mg per day of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      and 160 mg per day of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/4\">",
"       4",
"      </a>",
"      ]. The 78 meq of sodium represents the recommended 88 meq intake minus 10 meq in nonurinary losses. Patients who gain weight despite excreting more than 78 meq of sodium per day (or urine sodium &gt; urine potassium on a random sample) are not compliant with the diet. (See",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/41/21151?source=see_link\">",
"       \"Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The development of prohibitive diuretic-related complications, such as progressive azotemia, hepatic encephalopathy, or progressive electrolyte imbalance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistant ascites in patients with cirrhosis must be differentiated from malignant ascites due to peritoneal carcinomatosis, Budd-Chiari syndrome (hepatic vein thrombosis), or from chylous malignant ascites. These disorders are typically refractory to diuretic therapy because of an inability to mobilize the ascitic fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/5\">",
"     5",
"    </a>",
"    ]. In contrast, massive hepatic metastasis, another cause of malignant ascites, is due to intrahepatic portal hypertension and can be treated in a similar fashion to patients with cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another form of diuretic-resistant ascites, called nephrogenic ascites, occurs in patients with end-stage renal disease who are usually being treated with maintenance dialysis. The pathogenesis of this disorder, which is usually",
"    <strong>",
"     not",
"    </strong>",
"    due to liver disease or portal hypertension, may be related to an increase in peritoneal capillary permeability induced in part by inadequate dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/6\">",
"     6",
"    </a>",
"    ]. The serum-ascites albumin gradient is &lt;1.1",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    consistent with the absence of portal hypertension unless the patient has cirrhosis or heart failure in addition to their renal failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19145?source=see_link\">",
"     \"Initial therapy of ascites in patients with cirrhosis\"",
"    </a>",
"    .) Some patients respond to more intensive dialysis, but definitive therapy is renal transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;True diuretic-resistant ascites is usually associated with advanced cirrhosis, marked neurohumoral activation (of the sympathetic and renin-angiotensin-aldosterone systems), and very low urinary excretion of sodium, frequently less than 10",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    despite maximal tolerated doses of diuretics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Neurohumoral activation results in renal vasoconstriction and enhanced sodium reabsorption in the proximal tubule (under the influence of angiotensin II and norepinephrine) and collecting tubules (under the influence of aldosterone). Even among patients with nonazotemic cirrhosis, those with a greater degree of neurohumoral activation show diminished diuretic responsiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/1/21527?source=see_link\">",
"     \"Pathogenesis of ascites in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The development of true diuretic resistance in a previously diuretic-sensitive patient is most often due to progression of the liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/9\">",
"     9",
"    </a>",
"    ]. However, it can also be due to two other complications of cirrhosis: hepatocellular carcinoma",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    portal vein thrombosis. A liver and spleen ultrasound with Doppler or CT scan and measurement of serum alpha fetoprotein can help diagnose or exclude these complications.",
"   </p>",
"   <p>",
"    Progression to diuretic-resistance is generally an",
"    <strong>",
"     irreversible",
"    </strong>",
"    process unless there is a reversible component to the liver disease (eg, alcoholic hepatitis) or the patient undergoes a successful liver transplant, transjugular intrahepatic portosystemic stent shunt (TIPS), or peritoneovenous shunt. As urinary sodium excretion dwindles despite diuretics, progressive azotemia and electrolyte imbalance (eg, hyponatremia) are expected. Diuretics are generally",
"    <strong>",
"     discontinued",
"    </strong>",
"    in such patients.",
"   </p>",
"   <p>",
"    Diuretics do",
"    <strong>",
"     not",
"    </strong>",
"    cause the hepatorenal syndrome. This association is inappropriately suggested because most patients are taking diuretics when the hepatorenal syndrome is diagnosed. However, diuretics can cause azotemia, particularly if fluid is removed too rapidly in patients without peripheral edema. Diuretic-induced azotemia improves with the cessation of therapy and fluid repletion. In comparison, the hepatorenal syndrome typically worsens inexorably, even after diuretics are stopped. Vasoconstrictor treatment of hepatorenal syndrome can be successful. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/50/29482?source=see_link\">",
"     \"Hepatorenal syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1323127675\">",
"    <span class=\"h1\">",
"     SIMPLE THERAPEUTIC OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in treatment of patients who appear to have refractory ascites while on beta blockers (especially if azotemia is present) is to stop the beta blockers. This step can improve blood pressure, renal function, and diuretic-responsiveness. Alternative approaches for prevention of variceal bleeding may be required (see below).",
"   </p>",
"   <p>",
"    For similar reasons, angiotensin receptor blockers or enzyme inhibitors should also be stopped. Patients should be questioned about the use of NSAIDs, which should be discontinued. If these measures are not effective",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypotension is present,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/35/2613?source=see_link\">",
"     midodrine",
"    </a>",
"    can be added. Midodrine can improve blood pressure, renal function, and diuretic-responsiveness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1323127682\">",
"    <span class=\"h2\">",
"     Safety concern with beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonselective beta blockers are used routinely to prevent variceal bleeding in patients with cirrhosis and esophageal varices. However, their safety in patients with refractory ascites is uncertain. A prospective observational study found that patients with refractory ascites who received nonselective beta blockers had worse survival compared with those who did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/10\">",
"     10",
"    </a>",
"    ]. Whether the beta blockers accounted for the increased mortality is unclear since the study was not randomized. In particular, patients who did not receive the beta blockers appeared to be less likely to have varices and to be sicker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, approximately two-thirds of the deaths on beta blockers were due to hepatocellular cancer (HCC) or sepsis, while there is no clear pathogenic basis for beta blockers in the evolution of HCC.",
"   </p>",
"   <p>",
"    Thus, more studies will help clarify the risk and benefits of beta blockers in patients with refractory ascites and varices. In the meantime, our experience with beta blockers in refractory ascites also raises concerns about their effectiveness and safety, and thus the new study strongly supports our clinical practice. We have found that patients with decompensated cirrhosis (ie, with ascites or a history of hepatic encephalopathy) do not tolerate them well, often developing worsening ascites",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    encephalopathy. A related concern is the potential to reduce renal perfusion in patients whose renal perfusion pressure and ability to maintain natriuresis are already compromised. Furthermore, our general impression about beta blockers is that patients are often noncompliant, especially when they experience side effects attributable to them. We have not had much success in trying to improve compliance in such patients.",
"   </p>",
"   <p>",
"    Thus, we generally do not use beta blockers in patients with decompensated cirrhosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    refractory ascites. Our approach is to use beta blockers as primary prophylaxis in patients who have compensated cirrhosis and large esophageal varices, although variceal ligation can be used for primary prophylaxis instead of beta blockers as recommended by the AASLD guidelines. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/49/27418?source=see_link\">",
"     \"Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/23/17786?source=see_link\">",
"     \"Prevention of recurrent variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In those who have variceal bleeding despite the beta blockers, we perform esophageal band ligation. We sometimes use beta blockers as secondary prophylaxis in combination with variceal banding in patients who have variceal bleeding (and no other evidence of hepatic decompensation) but have a low threshold to discontinue them. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3704?source=see_link&amp;anchor=H5#H5\">",
"     \"Major side effects of beta blockers\", section on 'Beta blocker withdrawal'",
"    </a>",
"    .) In patients who present with bleeding, azotemia, or hypotension, we discontinue the beta blockers. The risks versus benefits of beta blockers must be weighed carefully in each patient with cirrhosis. Those patients who develop worsening hypotension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    refractory ascites on a beta blocker probably should have it stopped and not have it restarted. Those whose blood pressure and azotemia improve off the beta blocker could have it restarted cautiously, with careful monitoring of blood pressure and renal function. Our banding approach is aggressive (12 to 16 bands on the first session, 5 to 8 on the second, and 0 to 3 on the third followed by an upper endoscopy and banding as needed every three to six months). Our impression is that less aggressive banding regimens increase the risk of rebleeding between sessions, although our approach has not been formally compared with other approaches. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/49/27418?source=see_link\">",
"     \"Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/23/17786?source=see_link\">",
"     \"Prevention of recurrent variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1323127690\">",
"    <span class=\"h2\">",
"     Oral midodrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/35/2613?source=see_link\">",
"     midodrine",
"    </a>",
"    is effective in combination with parenteral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    in reversing type I hepatorenal syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/50/29482?source=see_link\">",
"     \"Hepatorenal syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is also accumulating evidence that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/35/2613?source=see_link\">",
"     midodrine",
"    </a>",
"    may be useful in treatment of refractory ascites without use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Midodrine is an oral vasopressor that will usually increase blood pressure in advanced cirrhosis, resulting in improved renal perfusion. Some of these patients are severely hypotensive, with systolic pressures in the 70s and 80s. Nurses and sometimes clinicians may be reluctant to give diuretics to these patients. Midodrine at a dose of 7.5 mg to 10 mg orally three times daily (with titration of the dose to achieve the desired increase in blood pressure) can improve renal perfusion, increase renal sodium excretion, and reduce ascites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Based upon the available data and our own clinical experience, we have begun using midodrine in hospitalized patients with cirrhosis who have hypotension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    refractory ascites and who do not respond to dietary modifications, education, and appropriately-prescribed diuretics. We start with 5 mg orally three times daily and adjust the dose (by increments of 2.5 mg for each dose) every 24 hours (maximal dose 17.5 mg three times daily) to achieve an increase in systolic blood pressure of approximately 10 to 15 mmHg. (",
"    <a class=\"graphic graphic_algorithm graphicRef83820 \" href=\"mobipreview.htm?34/10/34990\">",
"     algorithm 1",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MORE INVASIVE THERAPEUTIC OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with diuretic-resistant ascites have pre-hepatorenal syndrome and a poor prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/3\">",
"     3",
"    </a>",
"    ]. The two-year survival rate of all patients with cirrhosis after the development of ascites is approximately 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/9,15\">",
"     9,15",
"    </a>",
"    ]. In comparison, survival in patients with diuretic-resistant ascites is 50 percent at six months and 25 percent at one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/16\">",
"     16",
"    </a>",
"    ]. Similar prognostic stratification can be achieved using baseline urinary sodium excretion. In one series, for example, patients with ascites and urinary sodium excretion below 10 meq per day had a mean survival rate of five to six months compared to over two years in those with ascites and a higher rate of sodium excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are three major therapeutic options in patients with diuretic-resistant ascites in the setting of cirrhosis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Liver transplantation",
"     </li>",
"     <li>",
"      Serial therapeutic paracentesis approximately every two weeks",
"     </li>",
"     <li>",
"      Transjugular intrahepatic portosystemic stent shunt (TIPS)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other modalities such as a peritoneovenous (LeVeen or Denver) shunt have very limited indications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of ascites in a previously compensated cirrhotic patient is an accepted indication for listing for liver transplantation, provided that there are no contraindications, such as active alcohol use. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/61/25559?source=see_link\">",
"     \"Patient selection for liver transplantation\"",
"    </a>",
"    .) Patients usually progress from diuretic-sensitive to diuretic-resistant ascites over a period of months to years if they do not die from other complications of cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients developing diuretic-resistant ascites should ideally already be listed for and awaiting liver transplantation. While liver transplantation is definitive therapy for refractory ascites, patients often have a long waiting time until an organ becomes available, making the approaches described below important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Therapeutic paracentesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contrary to old dogma based upon anecdotal observations of hemodynamic deterioration after therapeutic paracentesis, the safety of this approach in patients with cirrhosis and tense ascites has been proven in randomized controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Large-volume paracentesis (LVP) ameliorates the shortness of breath and early satiety that these patients experience. It also may be associated with collateral advantages, such as reductions in the hepatic venous pressure gradient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/21\">",
"     21",
"    </a>",
"    ], intravariceal pressure, and variceal wall tension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. These parameters are considered important predictors of variceal bleeding, and the improvement after LVP may decrease the risk of bleeding.",
"   </p>",
"   <p>",
"    Retrospective studies have suggested a risk of deterioration in hospitalized patients following LVP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/24\">",
"     24",
"    </a>",
"    ]. However, the risk attributable to the paracentesis is unclear given the difficulty in adjusting for underlying severity of illness and comorbidities in these patients, and understanding whether they were truly diuretic-resistant.",
"   </p>",
"   <p>",
"    The real issue is not the proven value of a single LVP for tense ascites but the role of serial LVP for recurrent tense ascites. Most of these patients, in our experience, are noncompliant with their sodium-restricted diet",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medications and are masquerading as diuretic-resistant. Many feel so much better after an LVP that they prefer to come to the clinic frequently to have their ascites removed rather than follow the diet and take their medications.",
"   </p>",
"   <p>",
"    The problem with this approach is that repeated LVPs cause protein and complement depletion compared to",
"    <span class=\"nowrap\">",
"     diet/diuretic",
"    </span>",
"    therapy. Although this may in theory indirectly predispose to ascitic fluid infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/25\">",
"     25",
"    </a>",
"    ], no definitive data are available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/26\">",
"     26",
"    </a>",
"    ]. Thus, it seems more reasonable to treat diuretic-sensitive patients with diet and diuretics and to reserve serial LVPs for patients who are truly diuretic-resistant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/2\">",
"     2",
"    </a>",
"    ]. The paracentesis volume generally consists of as much fluid as can be removed without excessive manipulation of the patient.",
"   </p>",
"   <p>",
"    The frequency with which LVP is required and the volume of fluid removed provide insight into patient compliance. Patients who are consuming 88 meq (2000 mg) of sodium per day and are excreting no sodium in the urine should require paracentesis of approximately 8.4 liters every two weeks (",
"    <a class=\"graphic graphic_table graphicRef53969 \" href=\"mobipreview.htm?12/29/12763\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Scheduling two-week returns to the clinic works well in our experience, and the typically flaccid, compliant abdomens in these patients permit the accumulation of 8 liters of fluid without the development of \"tenseness.\" Patients with some sodium excretion in the urine should require the removal of less fluid, while those requiring the removal of a total of more than 8.4 liters every two weeks are not complying with their diet and should receive more diet education rather than rapid repeat LVPs.",
"   </p>",
"   <p>",
"    A single therapeutic paracentesis is helpful in patients with tense ascites, and serial total LVPs can control fluid overload once patients become diuretic-resistant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Serial LVPs can be continued until liver transplantation, another treatment option is chosen (see below), or death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Need for routine testing of ascites",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of occult ascitic fluid infection in asymptomatic outpatients undergoing large volume paracentesis for resistant ascites is low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. As a result, the routine culture of fluid during paracentesis in such patients is probably not warranted. Our policy is to obtain a cell count and differential on all samples of ascitic fluid in the paracentesis clinic setting while obtaining cultures only in symptomatic patients or if the fluid is cloudy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Colloid replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for colloid replacement after LVPs remains controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/2,19,20,29\">",
"     2,19,20,29",
"    </a>",
"    ]. In a widely quoted study, 105 patients with tense ascites undergoing LVP were randomly assigned to receive albumin (10",
"    <span class=\"nowrap\">",
"     g/L",
"    </span>",
"    of ascites removed) or no albumin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/19\">",
"     19",
"    </a>",
"    ]. Patients not receiving albumin were more likely to show signs of hemodynamic deterioration including an increase in the plasma renin activity; these patients were also much more likely to develop worsening renal function",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe hyponatremia (20.8 versus 3.8 percent in those receiving albumin). One concern with these results is that almost one-third of patients had not received diuretics prior to entry into the study and cannot be considered diuretic-resistant.",
"   </p>",
"   <p>",
"    Patient selection is crucial for the evaluation of the changes in intravascular volume after large volume paracentesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/29\">",
"     29",
"    </a>",
"    ]. An increase in plasma renin activity after paracentesis has been considered as evidence of effective hypovolemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/20,30\">",
"     20,30",
"    </a>",
"    ] and labeled postparacentesis circulatory dysfunction (PCD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/20\">",
"     20",
"    </a>",
"    ]. In a study involving a single 5 liter paracentesis in patients with truly diuretic-resistant ascites, plasma renin did not increase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/31\">",
"     31",
"    </a>",
"    ]. In a controlled trial, total paracentesis was performed in patients with cirrhosis who were randomized to receive replacement with albumin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    70, or polygeline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/20\">",
"     20",
"    </a>",
"    ]. PCD was much less common with albumin administration (19 versus 34 and 38 percent, respectively). This benefit, which may reflect the longer half-life of albumin, was limited to patients in whom at least 5 liters of ascitic fluid were removed. However, the need for diuretic treatment after discharge was higher in patients who had already developed PCD than in patients who did not, suggesting that many patients were not diuretic-resistant. Patient survival was significantly shorter in patients who developed PCD, but there were no differences in survival among the three treatment groups.",
"   </p>",
"   <p>",
"    The optimal dose of albumin has not been well-studied. The only dose-finding study compared 4",
"    <span class=\"nowrap\">",
"     g/L",
"    </span>",
"    of fluid removed with 8",
"    <span class=\"nowrap\">",
"     g/L;",
"    </span>",
"    there was no difference in plasma renin or renal function at six days and no survival difference at six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Postparacentesis plasma volume expansion does help prevent asymptomatic laboratory abnormalities, and some of these abnormalities are associated with shortened survival. Although no high-quality controlled trial has shown a direct survival advantage of one expander over another or compared to no expander, a meta-analysis demonstrated a survival advantage with albumin infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/33\">",
"     33",
"    </a>",
"    ]. More studies with careful selection of truly diuretic-resistant patients are needed. Meanwhile, it seems reasonable to forego albumin after paracenteses of 5 liters or less [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/29,31\">",
"     29,31",
"    </a>",
"    ]. For larger paracenteses, albumin (6 to 8",
"    <span class=\"nowrap\">",
"     g/L",
"    </span>",
"    of fluid removed) can be administered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/2\">",
"     2",
"    </a>",
"    ]. Most studies were performed in Europe, where only a 20 percent solution is available. In the United States, two formulations are available, a 25 and a 5 percent solution. Twenty-five percent albumin can be given if the patient is hypervolemic, while 5 percent albumin can be given if dehydration is suspected. The 25 percent solution is the most commonly used solution. Both solutions are isotonic, with sodium concentrations of 130 to 160",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    The 5 percent solution provides five times the sodium load of the 25 percent solution. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Summary and recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Prophylactic use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/35/2613?source=see_link\">",
"     midodrine",
"    </a>",
"    (an oral alpha-adrenergic agonist) has also been suggested as a less expensive alternative to albumin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/34\">",
"     34",
"    </a>",
"    ]. More studies are needed before considering the therapeutic utility of either of these approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Transjugular intrahepatic portosystemic stent-shunt",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prerequisite for the development of ascites is portal hypertension. Thus, measures directed at the reduction of portal pressure could theoretically eliminate the cause for ascites formation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/1/21527?source=see_link\">",
"     \"Pathogenesis of ascites in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TIPS is a side-to-side portacaval shunt, usually placed through the right internal jugular vein under local anesthesia by an interventional radiologist. In two uncontrolled studies of 75 patients, TIPS led to an increase in urine output, a marked or complete reduction in ascites, and cessation of diuretic therapy or the use of much lower diuretic doses in approximately 75 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. There may also be a delayed improvement in renal function, including a lower plasma creatinine concentration and improved sodium excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/35,37\">",
"     35,37",
"    </a>",
"    ]. In one study, for example, the average plasma creatinine concentration was 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (132",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    at baseline, was unchanged at one week, and fell to 0.9",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (80",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    by six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/35\">",
"     35",
"    </a>",
"    ]. Other potential benefits include improvements in the nutritional status of the patient and quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several randomized controlled trials have compared TIPS to large volume paracentesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/39-43\">",
"     39-43",
"    </a>",
"    ], and at least three meta-analyses have been published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/44-46\">",
"     44-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of four randomized trials (with a total of 264 patients) found no difference in 30-day or 24-month mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/44\">",
"       44",
"      </a>",
"      ]. TIPS was associated with a significant reduction in ascites re-accumulation at three months (OR 0.07, 95% CI 03-0.18) and 12 months (OR 0.14, 95% CI 0.06-0.28). Hepatic encephalopathy occurred significantly more often after TIPS.",
"     </li>",
"     <li>",
"      A later meta-analysis included five trials with a total of 330 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/45\">",
"       45",
"      </a>",
"      ]. The authors evaluated characteristics of the individual trials that might have a bearing on the likelihood of mortality. The differences in mortality among trials were explained mostly by baseline levels of serum bilirubin and the proportion of patients in each trial for whom TIPS was successful (ranging from 77 to 100 percent). The analysis identified one trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/39\">",
"       39",
"      </a>",
"      ] that was an outlier. After excluding this trial, TIPS was significantly more effective than LVP in reducing the likelihood of recurrent ascites (OR 0.14, 95% CI 0.07-0.27) but was more likely to be associated with encephalopathy (OR 2.26, 95% CI 1.35-3.76). Mortality in the TIPS group was reduced by a statistically nonsignificant amount (OR 0.74, 95% CI 0.40-1.37); this does not exclude a clinically important reduction or increase in mortality with TIPS.",
"     </li>",
"     <li>",
"      A third meta-analysis of individual patient data (149 allocated to TIPS and 156 to large volume paracentesis) found that TIPS was significantly more effective in preventing recurrent tense ascites [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/46\">",
"       46",
"      </a>",
"      ]. In addition, transplant-free survival was significantly better in the TIPS group. The average number of hepatic encephalopathy episodes was greater in the TIPS groups, although the probability of developing a first episode of hepatic encephalopathy was similar.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unfortunately, the primary studies included in these meta-analyses were started (and many were completed) before many of the improvements were achieved in the technical aspects of TIPS and in the selection of appropriate patients. No study, for example, incorporated the MELD score for patient selection; MELD was developed to predict 90-day TIPS mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/47\">",
"     47",
"    </a>",
"    ]. In addition, none used a coated stent (see below). Thus, we probably cannot use these studies to predict outcomes of TIPS in the current era.",
"   </p>",
"   <p>",
"    The following illustrate the findings in individual studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial that included a total of 60 patients found that patients randomized to TIPS were more likely to be free of ascites at three months (61 versus 18 percent) and had a higher survival without the need for transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/40\">",
"       40",
"      </a>",
"      ]. The frequency of new hepatic encephalopathy was not significantly different between the two groups.",
"     </li>",
"     <li>",
"      Another controlled trial that included 70 patients found that TIPS was associated with a lower rate of ascites recurrence and a decreased risk of hepatorenal syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/41\">",
"       41",
"      </a>",
"      ], although TIPS did not improve survival and was associated with an increased frequency of severe hepatic encephalopathy and higher costs. However, the cost data were not at all representative of costs in the United States (eg, $216 per tap including albumin), and diuretic use appears to have been minimal in the TIPS group.",
"     </li>",
"     <li>",
"      A large United States multicenter randomized trial found that ascites was much better controlled in the TIPS group, but there was no survival advantage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, a multicenter European trial found that TIPS was associated with significantly better survival without liver transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/42\">",
"       42",
"      </a>",
"      ]. Most deaths were due to progressive liver dysfunction. In the multivariate analysis, treatment with paracentesis and higher MELD score independently predicted death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the results are heterogeneous, increasing evidence suggests that TIPS is more effective than LVP in controlling ascites in carefully selected patients and may possibly be associated with a survival advantage. However, complications of TIPS must also be considered. Hepatic encephalopathy occurs in approximately 30 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. In a subset of patients, encephalopathy can become incapacitating, and may be associated with progressive liver failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/35\">",
"     35",
"    </a>",
"    ]. The encephalopathy can usually be managed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    therapy; in resistant cases, the stent blood flow can be reduced by a \"wasp waist\" constrictor or the shunt can be occluded.",
"   </p>",
"   <p>",
"    Another significant problem after TIPS placement is the development of early thrombosis or delayed shunt stenosis. These problems occurred in 22 to 50 percent of patients, leading to the need for redilatation of the shunt [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/35,38,39,48\">",
"     35,38,39,48",
"    </a>",
"    ] in the pre-polytetrafluoroethylene (Gore-Tex)-covered stents era. New stents show excellent patency rates in a randomized trial; this may be a breakthrough in technology that may substantially reduce the need for redilatation of the stent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/50\">",
"     50",
"    </a>",
"    ]. Coated stents rather than the older uncoated stents are standard of practice.",
"   </p>",
"   <p>",
"    A more detailed understanding of the best candidates for TIPS may improve outcomes with TIPS. The model for end-stage liver disease (MELD) score, for example, was developed to predict 90-day survival after TIPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15770?source=see_link\">",
"     \"Model for End-stage Liver Disease (MELD)\"",
"    </a>",
"    .) Newer trials will screen patients better than prior trials and should probably incorporate MELD score and exclude patients with a high score. In addition, echocardiograms are now usually performed to screen for subtle heart failure. Patients with cirrhosis and ascites usually have ejection fractions of 70 to 75 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/51\">",
"     51",
"    </a>",
"    ]. Cardiac function can deteriorate after TIPS; a baseline ejection fraction of &gt;60 percent may be the minimum for candidates for TIPS.",
"   </p>",
"   <p>",
"    In summary, TIPS has great promise in the treatment of diuretic-resistant ascites. It is our observation that the main function of TIPS for ascites is to convert diuretic-resistant patients to diuretic-sensitive. Poor results can be expected if no diuretics are used. TIPS is effective in a subset of patients with refractory ascites and may be more effective than large-volume paracentesis in carefully selected patients. However, discordant data have been published with regard to its effect on mortality in these patients. Furthermore, complications including encephalopathy and death have sobered the enthusiasm for this technique. Ongoing large multicenter trials using the coated stent will help to better define the place of TIPS in the treatment of diuretic-resistant cirrhotic ascites. At present, it is probably best avoided in patients with Child-Pugh C class (score greater than 12), high MELD scores (greater than 18), or severe spontaneous (ie, in the absence of gut bleeding, infection, or dehydration) hepatic encephalopathy. A guideline issued by the American Association for the Study of Liver Diseases recommends that TIPS should be used only in patients who are intolerant of repeated large volume paracentesis. The AASLD guideline for the role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/52\">",
"     52",
"    </a>",
"    ], as well as other AASLD guidelines, can be accessed through the AASLD web site at",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Pages/default.aspx\">",
"     www.aasld.org/practiceguidelines/Pages/default.aspx",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Peritoneovenous shunt",
"    </span>",
"    &nbsp;&mdash;&nbsp;A peritoneovenous shunt, which drains into the internal jugular vein, reinfuses ascites into the vascular space. This technique was popularized as a \"physiologic\" treatment of resistant ascites (and of the hepatorenal syndrome). However, this procedure has been virtually abandoned due to an excessive rate of complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/53-55\">",
"     53-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The only remaining indication for peritoneovenous shunt is the rare patient with diuretic-resistant ascites who is not a candidate for transplantation or TIPS and is too obese or has too many abdominal surgical scars to permit safe, successful paracentesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/2,56\">",
"     2,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Surgical portasystemic shunts",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with TIPS placement, surgical portasystemic shunts significantly reduce the hepatic venous pressure gradient, the development of ascites, and the frequency of spontaneous bacterial peritonitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Shunt surgery has traditionally been associated with a high morbidity and mortality, and its use in the treatment of ascites is only of historical interest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Splenic artery embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports have described splenic artery embolization for management of bleeding gastric varices or cytopenias associated with portal hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/59-64\">",
"     59-64",
"    </a>",
"    ]. The resulting decrease in splenic blood inflow reduces flow through the splenic vein and subsequently decreases portal pressure. A case report described resolution of tense ascites in a patient who had undergone liver transplantation for Budd-Chiari syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/65\">",
"     65",
"    </a>",
"    ]. The patient was ineligible for TIPS because of extensive thrombosis of the portal vein. The use of this procedure for treatment of refractory ascites awaits more data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hypertonic saline plus loop diuretic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential efficacy of hypertonic saline in combination with loop diuretics was evaluated in a study involving 84 patients with cirrhosis and refractory ascites who were randomly assigned to either high dose intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    plus small volume hypertonic saline or to repeated paracentesis plus a standard diuretic regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/66\">",
"     66",
"    </a>",
"    ]. Those randomized to hypertonic saline had significantly better control of ascites, pleural effusions, and leg edema.",
"   </p>",
"   <p>",
"    The extent to which patients were compliant with a diuretic regimen and sodium restriction (and hence truly diuretic-resistant) was unclear. Furthermore, why hypertonic saline should cause patients to become more responsive to diuretics is uncertain. Thus, more studies are needed before this approach should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H367067826\">",
"    <span class=\"h3\">",
"     Vasopressin receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple vasopressin antagonists are commercially available, some of which have been studied in patients with cirrhosis. However, their role remains unsettled. The cost of these agents (10,000 to 15,000 dollars per month) and side effects must be taken into account before their routine use in patients with diuretic-resistant ascites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/67\">",
"     67",
"    </a>",
"    ]. Patients with hyponatremia are usually asymptomatic until the serum sodium is &lt;120",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    Treatment with a vasopressin antagonist may make the patient thirsty, and demyelination can occur if the serum sodium rises too rapidly.",
"   </p>",
"   <p>",
"    Furthermore, their efficacy is unclear. One of the largest controlled trials, involving 1200 patients with uncomplicated ascites as well as difficult-to-treat ascites found higher mortality in patients treated with satavaptan (one of the newer agents) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35465/abstract/68\">",
"     68",
"    </a>",
"    ]. The authors concluded that satavaptan, alone or in combination with diuretics, was not clinically beneficial in the long-term management of ascites in cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17608?source=see_link&amp;anchor=H12#H12\">",
"     \"Hyponatremia in patients with cirrhosis\", section on 'Vasopressin receptor antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ascites is truly diuretic-resistant in approximately 10 percent of patients with cirrhosis and ascites. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Liver transplantation is the only definitive therapeutic option, but the management of ascites is an important issue until transplantation and in those who are not transplant candidates.",
"     </li>",
"     <li>",
"      Beta blockers appear to reduce survival in patients with refractory ascites. We suggest they NOT be initiated in this setting and that they should be discontinued in patients with refractory ascites",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypotension (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest that patients with cirrhosis who have hypotension",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      refractory ascites and who do not respond to dietary modifications, education, discontinuation of beta blockers, and appropriately-prescribed diuretics be treated with oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/35/2613?source=see_link\">",
"       midodrine",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We start with 5 mg orally three times daily and adjust the dose every 24 hours (maximal dose 17.5 mg three times daily) to achieve an increase in systolic blood pressure of approximately 10 to 15 mmHg.",
"     </li>",
"     <li>",
"      We suggest that patients with diuretic-resistant ascites undergo serial paracentesis and follow a sodium-restricted diet (2 g per day) rather than undergo TIPS as initial therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, serial paracenteses should be viewed as a bridge to more definitive therapy (ie, liver transplantation or TIPS).",
"     </li>",
"     <li>",
"      Exceptions are patients who are not candidates for transplant or TIPS. With respect to the latter, spontaneous or otherwise problematic hepatic encephalopathy, alcoholic hepatitis, MELD score &gt;18, advanced age, or parenchymal renal disease are all relative contraindications to TIPS.",
"     </li>",
"     <li>",
"      TIPS may be more effective than serial paracenteses in carefully selected patients, but the effectiveness of TIPS in heterogeneous patient populations and centers with varying experience with TIPS has yet to be established. The place of TIPS in our treatment algorithm should become clearer with new technical improvements introduced in the TIPS manufacturing. Ongoing multicenter trials will help to better define its role.",
"     </li>",
"     <li>",
"      The necessity of plasma expansion after large volume paracentesis remains controversial. We suggest against using intravenous albumin after taps of &lt;5 liters (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest it be used (6 to 8 grams of",
"      <span class=\"nowrap\">",
"       albumin/liter",
"      </span>",
"      of fluid removed) when &gt;5 liters are removed (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/1\">",
"      Arroyo V, Gin&egrave;s P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/2\">",
"      Runyon BA, AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/3\">",
"      Runyon BA. Refractory ascites. Semin Liver Dis 1993; 13:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/4\">",
"      Stiehm AJ, Mendler MH, Runyon BA. Detection of diuretic-resistance or diuretic-sensitivity by the spot urine Na/K ratio in 729 specimens from cirrhosis with ascites: approximately 90% accuracy compared to 24-hr urine Na excretion. Hepatology 2002; 36:222A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/5\">",
"      Pockros PJ, Esrason KT, Nguyen C, et al. Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics. Gastroenterology 1992; 103:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/6\">",
"      Han SH, Reynolds TB, Fong TL. Nephrogenic ascites. Analysis of 16 cases and review of the literature. Medicine (Baltimore) 1998; 77:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/7\">",
"      P&eacute;rez-Ayuso RM, Arroyo V, Planas R, et al. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system. Gastroenterology 1983; 84:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/8\">",
"      Sal&oacute; J, Guevara M, Fern&aacute;ndez-Esparrach G, et al. Impairment of renal function during moderate physical exercise in cirrhotic patients with ascites: relationship with the activity of neurohormonal systems. Hepatology 1997; 25:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/9\">",
"      Gin&eacute;s P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/10\">",
"      Serst&eacute; T, Melot C, Francoz C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010; 52:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/11\">",
"      Wong F, Salerno F. Beta-blockers in cirrhosis: friend and foe? Hepatology 2010; 52:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/12\">",
"      Kalambokis GN, Tsianos EV. Vasoconstrictor therapy for patients with cirrhosis with ascites but without hepatorenal syndrome. Hepatology 2008; 48:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/13\">",
"      Singh V, Dhungana SP, Singh B, et al. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. J Hepatol 2012; 56:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/14\">",
"      Singh V, Singh A, Singh B, et al. Midodrine and Clonidine in Patients With Cirrhosis and Refractory or Recurrent Ascites: A Randomized Pilot Study. Am J Gastroenterol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/15\">",
"      D'Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986; 31:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/16\">",
"      Bories P, Garcia Compean D, Michel H, et al. The treatment of refractory ascites by the LeVeen shunt. A multi-centre controlled trial (57 patients). J Hepatol 1986; 3:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/17\">",
"      Arroyo V, Bosch J, Gaya-Beltr&aacute;n J, et al. Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites. Ann Intern Med 1981; 94:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/18\">",
"      Gin&eacute;s P, Arroyo V, Quintero E, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 1987; 93:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/19\">",
"      Gin&egrave;s P, Tit&oacute; L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988; 94:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/20\">",
"      Gin&egrave;s A, Fern&aacute;ndez-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 111:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/21\">",
"      Luca A, Feu F, Garc&iacute;a-Pag&aacute;n JC, et al. Favorable effects of total paracentesis on splanchnic hemodynamics in cirrhotic patients with tense ascites. Hepatology 1994; 20:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/22\">",
"      Nevens F, Bustami R, Scheys I, et al. Variceal pressure is a factor predicting the risk of a first variceal bleeding: a prospective cohort study in cirrhotic patients. Hepatology 1998; 27:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/23\">",
"      Kravetz D, Romero G, Argonz J, et al. Total volume paracentesis decreases variceal pressure, size, and variceal wall tension in cirrhotic patients. Hepatology 1997; 25:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/24\">",
"      Duggal P, Farah KF, Anghel G, et al. Safety of paracentesis in inpatients. Clin Nephrol 2006; 66:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/25\">",
"      Runyon BA, Antillon MR, Montano AA. Effect of diuresis versus therapeutic paracentesis on ascitic fluid opsonic activity and serum complement. Gastroenterology 1989; 97:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/26\">",
"      Sol&agrave; R, Andreu M, Coll S, et al. Spontaneous bacterial peritonitis in cirrhotic patients treated using paracentesis or diuretics: results of a randomized study. Hepatology 1995; 21:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/27\">",
"      Evans LT, Kim WR, Poterucha JJ, Kamath PS. Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. Hepatology 2003; 37:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/28\">",
"      Pascual S, Such J, P&eacute;rez-Mateo M. Spontaneous bacterial peritonitis and refractory ascites. Am J Gastroenterol 2000; 95:3686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/29\">",
"      Runyon BA. Patient selection is important in studying the impact of large-volume paracentesis on intravascular volume. Am J Gastroenterol 1997; 92:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/30\">",
"      Luca A, Garc&iacute;a-Pag&aacute;n JC, Bosch J, et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology 1995; 22:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/31\">",
"      Peltekian KM, Wong F, Liu PP, et al. Cardiovascular, renal, and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites. Am J Gastroenterol 1997; 92:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/32\">",
"      Alessandria C, Elia C, Mezzabotta L, et al. Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: standard vs half albumin doses. A prospective, randomized, unblinded pilot study. Dig Liver Dis 2011; 43:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/33\">",
"      Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology 2012; 55:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/34\">",
"      Singh V, Dheerendra PC, Singh B, et al. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study. Am J Gastroenterol 2008; 103:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/35\">",
"      Ochs A, R&ouml;ssle M, Haag K, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med 1995; 332:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/36\">",
"      Somberg KA, Lake JR, Tomlanovich SJ, et al. Transjugular intrahepatic portosystemic shunts for refractory ascites: assessment of clinical and hormonal response and renal function. Hepatology 1995; 21:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/37\">",
"      Wong W, Liu P, Blendis L, Wong F. Long-term renal sodium handling in patients with cirrhosis treated with transjugular intrahepatic portosystemic shunts for refractory ascites. Am J Med 1999; 106:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/38\">",
"      Nazarian GK, Ferral H, Bjarnason H, et al. Effect of transjugular intrahepatic portosystemic shunt on quality of life. AJR Am J Roentgenol 1996; 167:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/39\">",
"      Lebrec D, Giuily N, Hadengue A, et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists. J Hepatol 1996; 25:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/40\">",
"      R&ouml;ssle M, Ochs A, G&uuml;lberg V, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000; 342:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/41\">",
"      Gin&egrave;s P, Uriz J, Calahorra B, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002; 123:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/42\">",
"      Salerno F, Merli M, Riggio O, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 2004; 40:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/43\">",
"      Sanyal AJ, Genning C, Reddy KR, et al. The North American Study for the Treatment of Refractory Ascites. Gastroenterology 2003; 124:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/44\">",
"      Saab S, Nieto JM, Ly D, Runyon BA. TIPS versus paracentesis for cirrhotic patients with refractory ascites. Cochrane Database Syst Rev 2004; :CD004889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/45\">",
"      D'Amico G, Luca A, Morabito A, et al. Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology 2005; 129:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/46\">",
"      Salerno F, Camm&agrave; C, Enea M, et al. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007; 133:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/47\">",
"      Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/48\">",
"      Martinet JP, Fenyves D, Legault L, et al. Treatment of refractory ascites using transjugular intrahepatic portosystemic shunt (TIPS): a caution. Dig Dis Sci 1997; 42:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/49\">",
"      Sanyal AJ, Freedman AM, Shiffman ML, et al. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. Hepatology 1994; 20:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/50\">",
"      Bureau C, Garcia-Pagan JC, Otal P, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology 2004; 126:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/51\">",
"      Pozzi M, Carugo S, Boari G, et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 1997; 26:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/52\">",
"      Boyer TD, Haskal ZJ. American Association for the Study of Liver Diseases Practice Guidelines: the role of transjugular intrahepatic portosystemic shunt creation in the management of portal hypertension. J Vasc Interv Radiol 2005; 16:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/53\">",
"      Stanley MM, Ochi S, Lee KK, et al. Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. Veterans Administration Cooperative Study on Treatment of Alcoholic Cirrhosis with Ascites. N Engl J Med 1989; 321:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/54\">",
"      Gin&egrave;s P, Arroyo V, Vargas V, et al. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. N Engl J Med 1991; 325:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/55\">",
"      Rosemurgy AS, Zervos EE, Clark WC, et al. TIPS versus peritoneovenous shunt in the treatment of medically intractable ascites: a prospective randomized trial. Ann Surg 2004; 239:883.",
"     </a>",
"    </li>",
"    <li>",
"     Runyon, BA. Ascites and spontaneous bacterial peritonitis. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease, Pathophysiology/Diagnosis/Management, 7th ed, Feldman, M, Friedman, LS, Sleisenger, MH (Eds), WB Saunders, Philadelphia 2002. p.1517.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/57\">",
"      Castells A, Sal&oacute; J, Planas R, et al. Impact of shunt surgery for variceal bleeding in the natural history of ascites in cirrhosis: a retrospective study. Hepatology 1994; 20:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/58\">",
"      Rosemurgy AS, Goode SE, Zwiebel BR, et al. A prospective trial of transjugular intrahepatic portasystemic stent shunts versus small-diameter prosthetic H-graft portacaval shunts in the treatment of bleeding varices. Ann Surg 1996; 224:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/59\">",
"      N'Kontchou G, Seror O, Bourcier V, et al. Partial splenic embolization in patients with cirrhosis: efficacy, tolerance and long-term outcome in 32 patients. Eur J Gastroenterol Hepatol 2005; 17:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/60\">",
"      Shah R, Mahour GH, Ford EG, Stanley P. Partial splenic embolization. An effective alternative to splenectomy for hypersplenism. Am Surg 1990; 56:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/61\">",
"      Ou HY, Huang TL, Chen TY, et al. Emergency splenic arterial embolization for massive variceal bleeding in liver recipient with left-sided portal hypertension. Liver Transpl 2005; 11:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/62\">",
"      McDermott VG, England RE, Newman GE. Case report: bleeding gastric varices secondary to splenic vein thrombosis successfully treated by splenic artery embolization. Br J Radiol 1995; 68:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/63\">",
"      P&aring;lsson B, Hall&eacute;n M, Forsberg AM, Alwmark A. Partial splenic embolization: long-term outcome. Langenbecks Arch Surg 2003; 387:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/64\">",
"      Xu RY, Liu B, Lin N. Therapeutic effects of endoscopic variceal ligation combined with partial splenic embolization for portal hypertension. World J Gastroenterol 2004; 10:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/65\">",
"      Chang CY, Singal AK, Ganeshan SV, et al. Use of splenic artery embolization to relieve tense ascites following liver transplantation in a patient with paroxysmal nocturnal hemoglobinuria. Liver Transpl 2007; 13:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/66\">",
"      Licata G, Tuttolomondo A, Licata A, et al. Clinical Trial: High-dose furosemide plus small-volume hypertonic saline solutions vs. repeated paracentesis as treatment of refractory ascites. Aliment Pharmacol Ther 2009; 30:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/67\">",
"      Boyer TD. Tolvaptan and hyponatremia in a patient with cirrhosis. Hepatology 2010; 51:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35465/abstract/68\">",
"      Wong F, Watson H, Gerbes A, et al. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut 2012; 61:108.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1258 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.32.226.102-B08792FACF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_40_35465=[""].join("\n");
var outline_f34_40_35465=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1323127675\">",
"      SIMPLE THERAPEUTIC OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1323127682\">",
"      Safety concern with beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1323127690\">",
"      Oral midodrine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MORE INVASIVE THERAPEUTIC OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Therapeutic paracentesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Need for routine testing of ascites",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Colloid replacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Transjugular intrahepatic portosystemic stent-shunt",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Peritoneovenous shunt",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Surgical portasystemic shunts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Splenic artery embolization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hypertonic saline plus loop diuretic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H367067826\">",
"      - Vasopressin receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/1258\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1258|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?34/10/34990\" title=\"algorithm 1\">",
"      Treatment of ascites refractory to first-line treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1258|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/18/5422\" title=\"table 1\">",
"      AASLD ascites guideline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/29/12763\" title=\"table 2\">",
"      Na balance in cirrhotic ascites",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/50/29482?source=related_link\">",
"      Hepatorenal syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17608?source=related_link\">",
"      Hyponatremia in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19145?source=related_link\">",
"      Initial therapy of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3704?source=related_link\">",
"      Major side effects of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15770?source=related_link\">",
"      Model for End-stage Liver Disease (MELD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/1/21527?source=related_link\">",
"      Pathogenesis of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/41/21151?source=related_link\">",
"      Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/61/25559?source=related_link\">",
"      Patient selection for liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/23/17786?source=related_link\">",
"      Prevention of recurrent variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/49/27418?source=related_link\">",
"      Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_40_35466="Neoadjuvant therapy for breast cancer: Rationale, pretreatment evaluation, and therapeutic options";
var content_f34_40_35466=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neoadjuvant therapy for breast cancer: Rationale, pretreatment evaluation, and therapeutic options",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/40/35466/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/40/35466/contributors\">",
"     William M Sikov, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/40/35466/contributors\">",
"     Antonio C Wolff, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/40/35466/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/40/35466/contributors\">",
"     Julie R Gralow, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/40/35466/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/40/35466/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/40/35466/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/40/35466/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H541772675\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 200,000 new cases of invasive breast cancer are expected to be diagnosed in the United States each year (one percent of which are in males), and about 40,000 patients will die from the disease. Neoadjuvant therapy refers to the systemic treatment of breast cancer prior to definitive surgical therapy (ie, preoperative therapy). This topic will review the rationale, patient selection, pretreatment evaluation, and treatment options for neoadjuvant therapy. Tumor response evaluation, surgical treatment, adjuvant treatment, and prognosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1529?source=see_link\">",
"     \"Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11989101\">",
"    <span class=\"h1\">",
"     OBJECTIVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;While all systemic therapy administered to patients with nonmetastatic invasive breast cancer is intended to reduce the risk of distant recurrence, the primary objective of neoadjuvant therapy is to improve surgical outcomes in patients for whom a primary surgical approach is technically not feasible and patients with operable breast cancer who desire breast conservation, but for whom either a mastectomy is required or a partial mastectomy would result in a poor cosmetic outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neoadjuvant therapy also allows for an early evaluation of the effectiveness of systemic therapy. This may permit the clinician to discontinue ineffective treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/3\">",
"     3",
"    </a>",
"    ]. However, identification of effective regimens (for patients who do not respond to the original treatment) continues to be the subject of ongoing research.",
"   </p>",
"   <p>",
"    In addition to these clinical objectives, neoadjuvant therapy gives researchers the opportunity to obtain tumor specimens (both fresh and formalin-fixed) and blood samples prior to and during the preoperative treatment. This enables research aimed at identifying tumor- or patient-specific biomarkers to proceed.",
"   </p>",
"   <p>",
"    Although it was hypothesized that overall survival would be improved with earlier initiation of systemic therapy in patients at risk of distant recurrence, clinical studies have not yet demonstrated a mortality benefit for pre- versus postoperative delivery of systemic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/1,3,6-12\">",
"     1,3,6-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11989615\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89686859\">",
"    <span class=\"h2\">",
"     Eligibility for primary surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Operability plays a role in the selection of patients for neoadjuvant treatment. While historically limited to patients with locally advanced breast cancer (in whom even a mastectomy may not be an option), it is frequently administered to women with operable breast cancer in an effort to improve cosmetic outcomes following surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89686878\">",
"    <span class=\"h3\">",
"     Inoperable disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with locally advanced breast cancer (clinical stage IIIA-IIIC (",
"    <a class=\"graphic graphic_table graphicRef65393 \" href=\"mobipreview.htm?29/14/29920\">",
"     table 1",
"    </a>",
"    )) are ideal candidates for neoadjuvant therapy because their cancers are often not amenable to upfront resection, much less breast conservation. Many patients with tumors larger than 5 cm, even if potentially operable, are considered to have locally advanced breast cancer on neoadjuvant therapy clinical trials. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/46/19177?source=see_link&amp;anchor=H528513711#H528513711\">",
"     \"Overview of the treatment of newly diagnosed, non-metastatic breast cancer\", section on 'Locally advanced breast cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89686907\">",
"    <span class=\"h3\">",
"     Operable disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with early stage breast cancer (stage I or II) are appropriate candidates for neoadjuvant therapy if breast conserving surgery is not possible due to a high tumor-to-breast ratio or an expected postoperative cosmetic outcome would be suboptimal due to tumor location. In addition, patients with small tumors may be offered neoadjuvant therapy if their breast cancer subtype is associated with a high likelihood of response. (See",
"    <a class=\"local\" href=\"#H89686026\">",
"     'Breast cancer subtypes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89686867\">",
"    <span class=\"h2\">",
"     Clinical status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neoadjuvant systemic therapy is a treatment option for patients who have medical contraindications to undergoing surgery at diagnosis, but in whom surgery is anticipated at a later date, such as women with breast cancer diagnosed during pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/34/2602?source=see_link&amp;anchor=H84662649#H84662649\">",
"     \"Breast cancer during pregnancy and lactation: Treatment\", section on 'Systemic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89686026\">",
"    <span class=\"h2\">",
"     Breast cancer subtypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neoadjuvant therapy is most appropriate for patients likely to have a good locoregional response, regardless of tumor size at presentation. This includes those with HER2-positive or estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor 2 (HER2) receptor negative (triple-negative) breast cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, patients with HER2-negative, ER-positive breast cancers are less likely to have a clinical or pathologic complete response to neoadjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/14\">",
"     14",
"    </a>",
"    ]. Therefore, until we can identify subsets of HER2-negative, ER-positive patients who are more likely to benefit from neoadjuvant chemotherapy (NACT), we prefer primary surgery rather than neoadjuvant therapy for these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89686033\">",
"    <span class=\"h3\">",
"     HER2-positive",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HER2-positive cancers have a relatively high rate of pathologic complete response to neoadjuvant chemotherapy, particularly if treatment includes a HER2-directed agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. This was demonstrated in the Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis (I-SPY 1) Trial, in which 221 patients with tumor &ge;3 cm received neoadjuvant chemotherapy consisting of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/20\">",
"     20",
"    </a>",
"    ]. Of 66 patients with HER2-positive disease, 20 received neoadjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    after it became available for use in the adjuvant setting. The main results were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pathologic complete response (pCR) rate following neoadjuvant chemotherapy alone was 39 percent (18 of 46 patients) for patients with HER2-positive disease. In contrast, the pCR rate was 18 percent for those with HER2-negative breast cancers (26 of 144 patients).",
"     </li>",
"     <li>",
"      Among HER2-positive patients treated with neoadjuvant chemotherapy plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      , the pCR rate was 60 percent (12 of 20).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study also demonstrated a high rate of pCR among HER2-positive patients, regardless of the status of the hormone receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 24 patients with hormone receptor-positive and HER2-positive disease, the pCR rate was 33 percent (8 of 24 patients).",
"     </li>",
"     <li>",
"      Among patients with hormone receptor-negative and HER2-positive disease, the pCR rate was 45 percent (10 of 22 patients).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with HER2-positive disease who receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    as part of their neoadjuvant therapy, pCR is associated with improvements in disease-free and overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/13,21\">",
"     13,21",
"    </a>",
"    ]. For this reason, we recommend the addition of targeted treatment against HER2 (ie, trastuzumab) to neoadjuvant chemotherapy in these patients. (See",
"    <a class=\"local\" href=\"#H541773077\">",
"     'HER2-directed therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89686158\">",
"    <span class=\"h3\">",
"     Triple-negative breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologic complete response rates to neoadjuvant chemotherapy among triple-negative breast cancer (TNBC) patients range from 27 to 45 percent, while the pCR rate for HER2-negative, hormone receptor-positive patients is generally less than 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/18-20,22\">",
"     18-20,22",
"    </a>",
"    ]. However, while TNBC patients who achieve a pCR appear to have a prognosis similar to patients with other breast cancer subtypes who achieve a pCR, TNBC patients with more than minimal residual disease at surgery have a much higher risk of early distant disease recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/20,23\">",
"     20,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/40/34441?source=see_link&amp;anchor=H98882362#H98882362\">",
"     \"Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer\", section on 'Treatment approach to triple-negative breast cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since these patients are not candidates for neoadjuvant endocrine or HER2-directed therapy, developing more effective chemotherapy regimens",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    identifying effective targeted therapies to augment the activity of chemotherapy in TNBC are areas of great research interest. (See",
"    <a class=\"local\" href=\"#H53705780\">",
"     'Choice of chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11990037\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with all patients presenting with a new diagnosis of breast cancer, histopathologic confirmation and evaluation of receptor status (ER, PR, and HER2) must be obtained before initiating treatment. Patients should undergo an appropriate initial staging work-up prior to neoadjuvant systemic therapy that may include imaging studies to rule out detectable metastatic disease, depending upon their clinical stage and other characteristics, the presence of which would likely alter overall treatment goals and plan. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/49/10009?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features, diagnosis, and staging of newly diagnosed breast cancer\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because neoadjuvant therapy is expected to impact pathologic findings at surgery, we prefer to confirm the status of regional nodes at baseline before initiation of neoadjuvant therapy. This information will influence decisions about RT following definitive surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11994795\">",
"    <span class=\"h2\">",
"     Tumor evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the start of neoadjuvant chemotherapy, radiopaque clips should be placed in the tumor. This can be done at the time of the diagnostic biopsy or at some other time prior to initiation of neoadjuvant therapy. Because the aim of neoadjuvant therapy is to shrink the primary tumor, the clip will aide in planning locoregional treatment (surgery and radiation therapy) and the subsequent pathologic assessment of the surgical specimen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/59/24504?source=see_link&amp;anchor=H6#H6\">",
"     \"Breast biopsy\", section on 'Clip placement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to placement of a clip in the tumor bed, tumor size should be documented prior to treatment. In most cases, ultrasound of the breast is sufficient to document tumor size. However, breast MRI is often helpful to evaluate disease extent, including assessing for the presence of multicentric disease or invasion of the underlying chest wall. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23002?source=see_link&amp;anchor=H10606323#H10606323\">",
"     \"MRI of the breast and emerging technologies\", section on 'Preoperative evaluation of newly diagnosed breast cancer patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11994803\">",
"    <span class=\"h2\">",
"     Node evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our approach to nodal assessment is based on the clinical exam of the axilla:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179172816\">",
"    <span class=\"h3\">",
"     Clinically suspicious axillary exam",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with palpable axillary adenopathy, we perform an ultrasound-guided fine needle aspiration (FNA)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    core needle biopsy of one or more suspicious nodes prior to neoadjuvant treatment to determine if the axillary nodes are pathologically involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/52/42825?source=see_link&amp;anchor=H365147057#H365147057\">",
"     \"Management of the regional lymph nodes in breast cancer\", section on 'Axillary ultrasound'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the FNA is negative, we suggest a sentinel lymph node biopsy (SLNB) to stage the axilla prior to treatment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/47/36602?source=see_link\">",
"       \"Sentinel lymph node dissection for breast cancer: Indications and outcomes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the FNA is positive, no further evaluation is required. Final decisions regarding locoregional treatment takes place following neoadjuvant therapy and will depend on the treatment response. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1529?source=see_link&amp;anchor=H1192519#H1192519\">",
"       \"Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosis\", section on 'Nodal evaluation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179173016\">",
"    <span class=\"h3\">",
"     Clinically benign axillary exam",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with a clinically negative axillary exam, a SLNB should be performed prior to initiation of neoadjuvant therapy. Results of this procedure may more accurately reflect the status of the axillary nodes if performed before initiation of neoadjuvant therapy as compared to following completion of that treatment, although the status of the lymph nodes after neoadjuvant therapy may have greater prognostic significance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the SLNB is negative, no further evaluation is necessary.",
"     </li>",
"     <li>",
"      If the SLNB is positive, further treatment will depend on the outcome following neoadjuvant chemotherapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1529?source=see_link&amp;anchor=H1192519#H1192519\">",
"       \"Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosis\", section on 'Nodal evaluation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At some centers, an axillary ultrasound with FNA of any enlarged or otherwise suspicious lymph node(s) is the initial diagnostic exam of choice even in patients with a clinically negative axillary exam. This is a reasonable alternative. (See",
"    <a class=\"local\" href=\"#H179172816\">",
"     'Clinically suspicious axillary exam'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179173117\">",
"    <span class=\"h1\">",
"     TREATMENT OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The options for neoadjuvant treatment include chemotherapy, endocrine therapy, and the incorporation of biologic therapy (eg, HER2-directed therapy) in appropriate patients. Much of the information regarding neoadjuvant therapy comes from trials utilizing chemotherapy, with recent studies assessing the role of biologics. There are limited data regarding the use of neoadjuvant endocrine therapy and clinical studies have predominantly evaluated only postmenopausal women.",
"   </p>",
"   <p>",
"    Our approach to treatment is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with triple-negative breast cancer (ie, ER-negative, PR-negative, and HER2-negative) who are not candidates for surgery or have larger tumors and desire breast conserving surgery should be offered neoadjuvant chemotherapy. These patients have an excellent chance of achieving a clinical and pathologic complete response to treatment. (See",
"      <a class=\"local\" href=\"#H89686158\">",
"       'Triple-negative breast cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most postmenopausal women with HER2-negative, estrogen receptor (ER)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      progesterone receptor (PR) positive breast cancers who are not candidates for initial resection, we suggest neoadjuvant chemotherapy rather than endocrine therapy. While few of these patients will achieve a clinical or pathologic complete response, tumor shrinkage may permit some unresectable patients to undergo surgery and some borderline patients to be offered breast conservation. However, those who are medically unfit for or refuse chemotherapy may be treated with neoadjuvant endocrine therapy. (See",
"      <a class=\"local\" href=\"#H19285752\">",
"       'Endocrine therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Premenopausal women with HER2-negative, ER-positive",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      PR-positive breast cancers who are not candidates for initial resection should be offered neoadjuvant chemotherapy. While few of these patients will achieve a clinical or pathologic complete response, tumor shrinkage may permit some unresectable patients to undergo surgery and some borderline patients to be offered breast conservation. Patients who refuse neoadjuvant chemotherapy should undergo primary surgery. However, those patients who refuse both neoadjuvant chemotherapy and primary surgery may be offered neoadjuvant endocrine therapy, but must be informed of the absence of data addressing the risks and benefits of such an approach. (See",
"      <a class=\"local\" href=\"#H19285752\">",
"       'Endocrine therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For patients with HER2-positive breast cancer who are not candidates for surgery or have larger tumors and desire breast conserving surgery, we recommend the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      to neoadjuvant chemotherapy over chemotherapy alone. (See",
"      <a class=\"local\" href=\"#H541773077\">",
"       'HER2-directed therapy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53705758\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with locally advanced breast cancer, neoadjuvant chemotherapy (NACT) is associated with high rates of clinical response and a higher likelihood for allowing cosmetically acceptable surgery. However, NACT does not improve disease-free or overall survival compared to adjuvant chemotherapy.",
"   </p>",
"   <p>",
"    The outcomes of NACT was demonstrated in a 2007 meta-analysis that included data from 5500 women participating in 1 of 14 trials reported between 1991 and 2001 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/25\">",
"     25",
"    </a>",
"    ]. Compared to adjuvant chemotherapy, NACT resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Equivalent overall survival (OS) (hazard ratio [HR] 0.98, 95% CI 0.87-1.09) and disease-free survival (DFS) (HR 0.97, 95% CI 0.89-1.07)",
"     </li>",
"     <li>",
"      Reduction in the risk of having a modified radical mastectomy performed (HR 0.71, 95% CI 0.67-0.75)",
"     </li>",
"     <li>",
"      An increased risk of locoregional recurrence (HR 1.21, 95% CI 1.02-1.43).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Those patients with a documented pathologic complete response at surgery had significant improvements in both OS (HR 0.48, 95% CI 0.33-0.69) and DFS (HR 0.48, 95% CI 0.37-0.63) compared to patients with residual invasive disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1529?source=see_link&amp;anchor=H1192223#H1192223\">",
"     \"Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosis\", section on 'Clinical response assessment after treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1529?source=see_link&amp;anchor=H1192781#H1192781\">",
"     \"Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosis\", section on 'Staging'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1529?source=see_link&amp;anchor=H441569536#H441569536\">",
"     \"Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosis\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53705780\">",
"    <span class=\"h3\">",
"     Choice of chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of specific chemotherapy drugs and regimens should be based on tumor biology and intrinsic subsets (ie, triple-negative, estrogen receptor-positive, HER2-positive). There is no reason to assume that regimens administered in the adjuvant setting would be less active when used prior to surgery.",
"   </p>",
"   <p>",
"    Commonly used regimens for patients with HER2-negative disease include (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/15/17650?source=see_link\">",
"     \"Treatment protocols for breast cancer\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AC &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       Doxorubicin",
"      </a>",
"      (60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      (AC) every two weeks (dose-dense) or three weeks for four cycles (",
"      <a class=\"graphic graphic_table graphicRef78493 \" href=\"mobipreview.htm?7/47/7934\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       AC/taxane",
"      </span>",
"      &mdash; AC followed by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      (175",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      every two or three weeks for four cycles or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      every three weeks for four cycles.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       AC/weekly",
"      </span>",
"      T &mdash; AC followed by weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      (80",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      for 12 weeks (",
"      <a class=\"graphic graphic_table graphicRef69273 \" href=\"mobipreview.htm?25/22/25966\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      FEC &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"       Fluorouracil",
"      </a>",
"      (600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ),",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      (90",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ),",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      (FEC) every three weeks for four cycles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/7,27\">",
"       7,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      FAC &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"       Fluorouracil",
"      </a>",
"      (600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ),",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      (60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ),",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      (FAC) every three weeks for four cycles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/6,28\">",
"       6,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      TAC &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       Docetaxel",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ),",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      (50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ),",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      for six cycles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      TC &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       Docetaxel",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      every three weeks for four to six cycles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/30\">",
"       30",
"      </a>",
"      ]. &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We administer dose-dense AC for four cycles followed by weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    for 12 weeks. This preference is based on the demonstrated efficacy and tolerability of this taxane regimen in the adjuvant and neoadjuvant settings, especially in patients with ER-negative disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. For patients who are particularly anxious about the potential toxicities of chemotherapy, we sometime initiate treatment with weekly paclitaxel first. Because reduction in tumor size to permit surgery is the primary objective of NACT, all planned treatment should be administered prior to definitive surgery, provided there is no evidence of disease progression on treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/21/41302?source=see_link\">",
"     \"Molecular intrinsic subtypes of breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37961?source=see_link&amp;anchor=H71308660#H71308660\">",
"     \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\", section on 'Choice of chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NACT regimens used for patients with HER2-positive breast cancer are listed below. (See",
"    <a class=\"local\" href=\"#H541773077\">",
"     'HER2-directed therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11994991\">",
"    <span class=\"h4\">",
"     Anthracycline-taxane based regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have demonstrated that anthracycline-based regimens incorporating a taxane (either concurrently or in sequence with anthracycline-based regimens) are associated with increased response rates in the neoadjuvant setting compared to use of a non-taxane-containing regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/12,33-39\">",
"     12,33-39",
"    </a>",
"    ]. As an example, in the NSABP B27 trial, 2411 patients received four cycles of neoadjuvant AC after which they were randomly assigned to one of three groups: one group received no further chemotherapy, another group was treated with four cycles of neoadjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    every three weeks, and the third group underwent surgery followed by four cycles of adjuvant docetaxel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/12,34\">",
"     12,34",
"    </a>",
"    ] . Compared to AC alone, incorporation of docetaxel prior to surgery resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A higher overall clinical response rate (CRR, 91 versus 86 percent)",
"     </li>",
"     <li>",
"      A higher pCR rate (26 versus 13 percent)",
"     </li>",
"     <li>",
"      No difference in OS (74 percent with neoadjuvant AC only and 75 percent in the arms containing",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      ) or DFS at eight years (DFS, 59 and 62 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11994998\">",
"    <span class=\"h4\">",
"     Non-anthracycline regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been limited trials of NACT comparing an anthracycline to nonanthracycline chemotherapy regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. However, a nonanthracycline regimen may be a reasonable option, particularly for patients with a contraindication to anthracyclines. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37961?source=see_link&amp;anchor=H27692287#H27692287\">",
"     \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\", section on 'Is an anthracycline necessary?'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examples of non-anthracycline regimens evaluated include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       Carboplatin",
"      </a>",
"      plus weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      &mdash; In a Brown University Oncology Group study, 53 patients were treated with carboplatin plus weekly paclitaxel [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/40\">",
"       40",
"      </a>",
"      ]. The pCR rate was 31 percent in patients who were HER2-positive and 67 percent in patients who were ER-negative patients. In contrast, in patients with ER-positive, HER2-negative disease, the pCR rate was 12 percent.",
"     </li>",
"     <li>",
"      Weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      plus weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      &mdash; In a study of 107 patients (85 percent with stage III disease), the CCR rate was 32 percent and the pCR rate was 19 percent. Higher pCR rates were noted in patients with hormone receptor-negative and HER2-positive cancers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H706507585\">",
"    <span class=\"h4\">",
"     Alternative regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether the addition of non-cross resistant agents with demonstrated activity in metastatic breast cancer might improve clinical and pathologic response rates seen with the use of an anthracycline",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a taxane is the subject of ongoing clinical research. However, there is no evidence that this approach improves survival outcomes or response rates. Thus, we suggest not administering additional agents to standard anthracycline- and taxane-based neoadjuvant chemotherapy. This was illustrated in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      &mdash; In the GeparQuattro trial, 1421 women received four cycles of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (EC) and then were randomly assigned to treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      alone, docetaxel plus capecitabine (DX), or docetaxel followed by capecitabine (D-X) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/42\">",
"       42",
"      </a>",
"      ]. There was no difference in either breast conservation or pCR rates.",
"     </li>",
"     <li>",
"      Addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      &mdash; NSABP B-40 randomly assigned 1206 patients to treatment with four cycles of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      , docetaxel plus gemcitabine, or docetaxel plus capecitabine. Following this, all patients received four cycles of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (with another randomization to treatment with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      throughout chemotherapy administration) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/43\">",
"       43",
"      </a>",
"      ]. Compared to docetaxel alone, the addition of gemcitabine or capecitabine had no impact on pCR or CCR rates. Treatment also had no impact on the rate of breast conservation surgery.",
"     </li>",
"     <li>",
"      Administration of platinum agents &mdash; Platinum-based chemotherapy agents have demonstrated some activity in the treatment of metastatic TNBC. Similarities of clinical features and gene expression array patterns between triple-negative cancers arising in women who carry deleterious mutations of the BRCA1 gene and sporadic TNBC had led to hypotheses that chemotherapeutic agents like the platinum analogues, which induce double-stranded DNA breaks, repair of which is impaired in BRCA1-deficient cells, may be effective in this group of patients. This has lead to small prospective trials that have evaluated platinum-based neoadjuvant chemotherapy for TNBC with pCR rates ranging from 12 to 29 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/23,40,44,45\">",
"       23,40,44,45",
"      </a>",
"      ]. Larger randomized studies of a platinum-based neoadjuvant regimen are required before these agents are incorporated as a standard treatment, particularly in patients with TNBC. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/40/34441?source=see_link&amp;anchor=H97090639#H97090639\">",
"       \"Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer\", section on 'Neoadjuvant chemotherapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H722485439\">",
"    <span class=\"h4\">",
"     Scheduling considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neoadjuvant chemotherapy is often administered using standard (ie, every three week) or dose-dense (every two week) schedules. We consider dose-dense chemotherapy appropriate for patients in the neoadjuvant setting, given the benefits of dose-dense sequential anthracycline and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    chemotherapy in the adjuvant setting, especially in patients with more aggressive breast cancer subtypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37961?source=see_link&amp;anchor=H32#H32\">",
"     \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\", section on 'Dose density'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, there is no compelling evidence that dose-dense treatment improves outcomes in the neoadjuvant setting. While several trials have included dose-dense treatment arms, other differences between treatment arms make an evaluation of scheduling difficult to evaluate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/27,31,48,49\">",
"     27,31,48,49",
"    </a>",
"    ]. The largest studies to illustrate this point are discussed below: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A German group randomly assigned 668 patients with large primary tumors or inflammatory breast cancer to treatment using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      every three weeks for four cycles or dose-dense epirubicin followed by paclitaxel (250",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      every two weeks for three cycles each (total treatment, six cycles) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/48\">",
"       48",
"      </a>",
"      ]. Both groups of patients then underwent surgery followed by three cycles of adjuvant CMF. Compared to patient who received standard dose neoadjuvant chemotherapy, the patients who received dose-dense therapy had:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A significantly higher pCR rate (odds ratio (OR) 1.89; 18 versus 10 percent)",
"     </li>",
"     <li>",
"      Significant improvement in both DFS (HR 0.71) and OS (HR 0.83)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dose-intensified",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (EC) every 14 days for six cycles was compared to FEC every 28-day for six cycles in 448 patients with locally advanced breast cancer. There were no significant differences in the pCR rate (10 versus 14 percent), PFS (median, 34 months in both arms), or five-year OS (51 versus 53 percent) between the treatment arms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53706464\">",
"    <span class=\"h4\">",
"     Response-adjusted sequential therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Response-adjusted sequential therapy refers to the use of one chemotherapy regimen for a set number of cycles followed by clinical assessment of response, with subsequent administration of either the same or a non-cross-resistant chemotherapy regimen based on the observed response to the first regimen. This design allows for independent evaluation of different drug regimens and the potential to individualize therapy based on a patient's tumor response. This approach has been evaluated in a limited number of studies in the neoadjuvant setting and is not recommended outside of a clinical trial.",
"   </p>",
"   <p>",
"    Examples of trials evaluating response-adjusted sequential therapy are discussed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the GeparTrio trial, 2090 patients with operable or locally advanced breast cancer were given two three-week cycles of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (TAC) followed by re-evaluation. Patients who did not respond were randomly assigned to either four more cycles of TAC or four cycles of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"       vinorelbine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      (NX) every 21 days, while responding patients were randomized to receive an additional four versus six cycles of TAC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/29,50,51\">",
"       29,50,51",
"      </a>",
"      ]. The main results were [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/50\">",
"       50",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Following two cycles of TAC, 30 percent of patients did not meet response criteria and were randomly assigned to TAC or NX. Comparing TAC to NX, there were no significant differences in sonographic response rates (51 percent in both groups), pCR rates (5 versus 6 percent), or breast conservation rates (57 versus 60 percent).",
"     </li>",
"     <li>",
"      However, patients switched to NX following non-response to TAC demonstrated significant improvement in DFS compared to patients who continued on TAC (HR 0.59). In addition, patients who had a response to TAC and continued on the same regimen for six (as opposed to four) additional cycles had a modest improvement in pCR rate (24 versus 21 percent, respectively) but a significant improvement in DFS (HR 0.78).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In another trial conducted by the German Breast Cancer Study Group, 1948 women with newly diagnosed breast cancer were assigned to EC, with or without concurrent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      every three weeks for four cycles. Patients with a clinical or ultrasonographic response to EC (n=1270) went on to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      every three weeks for four cycles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/52\">",
"       52",
"      </a>",
"      ]. Non-responding patients were randomized to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      weekly for 12 weeks with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/53\">",
"       53",
"      </a>",
"      ]. Among non-responding patients (n=403), the combination of paclitaxel plus everolimus resulted in:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      No difference in the pCR rate (4 versus 6 percent with single agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      No difference in the CRR (62 versus 52 percent)",
"     </li>",
"     <li>",
"      Results of this trial regarding the administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      are discussed below. (See",
"      <a class=\"local\" href=\"#H722485403\">",
"       'Incorporation of angiogenesis inhibitors'",
"      </a>",
"      below.) &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of response-adjusted sequential therapy is investigational. While the results from the GeparTrio clinical trial are intriguing, it is not yet clear that tailoring treatment to interim response ultimately increases the pCR rate or increases the likelihood that a patient will be a candidate for breast conserving surgery.",
"   </p>",
"   <p>",
"    The management of women during and after neoadjuvant chemotherapy is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1529?source=see_link&amp;anchor=H1192123#H1192123\">",
"     \"Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosis\", section on 'Treatment evaluation'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19285752\">",
"    <span class=\"h2\">",
"     Endocrine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the present time, we restrict administration of neoadjuvant endocrine therapy to postmenopausal patients who are not medically fit to receive or refuse chemotherapy. However, there is growing interest in studying neoadjuvant endocrine therapy in a broader cohort of postmenopausal patients.",
"   </p>",
"   <p>",
"    On the other hand, few studies have been performed evaluating neoadjuvant endocrine therapy in premenopausal women and none have been performed in the context of a randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Therefore, neoadjuvant endocrine therapy approach should be considered investigational as a treatment option for premenopausal women.",
"   </p>",
"   <p>",
"    If a premenopausal woman refuses (or is not a good candidate for) neoadjuvant chemotherapy, we suggest definitive surgical treatment. Premenopausal women who refuse surgery as well can be offered neoadjuvant endocrine therapy, but they should be aware that there is no data regarding the risks and benefits of this approach in this population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H82687818\">",
"    <span class=\"h3\">",
"     Endocrine therapy versus chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a small body of evidence suggesting that the use of endocrine therapy may be equivalent to chemotherapy in postmenopausal women. However, until more data are available, we recommend chemotherapy for most patients in the neoadjuvant setting.",
"   </p>",
"   <p>",
"    In a phase II trial, 239 postmenopausal women with hormone receptor-positive stage II-III breast cancer were randomly assigned them to neoadjuvant treatment with an aromatase inhibitor (AI) (either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/4/7238?source=see_link\">",
"     exemestane",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/49/22294?source=see_link\">",
"     anastrozole",
"    </a>",
"    ) for three months or chemotherapy (four cycles of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    every 21 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/56\">",
"     56",
"    </a>",
"    ]. The main results were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were no differences in overall response rates between",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/4/7238?source=see_link\">",
"       exemestane",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/49/22294?source=see_link\">",
"       anastrozole",
"      </a>",
"      , or chemotherapy (67, 62, and 63 percent, respectively).",
"     </li>",
"     <li>",
"      Compared to chemotherapy, neoadjuvant AI resulted in similar median time to clinical response (57 versus 51 days) and a similar rate of pCR (3 versus 6 percent).",
"     </li>",
"     <li>",
"      Breast conserving surgery was accomplished in 33 percent of patient assigned to an AI compared to 24 percent of patients assigned to chemotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another trial was performed by the Grupo Espa&ntilde;ol de Investigaci&oacute;n del C&aacute;ncer de Mama (GEICAM) and enrolled 95 patients with hormone receptor-positive breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/55\">",
"     55",
"    </a>",
"    ]. Patients were assigned treatment with four cycles of EC every three weeks followed by four cycles of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    every three weeks or 24 weeks of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/4/7238?source=see_link\">",
"     exemestane",
"    </a>",
"    (with the addition of the LHRH analog",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9574?source=see_link\">",
"     goserelin",
"    </a>",
"    every four weeks in premenopausal patients). Results of the study are summarized below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients assigned to chemotherapy were more likely to achieve a clinical response compared to those assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/4/7238?source=see_link\">",
"       exemestane",
"      </a>",
"      (66 versus 48 percent), including CCR (13 versus 6 percent). Chemotherapy resulted in three pCR; there were no pCR seen in patients treated with exemestane.",
"     </li>",
"     <li>",
"      More patients assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/4/7238?source=see_link\">",
"       exemestane",
"      </a>",
"      were able to undergo breast conserving surgery (56 versus 47 percent).",
"     </li>",
"     <li>",
"      Grade 3 and 4 toxicities were more common in patients assigned to chemotherapy (47 versus 9 percent), including febrile neutropenia (7 versus 0 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19285579\">",
"    <span class=\"h3\">",
"     Choice of endocrine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For postmenopausal women who are candidates for neoadjuvant endocrine therapy, we suggest the administration of an aromatase inhibitor (AI) rather than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    . This is based on evidence suggesting higher response rates with aromatase inhibitors across clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/57-60\">",
"     57-60",
"    </a>",
"    ]. Two of the largest trials to illustrate this point are discussed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/26/36261?source=see_link\">",
"       Letrozole",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      &mdash; A multi-national double-blind trial randomly assigned 337 women who were ineligible for breast conserving surgery to treatment with four months of letrozole (2.5 mg daily) or tamoxifen (20 mg daily), followed by surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/57,58\">",
"       57,58",
"      </a>",
"      ]. Compared to tamoxifen, letrozole resulted in:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A significantly higher ORR (55 versus 36 percent).",
"     </li>",
"     <li>",
"      A significantly higher rate of breast conserving surgery (45 versus 35 percent).",
"     </li>",
"     <li>",
"      A significantly higher response rate among HER2-positive patients (88 versus 21 percent) and a trend towards a higher overall response rate among HER2-negative patients (55 versus 42 percent), although this was not statistically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PROACT trial &mdash; In the PreOperative",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/49/22294?source=see_link\">",
"       Anastrozole",
"      </a>",
"      Compared with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       Tamoxifen",
"      </a>",
"      (PROACT) trial, 451 women with hormone receptor-positive breast cancer were randomly assigned treatment with three months of neoadjuvant anastrozole or tamoxifen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/60\">",
"       60",
"      </a>",
"      ]. Concomitant chemotherapy was given to 29 and 32 percent of patients, respectively. The main results were [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/60\">",
"       60",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      There was no significant difference in overall response rate between patients who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/49/22294?source=see_link\">",
"       anastrozole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      (40 versus 35 percent, respectively).",
"     </li>",
"     <li>",
"      In patients who did not receive chemotherapy and who were not considered candidates for breast conserving surgery at study entry, treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/49/22294?source=see_link\">",
"       anastrozole",
"      </a>",
"      improved surgical options in 43 percent compared to 31 percent with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19285586\">",
"    <span class=\"h4\">",
"     Is there a preferred aromatase inhibitor?",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no preferred agent among the different AIs. In the American College of Surgeons Oncology Group (ACOSOG) Z1031 trial, 377 postmenopausal women with stage II or III strongly estrogen receptor-positive breast cancer were randomly assigned treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/4/7238?source=see_link\">",
"     exemestane",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/49/22294?source=see_link\">",
"     anastrozole",
"    </a>",
"    for 16 to 18 weeks before surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/61\">",
"     61",
"    </a>",
"    ]. Treatment with any of the three agents resulted in similar clinical response rates: 63 percent with exemestane, 75 percent with letrozole, and 69 percent with anastrazole. There were no differences in the rate of breast conserving surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H722485417\">",
"    <span class=\"h3\">",
"     Duration of endocrine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients undergoing neoadjuvant endocrine therapy, we continue treatment for at least three to four months. If the tumor is amenable to surgery after three to four months, we recommend proceeding with definitive surgical treatment. However, if the tumor is responding to endocrine therapy, extending treatment to six months or longer, with clinical monitoring of response, may permit a higher percentage of patients to undergo breast conserving surgery. If at any time there is evidence of progression or non-response, we recommend surgery.",
"   </p>",
"   <p>",
"    A response to endocrine therapy may not be evident for at least three to four months and maximal response may not be achieved until much later. Thus, the duration of endocrine treatment prior to surgery must be individualized based on the patient&rsquo;s clinical status and the clinical response. In an open-label study, 32 women with a preoperative tumor size &ge;2 cm were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    2.5 mg daily for a minimum of four months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/62\">",
"     62",
"    </a>",
"    ]. Patients with a response were allowed to continue treatment up to a maximum duration of eight months. By month 4, 62 percent of responses were achieved, but 15 patients (47 percent) remained on treatment for a median duration of seven months. In total, 72 percent of patients were eventually able to undergo breast conserving surgery.",
"   </p>",
"   <p>",
"    The administration of primary endocrine therapy in older women who were deemed not surgical candidates is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/58/13226?source=see_link&amp;anchor=H20722981#H20722981\">",
"     \"General principles on the treatment of early stage and locally advanced breast cancer in older women\", section on 'Surgery versus primary endocrine therapy in women with hormone receptor-positive disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H541773077\">",
"    <span class=\"h2\">",
"     HER2-directed therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HER2-positive cancers have a relatively high rate of pCR to neoadjuvant chemotherapy, especially if the tumors are also hormone receptor-negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. In addition, a pCR after treatment with a HER2-directed agent plus chemotherapy is associated with a survival advantage, likely due to enhanced chemosensitivity of HER2-positive breast cancer cells. This was demonstrated in the TECHNO trial, in which 217 patients were treated with neoadjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    for four cycles, followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    for four cycles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/21\">",
"     21",
"    </a>",
"    ]. Trastuzumab was then continued after surgery for one year. At final pathologic analysis, the pCR rate was 39 percent. Compared to patients who did not have a pCR, pCR was associated with an improvement in both disease-free survival (hazard ratio [HR] 2.5, 95% CI 1.2-5.1) and overall survival (HR 4.9, 95% CI 1.4-17.4). For this reason, we recommend the addition of targeted treatment against HER2 to neoadjuvant chemotherapy in these patients.",
"   </p>",
"   <p>",
"    Currently available HER2-directed agents include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       Trastuzumab",
"      </a>",
"      &mdash; Trastuzumab is a monoclonal antibody that binds the extracellular domain of HER2.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/23/9592?source=see_link\">",
"       Lapatinib",
"      </a>",
"      &mdash; Lapatinib is an orally available tyrosine kinase inhibitor of epidermal growth factor and HER2.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/61/25557?source=see_link\">",
"       Pertuzumab",
"      </a>",
"      &mdash; Pertuzumab is a humanized monoclonal antibody that blocks the dimerization domain of HER2, preventing the formation of HER2 heterodimers with HER3 as well as other members of the HER receptor family.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179173605\">",
"    <span class=\"h3\">",
"     Trastuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    to chemotherapy was shown in a pooled analysis of two randomized studies that evaluated neoadjuvant chemotherapy with or without trastuzumab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/63\">",
"     63",
"    </a>",
"    ]. The addition of trastuzumab to chemotherapy resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An improvement in the rate of pCR (43 versus 20 percent; relative risk for achieving pCR [RR] 2.07, 95% CI 1.41-3.03).",
"     </li>",
"     <li>",
"      A reduction in the relapse rate (26 versus 39 percent; RR for relapse 0.67, 95% CI 0.48-0.94).",
"     </li>",
"     <li>",
"      A trend towards a lower mortality rate (13 versus 20 percent; RR for mortality 0.67, 95% CI 0.39-1.15), though this did not reach statistical significance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While the approved formulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    requires intravenous (IV) administration, a subcutaneous (SQ) preparation of the drug is currently in development and may be equally effective. This was shown in a phase III trial of 596 women assigned to eight cycles of chemotherapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    for four cycles followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    , plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    for four cycles every three weeks) with either concurrent IV trastuzumab (8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    loading dose then 6",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    or SQ trastuzumab (600 mg) also administered every three weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/64\">",
"     64",
"    </a>",
"    ]. Following surgery patients resumed their assigned trastuzumab preparation to complete a year of treatment. Compared to IV trastuzumab, SQ trastuzumab resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A similar pCR rate (39 versus 34 percent) and time to response (median, six weeks in both arms). Progressive disease during neoadjuvant treatment was rare (2 percent in both arms).",
"     </li>",
"     <li>",
"      A higher proportion of patients who had a serious adverse event (21 versus 12 percent), including febrile neutropenia (6 versus 3 percent) and infections (8 versus 4 percent). In addition, three fatal events associated with the SQ preparation were reported versus one in the IV arm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although SQ",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    is not commercially available, it may represent a more convenient modality of treatment for patients, particularly in the postoperative maintenance setting (ie, following neoadjuvant chemotherapy and surgery). However, further experience with this agent and longer follow-up of this trial are required. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11384?source=see_link&amp;anchor=H517953067#H517953067\">",
"     \"Adjuvant medical therapy for HER2-positive breast cancer\", section on 'HER2-directed agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89686946\">",
"    <span class=\"h4\">",
"     Choice of regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Commonly used regimens in the treatment of HER2-positive breast cancer mirror those used in the adjuvant setting (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11384?source=see_link&amp;anchor=H361579099#H361579099\">",
"     \"Adjuvant medical therapy for HER2-positive breast cancer\", section on 'Choice of chemotherapy'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       AC/TH",
"      </span>",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       Doxorubicin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (AC) every two weeks (ie, dose-dense treatment) or three weeks for four cycles followed by the combination of weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      for 12 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/65\">",
"       65",
"      </a>",
"      ] (",
"      <a class=\"graphic graphic_table graphicRef54687 \" href=\"mobipreview.htm?12/23/12671\">",
"       table 4",
"      </a>",
"      ) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      plus trastuzumab every three weeks for four cycles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      TCH &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       Carboplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      , plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      every three weeks for six cycles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       Docetaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      every three weeks for four to six cycles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our preferred regimen is",
"    <span class=\"nowrap\">",
"     AC/TH",
"    </span>",
"    with weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    . However, TCH is a reasonable alternative for patients at increased risk for cardiotoxicity related to the sequence of an anthracycline followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H89686973\">",
"     'Impact on cardiac function'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Given the benefit in survival seen in the adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    trials in which treatment with trastuzumab was extended to a year, all patients should resume trastuzumab following surgery and complete a 52 week course. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1529?source=see_link&amp;anchor=H544206597#H544206597\">",
"     \"Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosis\", section on 'HER2-directed treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11384?source=see_link&amp;anchor=H517953645#H517953645\">",
"     \"Adjuvant medical therapy for HER2-positive breast cancer\", section on 'Treatment overview'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89686973\">",
"    <span class=\"h4\">",
"     Impact on cardiac function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given concerns about the risk of cardiac dysfunction associated with concomitant administration of an anthracycline and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    , we favor their sequential use instead of the concomitant administration of these agents. We await further data on the sequencing of these agents to better inform the safety of trastuzumab in combination with anthracyclines. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42232?source=see_link\">",
"     \"Cardiotoxicity of trastuzumab\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The association between neoadjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    and cardiac dysfunction is controversial. In the GeparQuattro study, all HER2-positive patients (n=445) received trastuzumab every three weeks in addition to neoadjuvant chemotherapy consisting of four cycles of",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"      epirubicin",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"      cyclophosphamide",
"     </a>",
"    </span>",
"    (EC) followed by four cycles of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/68\">",
"     68",
"    </a>",
"    ]. Compared to those treated with chemotherapy alone (ie, HER2-negative patients), the addition of did not increase the risk of cardiac dysfunction. However, in a separate analysis that incorporated three randomized trials (including GeparQuattro), there was a significant increased risk of cardiac dysfunction reported (odds ratio 1.95, 95% CI 1.16 to 3.29) in patients receiving trastuzumab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179173612\">",
"    <span class=\"h3\">",
"     Lapatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with HER2-positive breast cancer who are candidates for neoadjuvant therapy, we suggest not administering",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    . The limited evidence available suggests it is inferior to trastuzumab in this setting.",
"   </p>",
"   <p>",
"    In the GeparQuinto trial, 620 patients were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    for four cycles and then randomly assigned to treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    plus either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/70\">",
"     70",
"    </a>",
"    ]. Treatment with chemotherapy plus trastuzumab resulted in a higher rate of pCR compared to lapatinib (odds ratio 0.68, 95% CI 0.47-0.97; 30 versus 23 percent, respectively) and was associated with less serious adverse events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104112470\">",
"    <span class=\"h3\">",
"     Combined HER2 blockade",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of dual HER2-targeted treatments with neoadjuvant chemotherapy is a promising new approach in HER2-positive patients, designed to overcome",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    resistance. However, this strategy should be considered investigational at this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89687024\">",
"    <span class=\"h4\">",
"     Lapatinib plus trastuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two randomized studies described below report significant improvements in pathologic complete response rates with the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    to the combination of chemotherapy and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Neo-ALTTO",
"      </strong>",
"      &mdash; In the NeoAdjuvant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/23/9592?source=see_link\">",
"       Lapatinib",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       Trastuzumab",
"      </a>",
"      Treatment Optimization trial (Neo-ALTTO, BIG",
"      <span class=\"nowrap\">",
"       01-06/EGF",
"      </span>",
"      106903), 453 women with HER2-positive stage II-III breast cancers were randomly assigned to lapatinib, trastuzumab, or the combination of trastuzumab plus lapatinib [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/71\">",
"       71",
"      </a>",
"      ]. All patients received six weeks of HER2-targeted therapy alone, followed by 12 weeks of weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      along with their assigned HER2-targeted treatment prior to surgery. Combined HER2-targeted therapy resulted in a significant higher clinical response rate at the end of treatment (80 versus 71 and 74 percent, with trastuzumab or lapatinib, respectively) and a significantly higher pCR rate (51 versus 30 and 25 percent, respectively), which was seen in both ER-positive and ER-negative subgroups. Despite this, the rate of breast conserving surgery was unchanged (41 versus 39 and 43 percent, respectively).",
"     </li>",
"     <li>",
"      <strong>",
"       CHER-LOB",
"      </strong>",
"      &mdash; In the CHER-LOB trial, 121 patients received weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      followed by FEC chemotherapy and were randomly assigned to treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/23/9592?source=see_link\">",
"       lapatinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      , or both [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/72\">",
"       72",
"      </a>",
"      ]. The pCR rate in patients who received dual HER2-targeted therapy was 47 percent (versus 25 and 26 percent in patients who received trastuzumab or lapatinib, respectively). As in Neo-ALTTO, the rate of breast conserving surgery was not significantly different across the three arms (69, 67, and 58 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the lack of improvement in the rate of breast conserving surgery, it is not clear what the ultimate advantage of combined HER2-blockade with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    is. Although the higher pCR rate may result in improvement in DFS and OS, the survival outcomes have not yet been reported. We await further data from these trials before adopting this approach into routine clinical practice. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1529?source=see_link&amp;anchor=H441569536#H441569536\">",
"     \"Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosis\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89687031\">",
"    <span class=\"h4\">",
"     Pertuzumab plus trastuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/61/25557?source=see_link\">",
"     pertuzumab",
"    </a>",
"    has been evaluated in the neoadjuvant setting with responses noted even without the use of chemotherapy. For now, however, we consider of the neoadjuvant use of pertuzumab investigational.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the NeoSPHERE trial, 417 women with HER2-positive breast cancer were randomly assigned treatment using one of four regimens:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every three weeks for four cycles) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      (group A), docetaxel plus trastuzumab and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/61/25557?source=see_link\">",
"       pertuzumab",
"      </a>",
"      (group B), pertuzumab plus trastuzumab alone (group C) or docetaxel plus pertuzumab (group D) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/73\">",
"       73",
"      </a>",
"      ]. After surgery, patients on the docetaxel arms received three cycles of FEC then completed a year of trastuzumab, while patients in group C received both docetaxel and FEC followed by trastuzumab. The main study results were as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The pCR rates were 29, 46, 17, and 24 percent in groups A, B, C, and D, respectively. Compared to patients with ER-positive disease, pCR rates were generally higher in women with hormone-receptor negative tumors (group A: 37 versus 20 percent; group B: 63 versus 26 percent; group C: 29 versus 6 percent; group D: 30 versus 17 percent).",
"     </li>",
"     <li>",
"      The addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/61/25557?source=see_link\">",
"       pertuzumab",
"      </a>",
"      to the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      combination did not appear to increase toxicity, including the risk of cardiac adverse events.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the TRYPHAENA trial, 223 women were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/61/25557?source=see_link\">",
"       pertuzumab",
"      </a>",
"      and randomly assigned to treatment with either concurrent FEC followed by concurrent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      (FEC-HP followed by D-HP), FEC alone followed by concurrent docetaxel (FEC - D-HP), or concurrent docetaxel and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      (TC-HP) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/74\">",
"       74",
"      </a>",
"      ]. After surgery, all patients completed a year of trastuzumab. The pCR rate was equivalent across arms (62 percent with FEC-HP followed by D, 57 percent with D-HP followed by FEC, and 66 percent with TC-HP). Although patients with ER-negative cancers were more likely to achieve a pCR (range, 65 to 84 percent), patients with ER-positive patients had high pCR rates as well (range, 46 to 50 percent). All three arms were associated with a low incidence of cardiac adverse events &le;5 percent. &nbsp; &nbsp; &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results are fascinating not only because of the higher pCR rate seen on the chemotherapy plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/61/25557?source=see_link\">",
"     pertuzumab",
"    </a>",
"    , but also the frequency of pCRs associated with dual HER2-targeted therapy alone (in the Neo-SPHERE trial), especially in patients with ER-negative disease. We await further study of the addition of pertuzumab in the neoadjuvant setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3858693\">",
"    <span class=\"h1\">",
"     TREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving neoadjuvant systemic therapy should be followed by clinical exam at regular intervals during treatment to ensure that disease is not progressing. At the end of treatment, the assessment of tumor response is important to help guide the surgical approach. The evaluation of patients on neoadjuvant treatment is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1529?source=see_link&amp;anchor=H441569536#H441569536\">",
"     \"Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosis\", section on 'Prognosis'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H201397\">",
"    <span class=\"h1\">",
"     NOVEL APPROACHES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H722485403\">",
"    <span class=\"h2\">",
"     Incorporation of angiogenesis inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although studies suggest that the incorporation of the angiogenesis inhibitor,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , to chemotherapy in patients receiving neoadjuvant treatment may improve outcomes, it is not clear which patients are likely to benefit from this approach or whether pCR after chemotherapy plus bevacizumab will improve DFS or OS. For now, we consider this approach investigational and recommend against incorporation of bevacizumab in neoadjuvant treatment outside of a clinical trial. Two trials that illustrate this point are discussed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial conducted by the German Breast Cancer Study Group, 1948 women with newly diagnosed HER2-negative breast cancer were assigned to chemotherapy (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      [EC] every three weeks for four cycles followed by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      every three weeks for four cycles) plus or minus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every three weeks for eight doses) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/52\">",
"       52",
"      </a>",
"      ]. Compared to treatment with chemotherapy only, the addition of bevacizumab resulted in:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A significant improvement in pCR (OR favoring",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      1.29, 95% CI 1.02-1.65). On subgroup analysis, this improvement was seen in patients with hormone receptor-negative disease (OR favoring bevacizumab 1.67, 95% CI 1.21-2.31) but not in those with hormone receptor-positive disease (OR 0.99, 95% CI 0.66-1.50). &nbsp;",
"     </li>",
"     <li>",
"      No improvement in the proportion of patients undergoing breast conserving surgery (62 percent in both arms).",
"     </li>",
"     <li>",
"      A significant increase in serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities including febrile neutropenia (14 versus 7 percent), mucositis (17 versus 3 percent), hand-foot syndrome (6 versus 3 percent), and arterial hypertension (3 versus 0.4 percent), but no increase in cardiac toxicity (1.4 versus 0.9 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NSABP B-40 &mdash; In NSABP B-40, 1206 patients were randomly assigned to four cycles of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      , docetaxel plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      , or docetaxel plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      followed by four cycles of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      . Patients were also randomly assigned to treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      or not for the first six cycles of chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/40/35466/abstract/43\">",
"       43",
"      </a>",
"      ]. Compared to chemotherapy alone, treatment with chemotherapy plus bevacizumab resulted in:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A significant increase in the pCR rate in the breast (35 versus 28 percent, respectively). However, in contrast to GeparQuinto, a significant increase in the pCR rate was seen in hormone receptor-positive patients (23 versus 15 percent) but not hormone receptor-negative patients (52 versus 47 percent).",
"     </li>",
"     <li>",
"      An increase in the pCR rate in the breast and nodes (28 versus 23 percent, respectively), though this was not statistically significant.",
"     </li>",
"     <li>",
"      A significant increase in serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities including hypertension (10 versus &lt;1 percent), hand-foot syndrome (11 versus 7 percent), mucositis (4 versus 1 percent), and headaches (4 versus &lt;1 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H760240842\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neoadjuvant therapy refers to the systemic treatment of breast cancer prior to definitive surgical therapy (ie, preoperative therapy). (See",
"      <a class=\"local\" href=\"#H541772675\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neoadjuvant therapy is administered with the objective to improve surgical outcomes in patients with breast cancer for whom a primary surgical approach is technically not feasible and patients with operable breast cancer who desire breast conservation, but for whom either a mastectomy is required or a partial mastectomy would result in a poor cosmetic outcome. In addition, neoadjuvant chemotherapy is appropriate for patients with HER2-positive or triple-negative breast cancer (ie, ER-negative, PR-negative, and HER2-negative) who are most likely to have a good locoregional response to treatment, regardless of the size of their breast cancer at presentation. (See",
"      <a class=\"local\" href=\"#H11989101\">",
"       'Objectives'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11989615\">",
"       'Patient selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients undergoing neoadjuvant chemotherapy, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      followed by weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients with a contraindication to anthracycline treatment, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      and cyclophosphamide (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients whose breast cancer is HER2-positive, we recommend the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      to neoadjuvant chemotherapy over chemotherapy alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H53705780\">",
"       'Choice of chemotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H541773077\">",
"       'HER2-directed therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with hormone receptor-positive, HER2-negative breast cancers who are candidates for neoadjuvant therapy, we suggest chemotherapy rather than endocrine therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, for patients who are not candidates for chemotherapy, we suggest endocrine therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest an aromatase inhibitor rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, premenopausal women who desire neoadjuvant endocrine therapy rather than chemotherapy should be informed of the lack of data to inform the benefits of this treatment approach. (See",
"      <a class=\"local\" href=\"#H11989615\">",
"       'Patient selection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H179173117\">",
"       'Treatment options'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients receiving neoadjuvant systemic therapy should be followed by clinical exam at regular intervals during treatment to ensure that disease is not progressing. At the end of treatment, the assessment of tumor response is important to help guide the surgical approach. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1529?source=see_link&amp;anchor=H1192123#H1192123\">",
"       \"Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosis\", section on 'Treatment evaluation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/1\">",
"      Gralow JR, Burstein HJ, Wood W, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 2008; 26:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/2\">",
"      Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006; 24:1940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/3\">",
"      Schwartz GF, Hortobagyi GN. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. Cancer 2004; 100:2512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/4\">",
"      Shannon C, Smith I. Is there still a role for neoadjuvant therapy in breast cancer? Crit Rev Oncol Hematol 2003; 45:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/5\">",
"      Walter P, Bernhard U, Menger M, et al. New immunosuppressive agents in experimental allogeneic heart transplantation. Transplant Proc 1990; 22:2324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/6\">",
"      Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 1994; 30A:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/7\">",
"      van der Hage JA, van de Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001; 19:4224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/8\">",
"      Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001; :96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/9\">",
"      Davidson NE, Morrow M. Sometimes a great notion--an assessment of neoadjuvant systemic therapy for breast cancer. J Natl Cancer Inst 2005; 97:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/10\">",
"      Gianni L, Baselga J, Eiermann W, et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 2005; 11:8715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/11\">",
"      Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005; 97:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/12\">",
"      Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/13\">",
"      von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30:1796.",
"     </a>",
"    </li>",
"    <li>",
"     Buzdar AU, Valero V, Theriault RL, et al. Pathological complete response to chemotherapy is related to hormone receptor status. Breast Cancer Res Treat 2003; 88: abstr 302.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/15\">",
"      Hayes DF. Targeting adjuvant chemotherapy: a good idea that needs to be proven! J Clin Oncol 2012; 30:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/16\">",
"      Coates AS, Colleoni M, Goldhirsch A. Is adjuvant chemotherapy useful for women with luminal a breast cancer? J Clin Oncol 2012; 30:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/17\">",
"      Schott AF, Hayes DF. Defining the benefits of neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2012; 30:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/18\">",
"      Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13:2329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/19\">",
"      Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11:5678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/20\">",
"      Esserman LJ, Berry DA, DeMichele A, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol 2012; 30:3242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/21\">",
"      Untch M, Fasching PA, Konecny GE, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 2011; 29:3351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/22\">",
"      Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J 2010; 16:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/23\">",
"      Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/24\">",
"      Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005; 23:7703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/25\">",
"      Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev 2007; :CD005002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/26\">",
"      Iwase S, Yamamoto D, Kuroda Y, et al. Phase II trial of preoperative chemotherapy for breast cancer: Japan Breast Cancer Research Network (JBCRN)-02 trial. Anticancer Res 2011; 31:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/27\">",
"      Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol 2003; 21:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/28\">",
"      Hortobagyi GN, Ames FC, Buzdar AU, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988; 62:2507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/29\">",
"      von Minckwitz G, K&uuml;mmel S, Vogel P, et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 2008; 100:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/30\">",
"      Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J Clin Oncol 2009; 27:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/31\">",
"      Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005; 23:5983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/32\">",
"      Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/33\">",
"      Evans TR, Yellowlees A, Foster E, et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J Clin Oncol 2005; 23:2988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/34\">",
"      Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006; 24:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/35\">",
"      Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002; 20:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/36\">",
"      Hutcheon AW, Heys SD, Sarkar TK, Aberdeen Breast Group. Neoadjuvant docetaxel in locally advanced breast cancer. Breast Cancer Res Treat 2003; 79 Suppl 1:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/37\">",
"      Schneeweiss A, Huober J, Sinn HP, et al. Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study. Eur J Cancer 2004; 40:2432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/38\">",
"      Di&eacute;ras V, Fumoleau P, Romieu G, et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 2004; 22:4958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/39\">",
"      von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 2005; 23:2676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/40\">",
"      Sikov WM, Dizon DS, Strenger R, et al. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. J Clin Oncol 2009; 27:4693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/41\">",
"      Chen XS, Nie XQ, Chen CM, et al. Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. Ann Oncol 2010; 21:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/42\">",
"      von Minckwitz G, Rezai M, Loibl S, et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol 2010; 28:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/43\">",
"      Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012; 366:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/44\">",
"      Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010; 28:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/45\">",
"      Byrski T, Dent R, Blecharz P, et al. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res 2012; 14:R110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/46\">",
"      Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/47\">",
"      Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006; 295:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/48\">",
"      Untch M, M&ouml;bus V, Kuhn W, et al. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol 2009; 27:2938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/49\">",
"      Ellis GK, Barlow WE, Gralow JR, et al. Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. J Clin Oncol 2011; 29:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/50\">",
"      Huober J, von Minckwitz G, Denkert C, et al. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 2010; 124:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/51\">",
"      Noske A, Loibl S, Darb-Esfahani S, et al. Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765). Breast Cancer Res Treat 2011; 126:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/52\">",
"      von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366:299.",
"     </a>",
"    </li>",
"    <li>",
"     Huober J, Hanusch C, Fasching PA, et al. Neoadjuvant Chemotherapy of Paclitaxel with or without Rad001: Results of the Non-Responder Part of the GEPARQUINTO Study. Cancer Research 2011;71(24 Suppl.):Abstract S3-6.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/54\">",
"      Torrisi R, Bagnardi V, Pruneri G, et al. Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. Br J Cancer 2007; 97:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/55\">",
"      Alba E, Calvo L, Albanell J, et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann Oncol 2012; 23:3069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/56\">",
"      Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 2007; 110:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/57\">",
"      Ellis MJ, Ma C. Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res Treat 2007; 105 Suppl 1:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/58\">",
"      Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 2001; 12:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/59\">",
"      Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005; 23:5108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/60\">",
"      Cataliotti L, Buzdar AU, Noguchi S, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative \"Arimidex\" Compared to Tamoxifen (PROACT) trial. Cancer 2006; 106:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/61\">",
"      Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. J Clin Oncol 2011; 29:2342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/62\">",
"      Krainick-Strobel UE, Lichtenegger W, Wallwiener D, et al. Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. BMC Cancer 2008; 8:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/63\">",
"      Petrelli F, Borgonovo K, Cabiddu M, et al. Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials. Anticancer Drugs 2011; 22:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/64\">",
"      Ismael G, Hegg R, Muehlbauer S, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol 2012; 13:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/65\">",
"      Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673.",
"     </a>",
"    </li>",
"    <li>",
"     Bayraktar S, Bayraktar UD, Reis IM, et al. Neoadjuvant Dose-Dense Docetaxel, Carboplatinum and Trastuzumab Chemotherapy for HER2 Overexpressing Breast Cancer. J Clin Oncol 2009; 27:15S, abstr e11557.",
"    </li>",
"    <li>",
"     Jones S, Collea R, Paul D, et al. Phase II Trial of Adjuvant TC (Docetaxel/ Cyclophosphamide) Plus Trastuzumab (HER TC) in HER2-Positive Early Stage Breast Cancer Patients. Cancer Research 2011; 71(24 Suppl.):Abstract PD07-03.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/68\">",
"      Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010; 28:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/69\">",
"      Bozovic-Spasojevic I, Azim HA Jr, Paesmans M, et al. Neoadjuvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe? Lancet Oncol 2011; 12:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/70\">",
"      Untch M, Loibl S, Bischoff J, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012; 13:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/71\">",
"      Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/72\">",
"      Guarneri V, Frassoldati A, Bottini A, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol 2012; 30:1989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/40/35466/abstract/73\">",
"      Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13:25.",
"     </a>",
"    </li>",
"    <li>",
"     Schneeweiss A, Chia S, Hickish T, et al.  Neoadjuvant Pertuzumab and Trastuzumab Concurrent or Sequential with an Anthracycline-Containing or Concurrent with an Anthracycline-Free Standard Regimen: A Randomized Phase II Study (TRYPHAENA). Cancer Research 2011; 71(24 Suppl.):Abstract S5-6.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14225 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-AF04787F30-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_40_35466=[""].join("\n");
var outline_f34_40_35466=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H760240842\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H541772675\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11989101\">",
"      OBJECTIVES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11989615\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H89686859\">",
"      Eligibility for primary surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H89686878\">",
"      - Inoperable disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H89686907\">",
"      - Operable disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H89686867\">",
"      Clinical status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H89686026\">",
"      Breast cancer subtypes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H89686033\">",
"      - HER2-positive",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H89686158\">",
"      - Triple-negative breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11990037\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11994795\">",
"      Tumor evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11994803\">",
"      Node evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H179172816\">",
"      - Clinically suspicious axillary exam",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H179173016\">",
"      - Clinically benign axillary exam",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179173117\">",
"      TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53705758\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H53705780\">",
"      - Choice of chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11994991\">",
"      Anthracycline-taxane based regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11994998\">",
"      Non-anthracycline regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H706507585\">",
"      Alternative regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H722485439\">",
"      Scheduling considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H53706464\">",
"      Response-adjusted sequential therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19285752\">",
"      Endocrine therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H82687818\">",
"      - Endocrine therapy versus chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19285579\">",
"      - Choice of endocrine therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19285586\">",
"      Is there a preferred aromatase inhibitor?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H722485417\">",
"      - Duration of endocrine therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H541773077\">",
"      HER2-directed therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H179173605\">",
"      - Trastuzumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H89686946\">",
"      Choice of regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H89686973\">",
"      Impact on cardiac function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H179173612\">",
"      - Lapatinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H104112470\">",
"      - Combined HER2 blockade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H89687024\">",
"      Lapatinib plus trastuzumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H89687031\">",
"      Pertuzumab plus trastuzumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3858693\">",
"      TREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H201397\">",
"      NOVEL APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H722485403\">",
"      Incorporation of angiogenesis inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H760240842\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/14225\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/14225|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/14/29920\" title=\"table 1\">",
"      TNM stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/47/7934\" title=\"table 2\">",
"      AC regimen for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/22/25966\" title=\"table 3\">",
"      AC-T for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/23/12671\" title=\"table 4\">",
"      AC followed by TH regimen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37961?source=related_link\">",
"      Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11384?source=related_link\">",
"      Adjuvant medical therapy for HER2-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/59/24504?source=related_link\">",
"      Breast biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/34/2602?source=related_link\">",
"      Breast cancer during pregnancy and lactation: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42232?source=related_link\">",
"      Cardiotoxicity of trastuzumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/49/10009?source=related_link\">",
"      Clinical features, diagnosis, and staging of newly diagnosed breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/40/34441?source=related_link\">",
"      Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/58/13226?source=related_link\">",
"      General principles on the treatment of early stage and locally advanced breast cancer in older women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23002?source=related_link\">",
"      MRI of the breast and emerging technologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/52/42825?source=related_link\">",
"      Management of the regional lymph nodes in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/21/41302?source=related_link\">",
"      Molecular intrinsic subtypes of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1529?source=related_link\">",
"      Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/46/19177?source=related_link\">",
"      Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/47/36602?source=related_link\">",
"      Sentinel lymph node dissection for breast cancer: Indications and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/15/17650?source=related_link\">",
"      Treatment protocols for breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_40_35467="Esophageal perforation prognostic variables";
var content_f34_40_35467=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F54174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F54174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prognostic variables for mortality associated with esophageal perforation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mortality (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Etiology (n = 431)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Spontaneous",
"       </td>",
"       <td>",
"        36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Iatrogenic",
"       </td>",
"       <td>",
"        19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Traumatic",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Location (n = 397)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cervical",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Thoracic",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abdominal",
"       </td>",
"       <td>",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Time to diagnosis (n = 396)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &lt;24 hrs",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;24 hrs",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This table shows the higher mortality rates associated with a sponteous perforation, a thoracic perforation, and a delay in diagnosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Brinster CJ, Singhal S, Lee L, et al. Evolving options in the management of esophageal perforation. Ann Thorac Surg 2004; 77:1475.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_40_35467=[""].join("\n");
var outline_f34_40_35467=null;
var title_f34_40_35468="Common causes pneumonia child";
var content_f34_40_35468=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common etiologic agents of pediatric pneumonia*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Microbial agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Susceptible hosts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Streptococcus pneumoniae",
"        </em>",
"       </td>",
"       <td>",
"        All",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Mycoplasma pneumoniae",
"        </em>",
"       </td>",
"       <td>",
"        Primarily children &ge;5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Chlamydophila pneumoniae",
"        </em>",
"       </td>",
"       <td>",
"        Primarily children &ge;5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Chlamydia trachomatis",
"        </em>",
"       </td>",
"       <td>",
"        First 3 months of life",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Treponema pallidum",
"        </em>",
"       </td>",
"       <td>",
"        First 3 months of life",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Mycoplasma hominis",
"        </em>",
"       </td>",
"       <td>",
"        First 3 months of life",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Ureaplasma urealyticum",
"        </em>",
"       </td>",
"       <td>",
"        First 3 months of life",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Staphylococcus aureus",
"        </em>",
"       </td>",
"       <td>",
"        Primarily children &lt;5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Streptococcus pyogenes",
"        </em>",
"       </td>",
"       <td>",
"        Primarily children &lt;5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Respiratory syncytial virus",
"       </td>",
"       <td>",
"        Primarily children &lt;5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Influenza A and B",
"       </td>",
"       <td>",
"        Primarily children &lt;5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Parainfluenza 1, 2, and 3",
"       </td>",
"       <td>",
"        Primarily children &lt;5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adenovirus",
"       </td>",
"       <td>",
"        Primarily children &lt;5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rhinovirus",
"       </td>",
"       <td>",
"        Primarily children &lt;5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Human metapneumovirus",
"       </td>",
"       <td>",
"        Primarily children &lt;5 years",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Excluding neonatal pneumonia (in infants &lt;28 days of age).",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Klein JO, Bacterial pneumonias, In: Textbook of Pediatric Infectious Diseases, Feigin RD, Cherry JD, Demmler GJ, Kaplan SL (Eds), WB Saunders, Philadelphia 2004, McIntosh K, N Engl J Med 2002; 346:429, Gaston B, Pediatr Rev 2002; 23:132, Boyer KM. Nonbacterial pneumonia. In: Textbook of Pediatric Infectious Disease, Feigin BD, Cherry JD, Demmler GJ, Kaplan SL (Eds), WB Saunders, Philadelphia 2004, and Sandora T, Harper MB. Pediatr Clin North Am 2005; 52:1059.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_40_35468=[""].join("\n");
var outline_f34_40_35468=null;
var title_f34_40_35469="Low protein diet in CRF";
var content_f34_40_35469=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F59277&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F59277&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Graph showing effect of dietary protein restriction on progression of nondiabetic chronic kidney disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 234px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cumulative fall in glomerular filtration rate (GFR) over three years in patients with nondiabetic chronic renal failure (mean baseline GFR 39 mL/min) receiving a normal (solid line) and low protein (dashed line) diet. Protein restriction had little or no overall beneficial effect. There was a trend toward more rapid loss of GFR in the first four months followed by a modest slowing of progression during the last 32 months.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Klahr, S, Levey, AS, Beck, GJ, et al, N Engl J Med 1994; 330:877.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_40_35469=[""].join("\n");
var outline_f34_40_35469=null;
var title_f34_40_35470="FOLFIRI plus panitumumab for colorectal cancer";
var content_f34_40_35470=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F86311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F86311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    FOLFIRI plus panitumumab chemotherapy for K-ras wild-type metastatic colorectal cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 28 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Panitumumab",
"        </strong>",
"       </td>",
"       <td>",
"        6 mg/kg IV",
"       </td>",
"       <td>",
"        Dilute to total volume 100 mL* with normal saline (NS) and administer over 60 minutes",
"        <sup>",
"         &Delta;",
"        </sup>",
"        using a low-protein-binding 0.2 micrometer or 0.22 micrometer in-line filter.",
"       </td>",
"       <td>",
"        Days 1 and 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Irinotecan",
"        </strong>",
"       </td>",
"       <td>",
"        180",
"        <sup>",
"         &loz;",
"        </sup>",
"        mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 500 mL 5 percent dextrose in water (D5W)",
"        <sup>",
"         &sect;",
"        </sup>",
"        and administer over 90 minutes (can be administered concurrently with leucovorin via y-site connection) after panitumumab; may be given concurrently with leucovorin via y-site connection.",
"       </td>",
"       <td>",
"        Days 1 and 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Leucovorin",
"        </strong>",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL D5W and administer over two hours; may give concurrent with irinotecan via y-site connection.",
"       </td>",
"       <td>",
"        Days 1 and 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fluorouracil (FU)",
"        </strong>",
"       </td>",
"       <td>",
"        400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Slow intravenous push over five minutes (administer immediately after leucovorin).",
"       </td>",
"       <td>",
"        Days 1 and 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fluorouracil (FU)",
"        </strong>",
"       </td>",
"       <td>",
"        2400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 500 to 1000 mL D5W and administer over 46 hours (begin immediately after FU bolus). To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose can be diluted in 100 to 150 mL NS.",
"       </td>",
"       <td>",
"        Days 1 and 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        MODERATE (30 to 90 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        Routine premedication not indicated. Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with granulocyte colony stimulating factors is not justified (risk of febrile neutropenia with this regimen was 2 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        ). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        A lower starting dose of FU and irinotecan may be needed for patients with baseline hepatic impairment. A lower starting dose of irinotecan may be needed for patients with severe renal impairment. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Diarrhea:",
"        </strong>",
"        Irinotecan is associated with early and late diarrhea, both of which may be severe. For patients who develop abdominal cramps and/or diarrhea within 24 hours of treatment, administer atropine (0.3 to 0.6 mg IV) and premedicate with atropine during later cycles. Patients must be instructed in the early use of loperamide as a treatment for late diarrhea.",
"        <strong>",
"         NOTE:",
"        </strong>",
"        Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Obtain CBC with differential and platelet count prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess electrolytes (including magnesium, calcium, and potassium) and liver and renal function prior to each dose. Monitor serum calcium, magnesium, and potassium levels weekly for eight weeks after completion of therapy",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Patients who develop diarrhea should be closely monitored and supportive care measures (eg, fluid and electrolyte replacement, loperamide, antibiotics, etc) provided as needed. Do not retreat until resolution of diarrhea for at least 24 hours without anti-diarrheal medication.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for skin rash and for evidence of keratitis or ulcerative keratitis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for signs or symptoms of pulmonary toxicity.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Delay treatment until absolute neutrophil count is &gt;1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        and the platelet count is &gt;100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        . US FDA-approved manufacturer's package insert suggests irinotecan dose reduction for grade 3 or worse hematologic toxicity during a prior cycle",
"        <sup>",
"         [3]",
"        </sup>",
"        . A different approach is used by some clinicians. If treatment is delayed for two weeks or delayed for one week on two separate occasions, the day 1 FU bolus is eliminated. With the second occurrence, reduce the FU infusion dose by 20 percent and reduce irinotecan dose to 150 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Diarrhea:",
"        </strong>",
"        Withhold treatment until resolution of diarrhea for at least 24 hours off antidiarrheal medications. Reduce irinotecan dose for patients with grade 2 or worse diarrhea during a prior treatment cycle",
"        <sup>",
"         [3]",
"        </sup>",
"        . Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dermatologic toxicity:",
"        </strong>",
"        Severe dermatologic reactions, such as acneiform rash, require delayed administration of panitumumab and/or dose reduction. Refer to UpToDate topic on \"",
"        <span class=\"emphasis\">",
"         Acneiform eruption secondary to epidermal growth factor (EGFR) inhibitors",
"        </span>",
"        \".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Pulmonary toxicity:",
"        </strong>",
"        Permanently discontinue panitumumab in patients developing pulmonary fibrosis/interstitial lung disease",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Other toxicity:",
"        </strong>",
"        If grade 2, hold treatment until less than or equal to grade 1; if grade 3 or 4, hold treatment until less than or equal to grade 2",
"        <sup>",
"         [2]",
"        </sup>",
"        . Withhold FU for grade 2 or worse diarrhea, and restart at a lower dose after complete resolution",
"        <sup>",
"         [4]",
"        </sup>",
"        . Reduce irinotecan dose for patients with grade 3 or worse other non-hematologic toxicities during a prior treatment cycle",
"        <sup>",
"         [3]",
"        </sup>",
"        . For grade 3 mucositis, eliminate FU bolus dose; prophylactic ice chips may be beneficial. Refer to UpToDate topic on \"Oral toxicity associated with chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, doses should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; CBC: complete blood count.",
"     <br/>",
"     * Doses higher than 1000 mg should be diluted to 150 mL with NS and administered over 90 rather than 60 minutes.",
"     <br/>",
"     &Delta; If the first panitumumab dose is well tolerated, subsequent infusions can be given over 30 minutes.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     A lower initial starting dose of irinotecan is recommended for age &ge;65, poor performance status, prior pelvic or abdominal radiotherapy, or elevated bilirubin. Whether a reduced starting dose is needed in patients who are homozygous for the UGT 1A1*28 allele (Gilbert's syndrome) and whether testing for this allele should be carried out prior to starting irinotecan is controversial. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"     <br/>",
"     &sect; Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).",
"     <br/>",
"     &yen; Leucovorin dose is given for d,l-racemic mixture",
"     <sup>",
"      [5]",
"     </sup>",
"     . Use half the dose for LEVOleucovorin (l-leucovorin).",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Peeters M, et al. J Clin Oncol 2010; 28:4706.",
"      </li>",
"      <li>",
"       Vectibix (panitumumab) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on June 8, 2012).",
"      </li>",
"      <li>",
"       Camptosar (irinotecan hydrochloride) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on February 14, 2012).",
"      </li>",
"      <li>",
"       Fluorouracil injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on February 14, 2012).",
"      </li>",
"      <li>",
"       Leucovorin calcium injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on February 14, 2012).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_40_35470=[""].join("\n");
var outline_f34_40_35470=null;
var title_f34_40_35471="Anatomy of thoracic inlet";
var content_f34_40_35471=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F79394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F79394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anatomic relationships of the thoracic inlet",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 328px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_40_35471=[""].join("\n");
var outline_f34_40_35471=null;
